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A b s t r a c t

The Role of PAG1 in the Activated B-Cell Subtype of
Diffuse Large B-Cell Lymphoma
Jared Henderson, M.S.
Advisory Professor: R. Eric Davis, M.D.
Diffuse Large B Cell Lymphoma (DLBCL) is the most common aggressive hematologic malignancy in
adults, but despite recent advances in treatment, many patients today still face poor outcomes. Of the
two types of DLBCL, activated B-cell (ABC) and germinal center B-cell (GCB), patients diagnosed with the
ABC subtype especially face a lack of effective treatment options. Unlike GCB-DLBCL, ABC-DLBCL is
characterized by chronic antigen-driven signaling by the B-cell receptor (BCR), indicating an escape
from immunologic tolerance mechanisms that normally regulate self-reactive B cells. While recent
therapies have focused on inhibiting the kinases that propagate BCR signaling with mixed success, we
believe that investigation into restoration of immunological tolerance may provide significant scientific
and biological knowledge and lead to the development of novel therapies. Here, we identified the gene
PAG1, which is expressed in normal B cells and GCB-, but not ABC-DLBCL, as a potential regulator of
BCR signaling and mediator of immunological tolerance. We investigated the role of PAG1 in DLBCL cells
and found that PAG1 regulates BCR signaling in both GCB and ABC contexts, and further that the forced
expression of PAG1 is highly toxic to ABC-DLBCL lines, triggering reduction in constitutive antigen
signaling and reorganization of the BCR. These results hint at a novel role for PAG1 in the maintenance
of B cell tolerance and in the pathogenesis of ABC DLBCL. In the course of studying the role of PAG1 in
BCR signaling, we also developed methods to catalog the activity of key mediators of BCR activation
through the use of a Förster resonance energy transfer (FRET) based assay in living cells, measuring
time-course, dose-response, and kinetic assays by flow cytometry. Together, these studies lay the
groundwork for further exploration into the role of PAG1 in B cell biology and for future work to
develop therapies which target the toxicity mechanisms that PAG1 activates.
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Chapter 1: Introduction

1.1 - Lymphoma & DLBCL
Diffuse Large B Cell Lymphoma (DLBCL) is the most common aggressive hematologic
malignancy in adults, representing up to 35% of non-Hodgkin lymphomas[1], with an incidence rate in
the United States of 5.6 per 100,000[2]. As is the case for many cancer types, advancements in patient
screening and treatment have increased the survival of DLBCL patients in recent years, with the
standard of care chemoimmunotherapy R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine
and prednisone) curing upwards of 50% of patients[3,4]. However, treatment of DLBCL largely remains
a one-size-fits-all approach despite major advances in the identification and categorization of patient
tumor subtypes and risk factors[5–8]. Recent advances in chimeric antigen receptor (CAR) T-cell
therapies for relapsed and refractory disease have significantly improved outcomes for patients who
fail front-line treatment, with durable complete responses in up to 40% of CAR-T treated patients[9].
Despite this welcome improvement for patients who are eligible and able to receive CAR-T therapy, a
significant number of patients face extremely poor outcomes and limited therapeutic options.
A major focus of the field in the past 20 years has been the molecular and genetic
characterization of the biological drivers of DLBCL tumorigenesis and survival mechanisms, with the
goal of being able to successfully stratify patient tumors into subsets that are predictive of response to
existing and emerging targeted therapies, thereby increasing patient responses and cure rates. To this
end, significant work has been done to characterize the mechanisms of mutagenesis and to catalog and
define the genetic and epigenetic signatures of distinct tumor subsets. An outgrowth of this work has
been a greater understanding of the heterogeneity of patient tumors, and with it an increasing
awareness of lymphomagenesis as a process intimately linked to disruptions in the stages of normal B
1

cell development[10,11]. The growing sophistication in DLBCL stratification has gone hand-in-hand with
concerted research into the developmental mechanisms of normal B cell biology, each of which has
informed the other to lay the groundwork for the conceptualization of B-cell lymphoma broadly, and
DLBCL particularly, as a disruption of the regulatory networks that determine normal B cell
development and function[10,12]. This partnership between research into normal and pathologic B
cells informs much of the recent breakthroughs in treatment modalities and investigations into new
therapeutics. As such, any discussion of B-cell lymphoma, and DLBCL in particular, must begin with a
discussion of the relationship of lymphoma cells to their normal precursors.

1.2 - DLBCL is a disease of germinal center B cells
The primary site of development and differentiation for mature B cells is the germinal center
(GC). The GC is an anatomical and histological structure within lymphoid organs such as the spleen,
lymph nodes, and Peyer’s patches, that functions to select and train B cells for the production of
antibodies[13]. Within the GC, B cells undergo somatic hypermutation (SHM) of the of immunoglobulin
variable regions, which in turn generates high-affinity antibodies for the humoral immune
response[14]. While the process of SHM in B cells is necessary and advantageous for the development
of effective antibody responses to invading pathogens, the genomic mutagenesis that drives SHM also
plays a significant role in lymphomagenesis, with approximately 80% of B Non-Hodgkin Lymphomas (BNHLs) being thought to arise from germinal center B cells[12,15].
The GC is originally formed by the rapid proliferation of naïve B cells after they migrate to the Tcell zone of peripheral lymphoid tissues following activation of the B cell receptor (BCR) by direct
antigen (Ag) exposure or presentation of antigen by macrophages or follicular dendritic cells[16].
Within the newly formed GC, B cells rapidly proliferate, with completion of a cell cycle in as little as 7
hours[17], in order to generate sufficient cell numbers for SHM to generate B cell clones with increased
antibody-antigen affinity. This extreme proliferation of a subset of GC B cells is maintained by a series
of tightly regulated transcriptional programs: upregulation of genes associated with cell proliferation,
2

the expression of anti-apoptotic proteins, and the suppression of DNA damage response
mechanisms[18,19]. However, the maintenance of this pro-proliferative regime in GC B cells is tenuous,
and is reliant upon constant engagement of the BCR coupled with costimulation through either CD40,
primarily through helper T cell interactions in the case of T-dependent antigens, or by activation of tolllike receptors, notably TLR7 and TLR9[20].
However, while these processes of selection, proliferation, and affinity maturation are critical
to the development of normal B cells that can produce antibodies capable of effectively binding
antigen, they also generate ideal conditions for lymphomagenesis. For example, the genetic mutation
and recombination events caused by RAG1 and RAG2, which are responsible for V(D)J recombination of
the IGH locus in the bone marrow, and further contribute to mutagenesis of the hypervariable region in
the germinal center, can generate breakpoints in the IGH locus and elsewhere in the genome. One
notable RAG1/2-dependent lymphomagenic event is the formation of the well-known IGH-BCL2
fusion[21]. This causes constitutive expression of the anti-apoptotic protein BCL2, effectively
eliminating an avenue of programmed cell death which otherwise constrains cell proliferation in the
GC. Similarly, AID (activation-induced cytidine deaminase), responsible for immunoglobulin class switch
recombination (CSR) and SHM in GC B cells, can also mutate and/or translocate genes critical to B cell
development and lymphomagenesis[22], such as BCL6[23] and MYC[24]. While RAG1/2- and AIDgenerated mutations make up only a portion of the body of lymphoma driver mutations, they illustrate
that cellular processes unique and necessary to B cell development and biology can and do drive
lymphomagenesis, and further that the developmental pressures exerted on B cells (such as rapid
replication, hypermutation and differentiation) provide the context and cellular conditioning to
promote escape from normal regulatory processes and thereby to trigger tumorigenesis.
During a germinal center reaction, B cells generally inhabit one of two “zones:” light and dark.
The dark zone contains B cells in a state of rapid proliferation and SHM, while B cells in the light zone
are selected based on their affinity for antigen. B cells rapidly move from the dark to light zones and
3

back again in an iterative process: rapid proliferation and SHM in the dark zone, selection for affinity
maturation of the hypervariable region (HVR) to bind limited antigen in the light zone, then back to the
dark zone for proliferation and further SHM, and so forth. During this development cycle, cell fate is
tied to signals received through the modified BCR and through interactions with other cells present in
the GC, most notably T cells and dendritic cells[13]. During this process, and for the purposes of this
discussion, B cells generally experience one of two possible fates: negative selection followed by cell
death, or exit from the GC triggered by differentiation into plasma cells or memory B cells. Both fates
are controlled by the coordinated action of key proteins, notably MYC[25,26], NFκB[27], BCL-6[28] and
BLIMP1[10]. Cells which fail to receive appropriately strong Ag stimulation through the BCR
accompanied by costimulation from T cells (through CD40), dendritic cells, or toll-like receptors (TLR)
will thereby fail to maintain adequate levels of MYC and NFκB expression, and are eliminated from the
GC pool, while cells receiving appropriate Ag signaling and costimulation downregulate the
transcriptional repressor BCL-6, which allows stochastic expression of a host of genes, the most notable
of which for GC exit is PRDM1, which encodes BLIMP1 (B lymphocyte-induced maturation protein
1)[29]. Expression of BLIMP1 then allows differentiation into plasma cells and exit from the GC.
It is during this intricate interplay of signaling, cell replication, and selection, that opportunities
arise to predispose B cells to tumorigenesis. Genetic lesions, many of which can be caused by SHM and
AID-based recombination, as well as those acquired through age-related deamination[7], act to disrupt
the delicate balance of transcriptional regulation that allows explosive growth as well as selective killing
of GC B cells to progress without harm to the host organism. Disruption of genes that regulate the B cell
GC reaction lead to Burkitt lymphoma, follicular lymphoma and DLBCL, with each lymphoma type
bearing unique oncogenic hallmarks unique to the stage of B cell development from which they are
derived, known as the cell-of-origin (COO) theory of lymphomagenesis.
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1.3 - Cell of origin subtypes in DLBCL and their clinical relevance
A major breakthrough in classification of DLBCL tumors was the landmark study by Alizadeh et
al. in 2000 that defined a distinction between DLBCL tumors by gene expression profiling[6]. By
comparing the gene expression of transformed lymphoma B cells with that of normal B cells, tumors
were separated into two classes: germinal center B-cell like (GCB) and activated B-cell like (ABC) DLBCL.
The separation of DLBCL tumors into ABC and GCB subtypes revealed that specific patterns of genetic
mutation were associated with each category, suggesting different oncogenic mechanisms at play, with
particular genetic lesions more likely to predispose B cells to lymphomagenesis at different stages of B
cell development. Additionally, the classification of ABC and GCB subtypes showed strong correlation to
the overall survival of patients, with ABC tumors resulting in worse patient outcomes[30], suggesting
the need for targeted therapies to treat ABC-specific physiology.
Since the original establishment of ABC/GCB subtyping of DLBCL, a significant body of research
has been generated exploring the pathogenesis of each subtype. The GCB subtype is characterized by
mutations to epigenetic modifiers; such as EZH2 and KTM2D[31], which regulate cell proliferation and
differentiation; and genes that regulate cell motility within the GC, such as S1PR2 and GNA13[32],
among others. Conversely, in ABC tumors, the primary oncogenic mutations are those that hijack the
BCR signaling pathway and activate NFκB[33], including those in CD79A, CD79B, CARD11[34], and
MYD88[35]. These mutations, along with others which directly affect transcription, such as BLC-6
translocation[36] and SPIB mutation[37], serve to prevent terminal differentiation of constitutively
active B cells through repression of PRDM1. Thus, a clear relationship emerges between disruption of
the normal mechanisms of B cell regulation within the GC and the oncogenic lesions specific to
lymphomagenesis of the GC B cell, which informs treatment and patient outcome.
Recent work by two groups has expanded upon the original two categories of DLBCL
classification, identifying five distinct subtypes of DLBCL, determined by genetic driver mutations that
predispose cells to lymphomagenesis and further tie the mutational signature of DLBCL tumors to
5

parent B cell populations[7,8]. These new classification schemes use integrative analysis of genomic
profiles of DLBCL tumors rather than the gene expression profiling system used as the gold standard
diagnostic in the ABC & GCB subtype paradigm[38]. By using genomic profiling, additional information
such as chromosomal rearrangement, copy number variation, and driver gene mutations can be
considered in categorizing patient tumors, which in principle allows greater predictive and prognostic
power at diagnosis. Schmitz et al. proposed four distinct subsets named BN2, MCD, N1 and EZB, with
the majority of GCB tumors being classified as EZB and ABC tumors classified as one of BN2, MCD, or N1
subtypes[8]. However, a major weakness of this classification scheme is that approximately 50% of
DLBCL cases remain unclassified. The competing system proposed by Chapuy et al. identified five
subsets or “clusters”: C1-C5. In this system, ABC type tumors are largely divided between C1 and C5,
while GCB type tumors are split between C3 and C4, with the C2 cluster largely representing TP53
mutation and genomic instability[7]. Notably, this classification scheme significantly reduces the
unclassified portion of tumors to only 4% of DLBCL cases represented in the study. Each of the above
schemes for reclassification of DLBCL tumors have clear tradeoffs if eventually widely adopted, such as
the relative completeness of the categorization scheme by Chapuy, which leaves very few tumors
unclassified, but has more inclusive and potentially less actionable categorization; compared to the
highly specific but narrow categories proposed by Schmitz which provide clear prognostic and
therapeutic information, but leaves a majority of tumors without classification.
The establishment and adoption of these new classification schemes promises a much clearer
rationale for targeted molecular therapies based on DLBCL subtype. For example, tumors with
oncogenic mutations in CD79B and MYD88, which have been previously identified only as a subset of
ABC type tumors as discussed above, are classified within the overlapping categories MCD and C5 and
are associated with particularly poor patient outcomes. However, their largely ABC-type counterparts
with BCL6 and NOTCH2 mutation, identified within BN2 and C1 categories, show relatively improved
response to standard therapy. The divergent response to standard immunochemotherapy and the clear
6

establishment of specific driver mutation by subtype makes the rationale for more aggressive and
targeted treatment clear, as the MCD/C5 category of tumor is likely to have improved patient
responses when treatment is paired with the Btk inhibitor ibrutinib since these tumors are reliant on
mutations which activate BCR signaling and on constitutive activity of the NFκB pathway[39], while
patients with BN2/C1 classification may be spared the more aggressive treatment regimens proscribed
to patients with ABC-type tumors.
Additional benefits of this method of classification include the recent rapid and continuing
reduction in price for genomic diagnostics as well as the relative ease of collecting and processing
tumor genomic material versus the challenges of performing RNA-based gene expression profiling.
However, at present these new classification systems have not been widely adopted in the clinic, and
while this work may eventually become clinically useful, the previously established and widely used
system which divides DLBCL into ABC and GCB subtypes remains relevant to ongoing clinical and
laboratory work in DLBCL, and will be used as the basis of further discussion here.

1.4 - The B-cell receptor (BCR) is a unique target for B-cell malignancies
Partly as a consequence of being derived from distinct GC parent populations, GCB and ABC
DLBCL have been shown by our lab and others to be distinct in the way they rely upon BCR signaling to
survive and proliferate[8,40,41]. GCB-DLBCL relies on "tonic" signaling similar to that received by naive
B-cells, where BCR signaling is Ag-independent. Conversely, ABC-DLBCL relies on chronic antigen (Ag)driven signaling, similar to the type of signal received by normal B-cells upon encountering cognate
Ag[33,42] (Figure 1), either by direct stimulation through the BCR by presumed self-antigen, or by
activating mutations downstream of the BCR, as in CARD11 mutation[34]. Due in part to differences in
signal diversity and intensity, ABC-DLBCL is typically more aggressive and leads to worse patient
outcomes than GCB-DLBCL[8]. Targeting the Ag-dependent BCR signaling axis has been explored
therapeutically, as in the case of ibrutinib, which blocks activity of the tyrosine kinase BTK, to which
most ABC-DLBCL cells are addicted. While ibrutinib is initially toxic to most ABC-DLBCL tumors,
7

resistance and regression typically occur quickly, illustrating the need for additional targeted
therapies[43].
The BCR complex and its downstream signaling pathway are a unique target for B-cell
malignancies because 1) BCR signaling is often critical to the survival of malignant B-cells, and 2) the
BCR is a unique complex found only in B-cells, offering a specific rational target with limited toxicity to
other tissues[8]. However, despite the clear case for BCR signaling as a therapeutic target and the
approval of several drugs which target BCR signaling, the development of successful treatments has
been slow, hampered in part by a lack of fundamental knowledge about the altered mechanisms of BCR
signaling in various B-cell malignancies[42].

Figure 1: Schematic representation of BCR signaling in ABC and GCB DLBCL
Schematic representation of “chronic active” BCR signaling in ABC-DLBCL and “tonic” signaling in GCBDLBCL. Molecules known to actively signal are highlighted in yellow, molecule under investigation
(PAG1) is highlighted in blue with hypothetical function shown.
8

1.5 - ABC-DLBCL cells avoid normal tolerance mechanisms
An important open question in DLBCL pathology is how malignant B-cells, and especially ABCDLBCL tumor cells, avoid immunological tolerance mechanisms. Normal B-cells cannot tolerate chronic
antigen stimulation and undergo anergy or a phenomenon known as antigen induced cell death (AICD)
when confronted with constitutive BCR signaling[44]. Even GCB-DLBCL cell lines are sensitive to chronic
antigen signaling and die by a form of AICD when chronically stimulated through the BCR[44], indicating
that despite malignant transformation, the core of Ag-induced tolerance mechanisms remain in place in
GCB-DLBCL, although not necessarily in ABC-DLBCL. This, then, poses the question: can latent tolerance
mechanisms be identified, restored, and harnessed therapeutically in B-cell malignancies to force selfelimination?
The impetus for exploration in the area of tolerance restoration arises from the recent limited
successes of therapeutic interventions using small-molecule inhibitors of the BCR signaling pathway,
such as for Btk (ibrutinib)[45], Syk (entospletinib)[46], mTOR (everolimus & temsirolimus)[47,48],
among others[49]. Despite the apparent addiction of ABC-DLBCL tumors to chronic antigen
signaling[33], the nature of signal transduction in B cells is highly complex, with redundant molecular
signals acting along multiple interweaving axes, rendering it challenging to achieve complete inhibition
of BCR signaling. While this problem is not unique to DLBCL, as many other tumor types as have been
shown to activate alternate pathways to overcome therapeutic inhibition of what was thought to be an
essential pathway[50], the potential for effective therapies that attack BCR signaling in ABC tumors with
low toxicity to healthy tissue has maintained interest in understanding the underlying escape
mechanisms. We supposed that one potential answer to the problem of inhibitor escape was to instead
identify targets with the possibility to reactivate tolerizing signals that have been silenced during
progression toward cancer, thereby turning the molecular machinery involved in chronic antigen
activation of the tumor cell into a self-actualizing anti-tumor signaling platform.

9

We began by identifying proteins with differential expression between ABC and GCB subtypes
of DLBCL but that could also be potentially involved in BCR signal regulation, recognizing that GCB
tumors retain their ability to undergo AICD, and may therefore express proteins which function to turn
on apoptotic machinery or tolerizing signaling processes, but that will necessarily be suppressed or not
expressed in ABC tumors.
During our exploration of potential targets, we identified the gene PAG1 (phosphoprotein
associated with glycosphingolipid-enriched microdomains 1), which is a poorly understood negative
regulator of TCR signaling that is highly expressed in B cells in the germinal center and in GCB-DLBCL,
expressed to a lesser extent in activated and memory B-cells, but is almost completely absent both at
the transcriptional and protein level in ABC-DLBCL tumors and cell lines despite the lack of genetic
mutation or deletion[51–53]. We therefore hypothesized that PAG1 loss may play a role in the
pathogenesis of ABC tumors or in the maintenance of chronic Ag signaling.

1.6 - PAG1 is an interesting research subject in DLBCL
The role of PAG1 in normal B cells is poorly understood, and though PAG1 has been implicated
as having a role in the negative regulation of BCR-triggered activation of B cells[54], other studies have
pointed to PAG1 acting as an enforcer of positive feedback signaling after BCR activation[55]. In primary
B cells, PAG1 is expressed at all developmental stages[52], but during early development, B cells
experience moderate increases in PAG1 gene expression with the expression of CD19, and then
decrease PAG1 expression after reaching maturity and migration to the periphery[56], which suggests a
role in the regulation of “tonic” B cell signaling during the early stages of antigen receptor
rearrangement and expression. Later in B cell development, PAG1 is highly upregulated in GC B cells,
but again downregulated following exit from the GC, suggesting a different role in proliferation and
differentiation during the GC reaction[57]. While germline PAG1 knockout (KO) mice were generated
and not found to show overt anomalies in B or T cell development[58,59], a follow-up study in T cells
from the same KO mouse strain showed increased proliferation and cytokine production in response to
10

Ag stimulation after immunologic boost, as well as increased susceptibility to experimental
autoimmune encephalomyelitis (EAE) and resistance to anergy[60]. Similar effects of germline KO in B
cells have not been investigated. However, it remains likely that conditional KO in B cells would provide
a more effective method of investigating the impact of PAG1 loss, as many mechanisms of
compensation for germline KO of PAG1 have been proposed[61], particularly if coupled with models in
which auto-reactive B cells are ordinarily eliminated by tolerance mechanisms. Together, the body of
work regarding PAG1 in B cells suggests a role in the regulation and development of B cells through
modulation of BCR signaling, but relatively little work has been done to definitively establish what that
role is in normal B cells, and there has been even less reporting on the role of PAG1 in the context of
lymphoma[54].

1.7 - Research goals and results overview
We set the goal of investigating the role of PAG1 in DLBCL, with our guiding hypothesis being
that PAG1 regulates BCR signaling in DLBCL tumor cells, and that the loss of PAG1 in chronic-signaling
ABC-DLBCL results in dysregulation of the BCR signaling pathway to allow immune tolerance evasion
and the maintenance pro-survival signaling. We present this investigation here in three parts.
In Chapter 3, we use both GCB- and ABC-DLBCL cell lines to investigate the consequences of
both forced PAG1 expression and knockout. By manipulating the level of PAG1 expression and
cataloging the effects on various components of the BCR signaling pathway and the cellular distribution
of the BCR itself, we show that PAG1 is involved in the regulation of the BCR and its cellular signaling
apparatus, and further that PAG1 reintroduction in ABC-DLBCL cells has significant consequences for
the maintenance of pathologic BCR structures and signaling.
In Chapter 4, we address the mechanism by which PAG1 exerts its effects on DLBCL cells
primarily through the generation and testing of a PAG1 mutant library in ABC cell lines, which reveals
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the complexity of the PAG1 protein’s effect on DLBCL cells. We also demonstrate that a previously
uncharacterized domain of PAG1 is functionally active in ABC cells and warrants further study.
Finally, in Chapter 5, we present new methods for FRET-based detection of kinase activity by
both conventional and spectral flow cytometry, designed in part to determine the effects of PAG1 in
DLBCL cells and to facilitate the discrimination of PAG1 partners in affecting BCR signaling, but with
applications in a wide range of cell biology.
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Chapter 2: Materials and Methods

Cell Lines and culture conditions
The following DLBCL cell lines were used:
Table 1: Cell Line Information and Electroporation Conditions

Cell Line Information and Electroporation Conditions
Cell Line

Disease
Type

Electroporation Conditions
Buffer, Voltage, Time (ms), Pulses

References

DB

GCB-DLBCL

R, 1700, 20, 1

Beckwith et al.[62]

SUDHL10

GCB-DLBCL

R, 1700, 20, 1

Epstein et al.[63]

SUDHL2

ACB-DLBCL

R, 1300, 10, 3

Epstein et al.[63]

SUDHL4

GCB-DLBCL

R, 1400, 20, 2

Epstein et al.[63]

SUDHL6

GCB-DLBCL

R, 1700, 20, 1

Epstein et al.[63]

SUDHL7

GCB-DLBCL

R, 1400, 20, 2

Epstein et al.[63]

HBL-1

ABC-DLBCL

R, 1200, 20, 2

Abe et al.[64]

HLY-1

ABC-DLBCL

T, 1400, 20, 1

Rimokh et al.[65] & Brown et al.[66]

HT

GCB-DLBCL

T, 1300, 30, 1

Beckwith et al.[62]

OCI-Ly10

ABC-DLBCL

R, 1300, 10, 3

Tweeddale et al.[67]

OCI-Ly19

GCB-DLBCL

R, 1500, 10, 3

Chang et al.[68]

OCI-Ly3

ABC-DLBCL

R, 850, 30, 2

Tweeddale et al.[67]

OCI-Ly7

GCB-DLBCL

R, 1700, 20, 1

Tweeddale et al.[67]

OCI-Ly8

GCB-DLBCL

R, 1400, 10, 3

Tweeddale et al.[67]

TMD8

ABC-DLBCL

T, 1600, 20, 2

Todha et al.[69]

U2932

ABC-DLBCL

R, 1400, 20, 1

Amini et al.[70]

Cell lines were cultured at 37°C with 5% CO2 in RPMI media with L-glutamine, supplemented
with 10% fetal bovine serum, 20 mM HEPES buffer, 1 mM sodium pyruvate, 100 U/mL penicillin and
100 µg/mL streptomycin. All cell lines were validated by STR DNA fingerprinting. A PCR-based
mycoplasma detection kit (Applied Biological Materials) was used periodically to test for mycoplasma
infection.
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Growth Assays
The absolute growth rates of WT and modified cell lines were assessed by the change over time in the
calculated absolute number of cells in culture[40]. At any point in time, this number was determined as follows:
an aliquot of well-suspended cells in culture, representing a known fraction of the culture volume, was removed
and stained for FCM as described above, so as to be able to identify a population (or populations) of interest (e.g.,
KO cells). In the last re-suspension of pelleted cells before FCM, the buffer included 10 μL of a stock solution
containing 6.0-8.0 μm polystyrene particles (beads; Spherotech Inc.; Catalog#: PP-60-10; a 1:20 dilution of the
original solution). The beads are a distinguishable separate population of events by FCM, with low forward scatter
and high side scatter. From the ratio of the FCM-determined counts of beads and the cell population of interest,
and the volume of the culture aliquot used, the absolute number of the cells of interest in the culture can be
calculated. If the culture is maintained over time by passaging via known dilutions, the growth curve of
exponential increase in absolute cell number (logarithmic) over time (linear) can be constructed.

Transfection of Sleeping Beauty constitutive and dox-inducible vectors
Transfection was performed by the Neon electroporation device (ThermoFisher Scientific), with
optimal conditions for individual cell lines listed in Table 1. For all experiments, 1 x 106 cells in 120 µL
volume of Neon buffer were used. Sleeping Beauty-based transposon vectors[71] were used for stable
expression of PAG1 or expression control protein, respectively. For each reporter and control
separately, 6 µg of transposon donor plasmid was co-electroporated with 4 µg of the transposase
coding plasmid pCMV(CAT)T7-SB100 (Addgene plasmid #34879)[72]. Drug selection was initiated two
days after electroporation, and cells were kept under selection pressure for a minimum of 7 days and a
maximum of 14 days.
Genomic Modification
Transfection was performed by Neon electroporation (Thermo Fisher) as described above.
Gene targeting used chimeric plasmids (Addgene) pX330-U6-Chimeric_BB-CBhhSpCas9 and pX335-U6Chimeric_BB-CBh-hSpCas9n(D10A)[73] for respective expression of wild-type orD10A“nickase” Cas9 .
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GuideRNA (gRNA) sequences were designed with the online CRISPR (clustered regularly interspaced
short palindromic repeats) Design Tool (http://crispr.mit.edu/). For knock-in, 1 or more Cas9/gRNA
plasmids was co-electroporated with a homologous recombination donor plasmid containing silent
mutations to prevent targeting of the donor plasmid or modified genomic locus. Homology arms and
sequences for insertion by homologous recombination were ordered as gBlocks Gene Fragments
(Integrated DNA Technologies) and captured via the StrataClone Ultra Blunt PCR Cloning Kit (Agilent)
for complete assembly in a plasmid. After verification of gRNA sequences, maxiprep DNA was used for
electroporation-based cell transfection. We used 7 μg of plasmid DNA (pX330 with cloned gRNA
sequence) per 120 μL of cell suspension (1 million cells per 100 μL) in electroporation buffer for each
electroporation. Targeted genes and corresponding sequences of CRISPR/Cas9 target sites are listed in
the table below.
Table 2: gRNA sequences used for gene knockout
Gene
GFP

Target Sequence (5’ to 3’)
GGGCGAGGAGCTGTTCACCGGGG

Location
GFP cDNA

Csk

GCAATACATTCTGTACCGGATGG

Exon 2

PAG1

GAAGCCGCGACAGCATAGTGGGG

EZR_5’
EZR_3’
IGHM

CXCR4

CAATGTCCGAGTTACCACCATGG
TTCGAGGCCCTGTAACAGCCAGG
AGATGAGCTTGGACTTGCGGGGG
GCTTCTACCCCAATGACTTGTGG

CD19

AKT1/2
PTEN
SYK

HBL-1_HV_01
HBL-1_HV_01

TGGAATGTTTCGGACCTAGGTGG
GGATCTTCATGGCGTAGTAGCGG
GCTAACGATCTCTTTGATGATGG
TTTCGGCAACATCACCCGGGAGG
GTTCACAGGGGTCCTGTCCCAGG
CCTCAGGTGAGTCCTCACGTCTC

Exon 2
Exon 2
Exon 2
Exon 2
Exon 1

First translated exon

Exon 5 of AKT1; exon 6 of AKT2
Exon 1

First translated exon
HBL-1 H-HVR V region
HBL-1 H-HVR J region

Knock-in (KI) and knockin-knockout (KI/KO) experiments
Knock-in (KI) experiments were also done by CRISPR/Cas9 methods by using homologous
recombination (HR). KI was used as a marker for KO of PAG1, Csk, and Ezrin, which are not detectable
by FCM except after fixation and permeabilization. KI was also used in HVR replacement experiments in
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U2932 and HBL-1 cell lines, as previously documented[41]. PAG1_GFP fusion proteins under control of
the endogenous PAG1 promoter were also generated by KI. Homology arms and KI sequences were
ordered as gBlocks Gene Fragments (Integrated DNA Technologies) and captured in a pSB-B-amp/kan
plasmid using the StrataClone Ultra Blunt PCR Cloning Kit (Agilent Technologies, Catalog # - 240218).
OVA-HVR Replacement
Sequencing of immunoglobulin hypervariable regions (HVRs) in U2932 cells was done as
described by Havranek et al.[41] Sequences for KI plasmids are listed in Appendix 1.
Table 3: gRNA sequenes used for HVR replacement in U2932
Name

Target Sequence (5’ to 3’)

Location

Use

U2932_HV_02

GCAAGAAAATGAAGCACCTGTGG

beginning of V

U2932 H-HVR replacement

U2932_HV_03

AAAGCAGGAGAGAGGTCGTGAGG

beginning of post J intron

U2932 H-HVR replacement

U2932_LV_01

TGGAGAAGAGCTGCTCAGTTAGG

V 5’ UTR

U2932 L-HVR replacement

U2932_LV_04

TAGATCACTTCATAGACACAGGG

beginning of post J intron

U2932 L-HVR replacement

Inducible B-cell receptor expression
To control expression of the BCR at varied surface levels, the general approach was to KO the
endogenous IgH chain and express a cDNA encoding a complete IgH chain (with HVR and constant
region) through a doxycycline (Dox)-inducible transposon-based system[71]. HBL-1 cells were first
transfected with pSBtet-Bla (Addgene Plasmid #30510) for inducible expression of a cDNA containing
the HBL-1 H-HVR joined to an IgM constant region. After selection of transduced HBL-1 cells with
blasticidin (ThermoFisher Scientific, #A1113903) at 20µg/mL, KO of the endogenous IgH chain was done
using px330 plasmids and gRNAs listed in Table 2. Sequence for expression of dox-inducible HBL-1_IgH
is included in Appendix 1.
Calcium Flux
To detect changes in response to BCR crosslinking, calcium flux experiments were performed as
follows: cells were loaded with either Indo-1 (ThermoFisher Scientific Cat. No I1226) or Fura Red, AM
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(ThermoFisher Scientific Cat. No. F3021) at final concentration 2 µM using cell loading medium (RPMI,
2% FBS, 25 mM HEPES, 0.05% of Pluronic® F-127) and incubation at 37° C in the dark for 45 min. After
two washes with DMEM/2% FBS medium, cells were re-suspended in cell loading medium without
Pluronic for analysis. For BCR crosslinking, F(ab’)2 anti-human IgM goat Ab (antibody) and F(ab’)2 antihuman IgG goat Ab (both Jackson ImmunoResearch) were used. Changes in intracellular calcium levels
were measured as Indo-I ratio: emission detected by 379/28 nm filter when excited with 335 nm laser
(higher with bound Ca2+) and emission detected by 509/20 nm (with 470 nm LP filter) when excited
with 335 nm laser (higher when Ca2+ unbound), or as Fura Red ratio: emission detected by 670/30 nm
filter when excited with 405 nm laser (higher with bound Ca2+) and emission detected by 695/40 nm
filter when excited with 488 nm laser (higher when Ca2+unbound), on an LSRFortessa flow cytometer
(BD Bioscience).
Drug Testing
To measure the effect of selected inhibitors on AKT activity, cells expressing the Lyn-AktAR2-EV
reporter as well as the control unphosphorylatable “dead” (inactive) version Lyn-AktAR2-EV-D were
incubated at selected concentrations of inhibitors for 1 hour at 37°C in a 5% CO2 incubator and then
immediately analyzed for FRET efficiency (E). To normalize the response of AKT activity, for each
individual cell line the baseline E of the “live” (active) reporter without any inhibitor was set as 100%
and the E of the inactive AKT activity reporter set to 0%. For kinetic studies, inhibitors were added
directly to FCM tubes during FCM measurement. Measurements of the effect of selected inhibitors of
PKA activity with the LPAR-AKAR-WT reporter and control LPAR-AKAR-mt unphosphorylatable “dead”
(inactive) version were conducted in the same way.
Drugs/inhibitors used in this study were: Ipatasertib (Selleckchem Cat: S2808), MK-2206
(Selleckchem Cat: S1078), GSK2334470 (Selleckchem Cat: SS7087), MLN0128 (Selleckchem Cat: S2811),
AKT inhibitor VIII (MedChemExpress Cat: HY-10355), Acalabrutinib (Selleckchem Cat: S8116), P505-15
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(Selleckchem Cat: S8032), Forskolin (Tocris Cat: 1099), KT5720 (Tocris Cat: 1288), Roflumilast (Tocris
Cat: 6641), RS 25344 (Tocris Cat: 3315), and Doxycycline hyclate (Sigma Cat: D9891).
Antibody Staining
Antibodies used for BCRsig panel were: Alexa Fluor 488 Mouse anti-Syk (pY348) (BD Cat No:
560081), Alexa Fluor 488 Mouse Anti-Btk (pY551)/Itk (pY511) (BD Cat No: 558130), Alexa Fluor 488
Mouse anti-BLNK (pY84) (BD Cat No: 558444), Alexa Fluor 488 Mouse anti-PLC-γ2 (pY759) (BD Cat No:
558507), Alexa Fluor 488 Mouse anti-Akt (pS473) (BD Cat No: 560404), Alexa Fluor 647 Mouse anti-S6
(pS235/pS236 (BD Cat No: 560435), Alexa Fluor 647 Mouse anti-NF-κB p65 (pS529) (BD Cat No:
558422), Alexa Fluor 647 Rabbit Anti-Active Caspase-3 (BD Cat No: 560626), Alexa Fluor 647 Mouse
Anti-ERK1/2 (pT202/pY204) (BD Cat No: 612593), and Alexa Fluor 647 Mouse anti-IκBα (BD Cat No:
560817). Samples were fixed by adding PFA to a final concentration of 4% in cell culture. Cells were
allowed to fix for 10 minutes at room temperature, then samples were pelleted at 200g, aspirated, and
resuspended in ice-cold methanol and placed in the freezer at -80°C until all samples were ready for
staining. Samples were then thawed, pelleted at 200g and washed twice with PBS. Each sample was
then separated into 5 wells of a 96 well plate, where a mixture of antibodies, one of each color (Alexa
Fluor 488 & 647) was added to each well, and pipetted vigorously. Samples were stained on ice for 30
minutes, then washed twice in cold PBS and transferred to FACS tubes for analysis.
Antibodies used to confirm KO of surface antigens in stable KO cell lines were: APC-conjugated
mouse anti-Human CD184 (CXCR4) from eBioscience (catalog #17-9999-42), and APC and Alexa Fluor
647-conjugated goat anti-human IgM from Thermo Fisher Scientific (catalog #A-21249).
Antibodies used for live-cell BCR stimulation and kinetic FRET assays were: DyLight 488 antihuman IgM F(ab’)2 (Jackson ImmunoResearch Cat: 709-486-073), PE anti-human IgM F(ab’)2 (Jackson
ImmunoResearch Cat: 109-116-129), Alexa Fluor 647 anti-human IgM F(ab’)2 (Jackson ImmunoResearch
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Cat: 109-606-129), Unconjugated anti-human IgM F(ab’)2 (Jackson ImmunoResearch Cat: 109-006-129),
and Unconjugated anti-human IgG F(ab’)2 (Jackson ImmunoResearch Cat: 109-006-097).
Antibodies used for surface staining of B-cell marker panels were: APC anti-human CD19 (BD
Cat: 555415), PE-Cy7 anti-human CD10 (BD Cat: 565282), BV421 anti-human CD184 (CXCR4) (BioLegend
Cat: 306518), APC/Cy7 anti-human CD27 (BioLegend Cat: 356424), BV785 anti-mouse/human CD44
(BioLegend Cat: 103059), FITC anti-human CD3 (BioLegend Cat: 317306), Alexa Fluor 647 anti-human
IgM F(ab’)2 (Jackson ImmunoResearch Cat: 109-606-129).
Surface-staining antibodies used to confirm KO in dox-inducible gene KO studies were: Alexa
Fluor 647 anti-human IgM F(ab’)2 (Jackson ImmunoResearch Cat: 109-606-129), Alexa Fluor 700 antihuman CD19 (BioLegend Cat: 302226), and APC anti-human CD184 (CXCR4) (BioLegend Cat: 306510).
Intracellular-staining antibodies used were: APC anti-human Syk (eBioscience Cat: 17-6696-42), PE antiAkt1 (BD Cat: 560049), and PE anti-human/mouse PTEN (Miltenyi Biotec Cat: 130-103-650). Fixation
and permeabilization was done using BD Fixation/Permeabilization Solution Kit (BD Cat: 554714)
according to manufacturer’s directions.
TurboID Biotin Ligase Assay
HBL-1 cells were first transfected with pSBtet-Bla (Addgene Plasmid #30510) plasmid
expressing either PAG1 or mCardinal cDNAs fused to TurboID or a custom-designed SplitTurboID cDNA.
After selection of transduced HBL-1 cells with blasticidin (ThermoFisher Scientific, #A1113903) at
20µg/mL, approximately 50 million cells were transferred to biotin-free RPMI medium (custom ordered
from Cell Culture Technologies) and supplemented with, 10% fetal bovine serum (biotin-depleted with
Magnetic Streptavidin Capture Beads (Promega V7820)), 20 mM HEPES buffer, and 1 mM sodium
pyruvate; and cultured at 37°C at 5% CO2 in the presence of 100 ng/mL doxycycline for 36 hours. Biotin
was then added to cell culture at 500µM, and in SplitTurboID cultures GA3-AM (Sigma-Aldrich
SML1959) was added to 10µM, and cells were returned to culture incubator for 20 minutes. Cells were
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then removed from the incubator and immediately chilled in an ice bath. Cell cultures were then
pelleted at 200g for five minutes. Pellets were then resuspended in 50mL cold PBS and rested for 5
minutes (to allow diffusion of excess biotin), which was repeated four times. Pellets were then lysed
using cell lysis buffer (CST #9803 + cOmplete & PhosSTOP [Roche]) according to manufacturers
instructions. Protein lysates were then incubated with a mixture of Protein A & Protein G Magnetic
Beads (Promega G8781 & G7471) to preclear proteins that nonspecifically bind to beads at room
temperature for one hour while mixing. Protein lysates were then transferred to tubes containing
Magnetic Streptavidin Capture Beads (Promega V7820) and incubated overnight at 4 degrees while
mixing. Magnetic beads were then isolated and rinsed in wash buffer (Tris-Buffered Saline + 0.1%
Tween20, TBS-T) four times. The remaining bead slurry was then resuspended in wash buffer with
additional protease inhibitor (cOmplete & PhosSTOP [Roche]) and stored at 4 degrees.
Samples were then processed for mass spectrometry by the Baylor College of Medicine Mass
Spectrometry Proteomics Core as follows: The precipitate of a 1D SDS-PAGE((1/4) NuPAGE (10%)
MOPS) was resolved and 4 bands were cut depending on the pattern, and performed an in-gel digest
with trypsin. The core sequenced 2 pooled peptide fractions per sample on a LumosETD mass
spectrometer. The results were searched against NCBI RefSeq database with Mascot search engine, an
MS1 area detector from Proteome Discoverer, and gene-centric protein identification and
quantification in gpGrouper (PMID:30093420). The results contained peptide peak (MS1 AUC) iBAQbased quantification for proteins. The core performed evaluation of quality control (QC) metrics and, as
applicable, principal component analysis (PCA), clustering (hierarchical, k-means).
Detection of Kinase Activity by FCM
3-measurement detection of Förster resonance energy transfer (FRET)
For FRET determination by conventional flow cytometry (FCM) on an LSRFortessa flow
cytometer (BD Biosciences), filters were chosen with respect to Cerulean3, the donor fluorophore used
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in all studies (C3; peak excitation and emission wavelengths, 433 nm and 475 nm), and the acceptor
circularly-permuted cpVenus[E172] (cpV; peak excitation and emission wavelengths, 515 nm and 528
nm). Donor fluorescence with donor excitation (IDD, donor channel) was measured with a 405 nm laser
and 480/40 filter; acceptor emission with donor excitation (IDA, FRET channel) was measured with a 405
nm laser and 550/49 filter; and acceptor emission with acceptor excitation (IAA, acceptor channel) was
measured with a 488 nm laser and 530/30 filter. FRET was also determined on a different LSR Fortessa
flow cytometer using more typical filter sets: a 405 nm laser and 450/50 filter for IDD measurement, a
405 nm laser and 525/50 filter for IDA measurement, and a 488 laser and 530/30 filter for IAA
measurement.
Calculation of FRET efficiency (E) between C3 and cpV was based on methods
developed by Chen et al.[74], which requires the determination of five constants specific for the
fluorophores and flow cytometer used (including its filters and settings). For each experiment,
coefficients were determined from FCM measurements made on cells of a single cell line (OCI-Ly7)
expressing control constructs. Four of these coefficients are cross-talk parameters: a and b were
determined from cells expressing only cpV (a = IDA/IAA and b = IDD/IAA), and c and d were determined
from cells expressing only C3 (c = IAA/IDD and d = IDA/IDD). Each coefficient was determined as the slope of
the regression line of event fluorescence for the appropriate combination of channels, using data from
single fluorophore-expressing control cells (mixed with non-fluorescent OCI-Ly7 cells to establish the
graphical origin). The b coefficient was empirically found to be best set by default to zero, because its
values were variable between experiments and had adverse and implausible effects on the G
coefficient and E.
The G coefficient, which relates sensitized acceptor emission to donor quenching[75,76], was
determined by using a pair of FRET controls in which C3 was fused to cpV, but with very different
intramolecular proximities between the fluorophores and therefore high differences in E. A rigid 230amino acid linker from TRAF2 was used between C3 and cpV to create a low-FRET control, C3-TRAF221

cpV[77]; and a linker-free C3-cpV fusion protein served as a high-FRET control. For each FRET control,
per-cell fluorescence intensity values (IDD, IDA, and IAA) were subtracted by the corresponding
autofluorescence averages for unmodified cells of the same cell line, and then used to calculate the
following parameters:
the corrected IAA value, Iaa = (dIAA – cIDA)/(d - ca);

Idd = (aIDD – bIDA)/(a - bd), simplified in practice as IDD; and
sensitized acceptor emission, Fc = IDA - aIaa – dIdd.
From a plot of FC vs. Idd for each control, events in the middle range of Idd (displaying linearity)
were selected for calculation of average values of FC, Idd, and Iaa. These were then used to calculate the
G coefficient, by the following equation[74]:
G = ((Fc2 / Iaa2) – (Fc1 / Iaa1)) / ((Idd1 / Iaa1) – (Idd2 / Iaa2)),
in which 1 and 2 are respectively the high-FRET and low-FRET controls.
For determination of FRET efficiency (E), samples were analyzed by FCM gating in FlowJo
software to exclude outlier events by first eliminating events with IAA fluorescence levels that
overlapped with unmodified autofluorescent control cells of the parental cell line. Second, auto-gating
was used to eliminate outlier events with fluorescence values greater than 1.5 standard deviations (SD)
from the mean in an orthogonal IDD vs. IAA plot. Then, for all samples expressing reporter constructs for
kinase activity, average autofluorescence values were subtracted from per-cell fluorescence intensity
values (IDD, IDA, and IAA) as above, which were then used for calculation of FC and Idd, followed by
calculation of a per-cell E value using G in the following equation:
E = (Fc / G) / (Idd + (Fc / G).
Single-cell E values for each sample were plotted as a moving median of E versus IAA. A single
average overall E value for each sample was calculated, using cells in the same range of reporter
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emission intensities for all comparable samples. For kinetic measurements of E, the average of single
cell E values in a selected IAA range was plotted vs. time.
Software for FRET data processing
A software package “fRet” was written in the R language to optimize processing of FCM
data. A detailed user’s manual, provided as supplemental material, illustrates primary FCM data and
provides guidance for selecting events for calculations in E determination. The software package itself is
available on request from the authors, along with sample data for user practice. In brief, the process of
analysis starts by applying light scatter gates with standard analysis software (e.g., FlowJo®) to FCM data
in .fcs files to identify live single cells expressing the reporter or control construct. Raw event values for
each measured sample are then exported into a .csv file, one for each sample, which can be directly
used for calculations with the software. Individual coefficients necessary for E determination are
calculated using control samples described above, including plotting of individual graphs (IDA vs. IAA for
acceptor single control, IAA vs. IDD and IDA vs. IDD for donor single control, and FC vs. Idd for FRET high and
low controls) for quality control. The actual E values for FRET high and low controls are also calculated,
for comparison to expected values or values from previous experiments. For experimental samples, the
moving median of E vs. IAA is calculated for each analyzed sample based on defined values for window
step and width; results are plotted and written as a .csv file, providing a single average value of E within
the selected IAA range. For kinetic mode analysis, the average E values within the defined IAA range are
plotted vs. time and results also written as .csv files.
FRET detection by spectral flow cytometry (SFCM)
We used an Aurora spectral flow cytometer (Cytek Biosciences; configuration 4L 16V14B-10YG-8R) with standard technical features
(https://f.hubspotusercontent00.net/hubfs/6765000/Website%20Downloadable%20Content/Guides%20a
nd%20Manuals/N9_20006_B_Aurora_UG.pdf, pp. 123-4), and detection of fluorescence in 8-16
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channels for each laser. For determination of E values by the 3-cube method on the Aurora, raw
fluorescence intensity values were taken from 3 of its channels, most similar to the optical settings
employed on the Fortessa: IDD was based on excitation with a 405 nm laser and one of its detection
channels (V4, 466-481 nm), IDA came from the 405 nm laser channel V7 (533-550 nm), and IAA came
from channel B3 (533-550 nm) for the 488 laser. For assessment of FRET by spectral unmixing (SU-FRET)
on the Aurora, we utilized built-in algorithms provided in SpectroFlo software, which use least-squares
linear regression to calculate an intensity matrix that minimizes the difference between the
experimental data and the reference spectra (spectral fingerprints) multiplied by the intensity
matrix[78]. Custom “FRET-Low” and “FRET-High” spectral fingerprints were created in SpectroFlo by
collecting data from OCI-Ly7 cells expressing the low-FRET or high-FRET controls, respectively, and used
with the spectral fingerprint of unmodified cells (autofluorescence) in unmixing of the fluorescence of
cells expressing kinase activity reporter constructs. Unmixed intensities were displayed real-time in an
orthogonal FRET-High vs. FRET-Low 2-parameter plot. For experiments using additional fluorophores,
reference data were added to the unmixing panel according to the Spectroflo user guide and unmixed
alongside FRET parameters as they would be for any other fluor. SpectroFlo software allows for
retention of spectral signatures in a long-term spectral library, and real-time FRET unmixing gives
equivalent results using same-day or stored FRET-Low and FRET-High spectra, thereby avoiding the
need to collect FRET reference spectra on a per-experiment basis; in contrast, we found that achieving
precise 3-measurement determination of E requires acquisition of data from control-bearing cells on a
same-day basis (data not shown).
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Chapter 3: Consequences of PAG1 Expression in DLBCL

3.1 - Introduction
As discussed in Chapter 1, Diffuse Large B Cell Lymphoma (DLBCL) is the most common
aggressive hematologic malignancy in adults, representing up to 35% of non-Hodgkin lymphomas[1].
However, despite categorization of patient tumors into one of two major subsets: germinal center Bcell like (GCB) and activated B-cell like (ABC) DLBCL, treatment of DLBCL largely remains a one-size-fitsall approach[5–8]. As such, identification of prognostic and therapeutic mechanisms to better treat
patients with DLBCL remains a priority for the field. DLBCL cells of both the GCB and ABC subtypes are
reliant on BCR signaling for survival, with GCB cells reliant on tonic BCR signaling, which predominantly
acts through the PI3K/Akt signaling axis[41], and ABC cells reliant on chronic Ag-based signaling, which
results in constitutive activation of NFκB and other critical pathways[33]. Thus, the BCR and its signaling
pathway represent excellent targets for therapeutic intervention due to the addiction of DLBCL tumor
cells of all types to BCR signaling. In exploring potential therapeutic vulnerabilities in the BCR signaling
pathway, we identified the gene PAG1 as a potential mediator of BCR signaling in B cells. PAG1 is highly
expressed in normal GC B cells and in GCB-DLBCL, but not expressed in ABC-DLBCL cells, and further
may play a role in the pathogenesis and disease progression of DLBCL. We believe that understanding
the functional consequences of PAG1 expression and loss has the potential to reveal mechanistic
insights for targeting BCR signaling in DLBCL.
PAG1 is a highly conserved transmembrane scaffold protein that has been implicated as a
negative regulator of antigen receptor signaling in T cells[79–81], with mixed reports on its role in the
regulation of BCR signaling in B cells[54,82]. Much of the focus on PAG1 in the literature revolves
around its association with Csk, a kinase which negatively regulates Src family tyrosine kinases (SFKs),
where PAG1 localizes Csk to the plasma membrane and serves as a signaling platform for the kinase
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activity of Csk[83], which in turn regulates the activity of SFKs[54,55,83]. PAG1 also directly interacts
with several SFKs, notably Lyn, Fyn, and Src[54,83–85], which are involved in the proximal steps of
antigen-driven BCR signaling. When partnered with PAG1, Fyn and Lyn each have both positive and
negative regulatory roles depending on cell type and on the phosphorylation status of PAG1.
Additionally, PAG1 is heavily post-translationally modified, containing 10 tyrosine residues that create
potential SH2 binding sites, two distinct proline rich regions that form SH3 binding sites, as well as a
PDZ domain binding motif that links PAG1 to the actin cytoskeleton via Ezrin[61]. These interactions
result in a complex and context-dependent role for PAG1 and demonstrate the ability of PAG1 to serve
as a signaling platform with both positive and negative regulatory capacity. A visual representation of
PAG1 interactions, binding partners, and signaling consequences is shown in Figure 2.
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Figure 2: A survey of literature-identified PAG1 interactions and functions
A) PAG links lipid rafts to the actin cytoskeleton. Lipid raft-resident PAG can associate via its C-terminal
PDZ-binding motif with the PDZ domains of scaffold protein EBP50. EBP50 is further linked to actinbinding protein Ezrin. Interestingly, PKA type I is also present in the complex and thus can phosphorylate
Csk (Ser-364) to potentiate its enzymatic activity toward SFKs. B) Mechanisms and consequences of PAG
upregulation in cancer cells. In some cancer cells, PAG is upregulated by unknown mechanisms. At the
plasma membrane, PAG organizes a lipid raft-resident oncogenic signalosome variably composed of Lyn,
Stat3, Syk and PI3K. The signalosome activates multiple signaling cascades and stimulates transcription
of other oncogenes. The Lyn-associated transcription factor Stat3 is activated by phosphorylation and
contributes to cell transformation.
Figure adapted by permission from Springer Nature Customer Service Center GmbH: Springer Nature
Oncogene, from PAG – a multipurpose transmembrane adapter protein, Hrdinka and Horejsi, Oncogene,
2014.
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While many of the known PAG1 partners listed above have been implicated in the pathogenesis
of autoimmunity and lymphoma, to our knowledge, the functional role of PAG1 in DLBCL cells has not
been investigated. However, the identification of PAG1 as a functional biomarker in DLBCL has been
established at both the mRNA and protein level by multiple groups[51–53]. Based on the evidence that
1) PAG1 is differentially regulated throughout B cell development; 2) PAG1 regulates BCR signaling in
both normal and transformed B cell models through modulation of SFK activity; and 3) PAG1 expression
is near-universally silenced in ABC, but not GCB-DLBCL, we hypothesized that PAG1 absence plays a role
in the maintenance of chronic Ag signaling in ABC-DLBCL.
We therefore set out to establish the role of PAG1 in DLBCL cells and characterize the cellular
consequences of PAG1 expression and loss. By establishing the role of PAG1 in DLBCL cells, we aim to
provide fundamental insight into the mechanisms by which tumor cells maintain BCR signaling and
avoid tolerance mechanisms while potentially discovering novel therapeutic targets for the treatment
of DLBCL.
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3.2 - Results
We first used publicly available datasets in the NCBI GEO database[86] to examine the
expression of PAG1 in normal B-Cells (Accession GSE12366[87] and GSE56314[88,89]) and in DLBCL
tumors (Accession GSE10846[38,90] and GSE34171[91,92]) (Figure 3) to confirm lack of PAG1
expression in DLBCL and to determine the normal pattern of PAG1 mRNA expression in human B cell
development. In normal B cells, PAG1 is expressed at low levels in naïve B cells, but at significantly
higher levels during GC development in cenctrocytes and centroblasts and is then downregulated
following exit from the GC in both memory B cells and in plasmablasts (Figure 3A). Although the role of
PAG1 in GC reactions has not been studied in B cells, this dynamic regulation of PAG1 through the
course of entry, cycling, and exit from the GC suggests the regulation of PAG1 expression by GC-specific
transcriptional programs and implies a role in the regulation of BCR and/or costimulatory signaling with
the GC. Additionally, the concordance with expression of PAG1 in GCB, but not ABC, DLBCL (Figure 3B)
aligns the expression of PAG1 with the cell-of-origin theory of lymphomagenesis and allows the
possibility that premature downregulation of PAG1 plays a role in ABC cell survival in the face of chronic
Ag signaling[33].
PAG1 is not expressed in ABC-DLBCL cell lines, but forced expression is toxic
In order to use established cell line models of DLBCL cancer cells, we first confirmed that the
expression of PAG1 in a panel of GCB and ABC DLBCL cell lines aligned with prior reports in primary
tumors and cell lines[51–53]. We examined the expression of PAG1 protein by intracellular staining by
FCM and found that PAG1 was highly and variably expressed in GCB, but not ABC, DLBCL cell lines
(Figure 4).
After establishing the lack of PAG1 expression in ABC cell lines, we forced expression of PAG1 in
both ABC and GCB DLBCL cell lines using sleeping beauty-based transposon vectors[71] for doxycycline
(Dox)-inducible expression of either PAG1 or control protein. We found that forced expression of PAG1
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was toxic to all ABC cell lines tested, with cells experiencing significant reduction in growth relative to
control lines (Figure 5A). Conversely, forced PAG1 expression in GCB cell lines was non-toxic when
expressed at similar levels (Figure 5B). While the selective toxicity of PAG1 expression in DLBCL
subtypes is suggestive of a role in regulation of the BCR and its signaling partners, the extent to which
PAG1 is involved in pathogenesis of DLBCL and in tolerance evasion remained unclear.
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Figure 3: Expression of PAG1 mRNA in normal B cells and DLBCL tumor cells
A) Expression level of PAG1 mRNA in normal B-cell subsets isolated from human tonsils (NCBI GEO
Accession GSE12366 and GSE56314). B) Expression level of PAG1 mRNA from freshly isolated patient
tumors (GEO Accession GSE10846 and GSE34171). All samples used the Affymetrix Human Genome
U133 platform.
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Figure 4: PAG1 expression in DLBCL cell lines
A) Expression of PAG1 in unmodified OCI-Ly7 (left) and TMD8 (right). Histogram of intracellular staining
after incubation with either anti-PAG1 antibody (blue) or isotype control (red) and secondary
incubation with goat anti-mouse (PE-conjugated) antibody and read by FCM. B) Expression of PAG1
protein in DLBCL cell lines, normalized to MFI of isotype control after staining as in A).
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Figure 5: Relative growth of DLBCL cell lines after forced PAG1 expression
Growth of cells expressing either control protein or PAG1 under the control of dox-inducible promoter
in ABC –DLBCL lines (A), or GCB-DLBCL lines (B), relative to growth of uninduced culture. Control protein
used was luciferase for SUDHL-2, HBL-1, HLY-1, OCI-Ly7, & OCI-Ly19; and mCardinal for TMD8, U2932,
& SUDHL-6.
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The effect of PAG1 loss and overexpression in GCB-DLBCL
In light of the finding that PAG1 expression causes immediate toxicity in ABC cells, and the fact
that the role of PAG1 is poorly understood in B cells generally, we elected to begin our exploration of
PAG1 in GCB cell lines, where we sought to establish two primary pieces of evidence: 1) that PAG1
does, in fact, mediate effects on BCR signaling and signal transduction, and 2) what the effect of PAG1
loss is in cells that do not experience chronic Ag stimulation of the BCR. Since GCB cells are thought to
respond to BCR stimulation similarly to normal B cells, express endogenous PAG1 in line with their
healthy germinal center counterparts, and exhibit a characteristic AICD phenotype upon strong BCR
crosslinking[44], we set out to determine what effect PAG1 loss or overexpression would have in GCB
model cell lines, focusing on the impact on overall cell growth and the associated AICD phenotype, as
well as BCR-proximal signaling.
We used a CRISPR/Cas9-mediated knockin/knockout (KI/KO), or “gene trap”, approach to
generate GCB lines with KO of PAG1, using homology directed repair (HDR) to knock-in GFP as a marker
of successful genetic modification. We were therefore able to determine that there was no growth
disadvantage in PAG1 KO vs WT cells (data not shown). This lack of initial phenotype following the loss
of PAG1 was expected, and is in line with data from animal models that showed no clear growth or
development disadvantage in naïve B cells after germline PAG1 KO[58,59]. We next examined whether
the loss of PAG1 in GCB-DLBCL caused a reduction in the strength of BCR-triggered calcium flux and
discovered that loss of PAG1 in the GCB cell line OCI-Ly19 had no effect on calcium flux, while OCI-Ly7
experienced only a moderate reduction in the speed of calcium flux at low-level stimulation, and
SUDHL-6 showed a moderate reduction in both the speed and magnitude of calcium flux in response to
forced BCR crosslinking (Figure 6A). This result was unexpected, as previous work by Davidson et al. in
splenic T-cells showed that increased PAG1 expression reduced TCR-triggered calcium flux through a
Fyn-mediated mechanism[93], and that previously activated T cells from PAG1 KO mice showed
increased calcium flux following TCR stimulation[60]. However, as described above, PAG1 has several
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known protein partners that are involved in both positive and negative regulation of BCR signaling, and
at least one report suggested that the response to antigen receptor stimulation may be reversed in BCR
vs TCR activation[94]. We interpreted the reduction in early-stage signal transduction, measured by
calcium flux, as confirmation that in GCB DLBCL cells PAG1 is likely to function as positive regulator of
early BCR signal transduction in part through the localization of SFKs, notably Lyn and Fyn, as has been
described in other B cell models[54,55].
We also examined the consequence of PAG1 overexpression in GCB cells, now using the
CRISPR/Cas9 mediated HDR method to generate PAG1_GFP fusion proteins under the control of the
endogenous PAG1 promoter to monitor the expression of PAG1 protein by flow cytometry (FCM) in live
cells by fluorescence level (see page 15 for more detail). We further modified these PAG1 3’GFP fusionexpressing cells to express additional PAG1_GFP fusion transcripts under dox-inducible control. Using
the level of GFP expression as a semi-quantitative marker of the amount of PAG1 expressed, we
performed another series of calcium flux assays with BCR stimulation (Figure 6B). These experiments
demonstrated that overexpression of PAG1 decreased both the quantity and speed of calcium flux in
both tested lines (Figure 6B). The dose-dependent decrease in calcium flux with increasing PAG1
expression, taken together with the finding that PAG1 KO also decreased initial calcium flux, albeit to a
lesser extent, suggested that PAG1 does indeed play a dual role as both positive and negative regulator
of BCR signaling, and further suggests that in GCB cells PAG1 function may be reliant on concentration
of endogenous protein partners, such as the SFKs Lyn and Fyn, but also of additional kinases and
scaffold partners, such as Csk. These results suggest a complex and context-dependent role for PAG1 in
regulation of the BCR signaling pathway.
However, the interpretation and applicability of these results to ABC cells is challenging, both
because calcium flux itself is a specific marker of “first wave” signal transduction[95], which is unlikely
to be relevant in the ABC cell model as chronic BCR signaling is altogether dissimilar to the highly
artificial and strong signals generated by BCR crosslinking in these GCB lines, and also because unlike in
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ABC cells, neither PAG1 KO nor PAG1 overexpression were shown to affect the growth or survival of
resting GCB cells (Figure 4). We therefore reasoned that our experimental approach would need to
examine longer-term consequences of BCR stimulation, such as cellular response to chronic Ag
stimulation.
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Figure 6: Effect of PAG1 expression on BCR-stimulated calcium flux in GCB-DLBCL cell lines
A) Calcium flux in response to BCR stimulation in either unmodified or PAG1 KO OCI-Ly19, SUDHL-6,
and OCI-Ly7 cells. BCR cross-linking with anti-IgM F(ab)2 fragments at doses shown or anti-IgG
isotype control at 1.0 µg/mL. B) Calcium flux in response to BCR stimulation in either PAG1 3'GFP
fusion dox-inducible PAG1_GFP expressing OCI-Ly7 or OCI-Ly19 cells. BCR cross-linking with anti-IgM
F(ab)2 fragments at 10µg/mL. Sample was run as mixed culture of PAG1 3'GFP fusion only cells and
PAG1 3'GFP fusion cells transfected with dox-inducible expression of PAG1_GFP fusion after
exposure to dox for 24 hours.. Baseline endogenous expression, as well as intermediate and high
levels of PAG1 expression were gated according to GFP levels (top panels), then the fura red ratio
reflecting calcium flux was plotted as a kinetic moving median for each gated sample (bottom
panels).
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The response to chronic Ag stimulation is a key differentiating quality between GCB and ABC
cell lines, and provides a useful comparison point in the examination of the consequences of BCR
stimulation in each cell-of-origin type. In cell culture models of activation induced cell death (AICD), in
which the BCR is stimulated by anti-BCR antibodies in the absence of additional costimulatory signals,
ABC cells grow normally, while GCB cells and transformed normal lymphoblastoid cell lines are
killed[44,96]. Our hypothesis that PAG1 serves as a regulator of tolerizing signals in B cells, and that its
loss in ABC tumors plays a role in tolerance escape necessarily implies that the loss of PAG1 would
reduce the effect of AICD in GCB cells by eliminating some component of the AICD feedback loop. We
therefore used the GCB cell lines OCI-Ly19 and SUDHL6, which were shown to have differing calcium
flux responses to PAG1 KO (Figure 6), to examine the consequence of PAG1 KO on AICD. In both cell
lines, PAG1 KO reduced cell death after chronic exposure to BCR stimulation (Figure 7). In SUDHL-6
PAG1 KO cells, which showed a reduction in calcium flux, there was a modest and consistent reduction
in cell arrest relative to unmodified cells, consistent with PAG1 serving as a regulator of tolerance and
AICD. In OCI-Ly19, however, unmodified cells experienced significant cell death and growth arrest at
every level of anti-BCR dosing, while PAG1 KO cells grew more rapidly than unstimulated cells at low
doses of anti-BCR. While higher doses of anti-BCR were still toxic to OCI-Ly19 PAG1 KO cells, it is
intriguing that PAG1 KO would allow cells to proliferate under conditions of chronic, low level antigen
stimulation of the BCR, as is seen in ABC cells, and is once again circumstantially suggestive that the loss
of PAG1 may predispose cells to escape anergy or AICD.
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Figure 7: PAG1 KO is moderately protective against AICD in GCB-DLBCL cells
Effect on growth of SUDHL-6 or OCI-Ly19 cells, either unmodified or with PAG1 KI/KO. Cells were cocultured at a 1:1 ratio for 3 days and incubated with indicated concentrations of anti-IgM F(ab)2
fragments, or anti-IgG F(ab)2 isotype control. Cell counts measured by FCM with PAG1 KI/KO cells
identified by GFP+ve gating.
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The effect of forced PAG1 expression in ABC-DLBCL
Extending these findings to ABC DLBCL cell line models, we hypothesized that the forced
expression of PAG1 was detrimental to the growth of ABC DLBCL cells due to the renewal of a negative
regulatory network that could silence or reduce the effect of chronic Ag signaling, thereby starving cells
of their most critical proliferation tool. However, Ag-driven BCR signaling is complex and acts through
several distinct but interconnected pathways[97]. In order to capture the net effect of forced PAG1
expression across several well-known signaling transducers, we used a phosphoflow panel, which we
refer to as “BCRsig”[98–100], with antibodies targeted against the major phosphorylation sites marking
activation of Syk, Btk, BLNK, PLCγ2, Akt, Erk1/2, NFκB p65, and S6, as well as total IκBα and an antibody
targeting activated caspase 3.
HBL-1 cells engineered for dox-inducible expression of either PAG1_BFP (to track expression of
PAG1) or BFP-only control protein were cultured separately with doxycycline for 24 and 48 hours. Cells
were then fixed and stained with the BCRsig panel, and PAG1_BFP vs BFP-only cells were compared by
histogram overlays (Figure 8A). PAG1 expression in HBL-1 cells reduced the phosphorylation of nearly
every marker of active BCR signaling, with dramatic reductions in phosphorylation of both Akt and S6 in
the PI3K signaling axis (Figure 8B). Additionally, the reduction of pNFκB p65, which is a primary driver of
survival and proliferation ABC-DLBCL[33], at 24 hours after expression of PAG1 indicates acute
disruption of chronic Ag-driven signal to which ABC cells are addicted. The BCRsig panel showed only
moderate reduction of the most BCR-proximal SFKs, including Syk and Btk, but shows a significant and
consistent reduction in pBLNK, where BLNK knockdown has been demonstrated to be toxic to ABC
cells[33]. Lastly, significant portion of cells expressing PAG1, but not BFP, stained positive for activated
caspase-3, indicating a PAG1-specific activation of apoptotic mechanisms (Figure 8A&B).

40

41

Figure 8: PAG1 reduces BCR signaling in HBL-1 cells
A) Histogram overlay of intracellular phosphoflow BCRsig panel in HBL-1 cells expressing either
PAG1_BFP (Blue) or BFP-only control (Red) under dox-inducible control after 24 hours. Phosphoflow
marker identified per histogram on the left. B) Change in BCRsig marker staining in PAG1-expressing cells
relative to BFP-only control at either 24 or 48 hours after dox. Percent change was calculated per marker
as: (MFI of PAG1 - MFI of BFP) / (MFI of BFP – MFI Unstained). Percent caspase-3 +ve events determined
by gating.
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However, a central challenge to interpretation of these findings is that the baseline activation
of BCR signaling in ABC cells is difficult to establish given that the magnitude of BCR signaling is submaximal, Ag-driven signaling is constitutive, and there are many mutations which enable ABC cells to
bypass membrane BCR signaling altogether, such as aggregation of the My-T-BCR complex[101], which
is facilitated by mutation of MYD88L265P and CD79BY196, both of which are present in HBL-1 cells, and
have been shown to activate downstream targets such as NFκB independently of surface BCR
ligation[101]. Nonetheless, we have shown that expression of PAG1 is toxic to HBL-1 cells (Figure 5)
which suggests that PAG1 forces silencing of the BCR signaling pathway though activation of negative
regulatory circuits or by qualitatively changing the signal propagation in ABC cells in a way that is
detrimental to the maintenance of pro-survival signaling, a possibility hinted at by the discovery that
the formation of the My-T-BCR complex was disrupted by treatment with the Btk inhibitor ibrutinib and
also by inhibition of the mTOR complex[101]. Though our results did not indicate a reduction in Btk
activity, the apparent reduction in pBLNK, which occupies a similarly proximal role in BCR signal
amplification, paired with the clear reduction in phosphorylation markers of active Akt and S6, which
operate along the mTOR axis, suggest that forced expression of PAG1 in ABC cells can recapitulate the
biological consequences of pharmacological inhibition, though any effect on the formation and
maintenance of the My-T-BCR complex itself remains speculative.
To better understand if and how these results are linked to BCR signaling, we developed a cell
line model with dox-inducible IgM expression so that we could examine the phosphorylation status of
the BCRsig panel after withdrawal of the BCR (Figure 9A). Briefly, these cell lines were generated by first
engineering HBL-1 cells that expressed the Ig heavy chain, IGHM, under dox-inducible control. Then we
used the CRISPR/Cas9 mediated KI/KO method described above to simultaneously eliminate the
endogenous IGHM gene while knocking in a puromycin resistance gene to the endogenous IGHM locus,
thereby eliminating the expression of an Ig heavy chain except by dox-induced expression. Accordingly,
we observed that BCR expression in these cells was both doxycycline-dependent and titratable (Figure
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9B), with dox-withdrawal resulting in a near-complete elimination of surface BCR (as compared to the
Ig-negative T cell line, Jurkat), and full dox-dosing of 200ng/mL expressing levels of BCR comparable to
unmodified HBL-1 cells. We therefore cultured HBL-1 dox-inducible BCR (iBCR) cells in the presence or
absence of doxycycline for four days, then fixed and stained each culture with the BCRsig phosphoflow
panel.
Comparison of phosphorylation between BCR positive and BCR negative HBL-1 cultures
revealed a somewhat paradoxical increase in phosphorylation of Syk in BCR-ve cells, but a decrease in
phosphorylation of ERK1/2, as well as Akt and S6. The increase in Syk phosphorylation was unexpected
in these cells, but could be explained by a reduction in BCR activation below the point required for
negative feedback mechanisms to be triggered, such as those mediated by Lyn-dependent activation of
phosphatases[102]. The moderate reduction in phosphorylation of Akt and S6 are in keeping with
reduction in tonic signaling that accompanies the loss of surface-localized Ig, which our group
previously demonstrated[41]. We also observed a fourfold increase in caspase-3 activation in BCRwithdrawn cells (from 3.3 to 12.6 percent), with caspase-3 activated cells having the lowest residual
amount of surface BCR (Figure 10B), demonstrating the triggering of apoptotic mechanisms in cells with
BCR loss. It was also surprising that the reduction of BCR levels did not correlate to a significant
reduction in pNFκB p65 or IκB. As discussed above, we hypothesized that the critical MYD88L265P and
CD79BY196 mutations in HBL-1 were sufficient to maintain signaling through the NFκB signaling pathway
even with relatively low levels of BCR, most likely located on endosomal signaling platforms as My-TBCR complexes. Though we expected phosphorylation of NFκB p65 to decrease dramatically after doxwithdrawal, this data suggests that even low levels of BCR are sufficient to maintain activation, but cells
at the lowest level of detectable surface BCR do show a concomitant drop in pNFκB p65 (Figure 10B).
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Figure 9: Doxycycline-inducible BCR design and results
A) Diagram showing the workflow and design to generate DLBCL cell lines with doxycycline inducible
BCRs. Image created at Biorender.com B) Histograms showing surface IgM staining in HBL-1 cells
engineered for dox-inducible BCR (iBCR), treated with displayed dose of doxycycline for four days,
alongside staining of the T cell line Jurkat (negative control), and unmodified HBL-1 cells (positive
expression control).
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Figure 10: Consequence of BCR loss on BCR signaling markers
A) Histogram overlay of intracellular phosphoflow BCRsig panel in HBL-1 dox-inducible BCR cells treated
with either 200 ng/mL (red) or 0 ng/mL (blue) doxycycline for 4 days. Phosphoflow marker identified per
histogram on the left. B) Samples as in A, with Y-axis displaying expression of surface IgM identified by
surface staining before fixation and permeabilization to demonstrate the relationship between surface
IgM level and BCR signal marker phosphorylation.
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A comparison of the signaling consequences of BCR withdrawal and forced PAG1 expression in
HBL-1 cells shows striking similarity in the reduction of phosphorylation markers of BCR activation,
which is most observable in the net downstream effects of reduction in Akt and S6 activity and in the
activation of caspase-3. Although circumstantial, when combined with the observed effects of PAG1
loss and overexpression in GCB-DLBCL cell lines, this data aligns with our hypothesis that PAG1-induced
toxicity in ABC lines is related to the regulation of the BCR signaling network. However, these data also
suggest that forced PAG1 expression is not simply reducing the magnitude of baseline chronic signaling
in HBL-1. PAG1 may be playing an active role in fundamentally altering the downstream signaling
consequences of BCR activation, as demonstrated by the fact that PAG1 expression did not affect the
baseline phosphorylation of Syk, a key initiator of BCR signal engagement, but significantly decreased
the phosphorylation of BLNK, which acts slightly downstream of Syk. Compared to BCR withdrawal, in
which Syk phosphorylation was increased absent any changes in the activity of BLNK, it is conceivable
that PAG1 influences the total output of the BCR signaling network in a way that has a net downstream
effect similar to that of BCR elimination, although with some different aspects, and without its precise
mechanism(s) being known.
Modeling the effect of PAG1 without chronic antigen signaling
A critical biological and experimental hurdle to overcome when determining the consequence
of BCR signaling in ABC cells is that the state of chronic Ag stimulation is both a requirement for cell
survival and a parameter that must be altered experimentally to investigate its signaling consequences
within the cell. Adding to the complexity of experimental manipulation of BCR signaling in ABC cells is
the reality that, for most ABC cell lines, the cognate self-Ag recognized by the BCR is either unknown or
is the BCR itself; in the case of the HBL-1 cell line, the endogenous IgH V gene segment of the BCR is
VH4-34[103], which is implicated in self-recognition triggering chronic activation in chronic lymphocytic
leukemia (CLL)[104,105] and recently in ABC-DLBCL[103]. This inherent self-recognition limited our
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ability to dissociate the effects of forced PAG1 expression and BCR signaling in standard ABC-DLBCL cell
lines.
Our lab previously established that ABC cells with BCRs engineered for tetanus toxoid (TTox)reactivity caused growth reduction similar to BCR KO in U2932 cells, which have no lymphomagenic
mutations in CD79B or MYD88, but are PTEN deficient, and may therefore tolerate loss of Ag-driven
signaling by compensatory tonic BCR signaling[41]. Based on these findings, and to better contextualize
the effect of forced PAG1 expression with and without constitutive Ag signaling without complete
elimination of the BCR in an ABC cell line model, we engineered U2932 cells to express a BCR that
recognized ovalbumin (OVA), referred to as U2932-OVA, which would presumably not be stimulated in
standard culture conditions (Figure 11A). We also generated U2932 cells by using the same IGHM KI
technique as in the OVA-BCR model, but instead used KI to express the endogenous U2932 BCR as a
modification control line, referred to as U2932-U2932. Using this model, we were able to maintain
surface BCR levels while eliminating the constitutive Ag signaling that the cell’s endogenous HVRs
provide through recognition of self-antigen.
We observed that replacement of the HVR with OVA-specific recognition sequences in U2932
cells significantly increased the amount of surface BCR relative to endogenous U2932 HVRs, but did not
affect the total Ig present in the cells (Figure 11B). We attribute this to the fact that the endogenous
U2932-BCRs can recognize, bind, and internalize a membrane-bound surface antigen, resulting in
constant recirculation of Ig molecules in which a significant portion of total Ig is internal, while OVA-BCR
cells have no cognate antigen, and therefore remain on the cell surface without internalization.
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Figure 11: OVA-HVR replaced U2932 cells have higher surface BCR levels than endogenous U2932
HVR-expressing cells
A) Model of HVR-replaced U2932 BCR internalization. OVA-HVR U2932 cells (U2932-OVA) cells lack
cognate antigen at the surface of the plasma membrane, and the BCR remains surface localized.
Endogenous U2932-HVR (U2932-U2932) cells express self-antigen at the surface of the plasma
membrane and internalize the BCR after antigen binding. B) Anti-IgM staining of surface BCR (left), or
total Ig after cell fixation and permeabilization.
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Figure 12: PAG1 expression increases surface BCR levels in HVR-replaced U2932 cells regardless of
HVR sequence
Histograms showing anti-IgM staining of surface BCR in U2932 HVR-replaced cell lines (left), and graph
(right) of the median fluorescence intensity (MFI) of BCR staining from the plots on the left.
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We next asked whether the elimination of Ag-driven signaling in U2932 was sufficient to blunt
the effects of forced PAG1 expression in these HVR-replaced cells, and further modified U2932 HVRreplaced cells with dox-inducible expression of PAG1 or mCardinal control and found that forced PAG1
expression was equally toxic in U2932-OVA and U2932-U2932 cell models (not shown). However, we
discovered that after expression of PAG1, the amount of surface BCR in both OVA and U2932 HVRreplaced cells significantly increased (Figure 12). Most striking, however, was the fact that expression of
PAG1 in U2932-U2932 cells eliminated the gap in the level of surface expression between endogenous
and OVA-HVR cells. We interpreted this to mean that PAG1 was functioning to not only halt internal
signaling and signal propagation (Figure 8), but to prevent the internalization of BCR units altogether.
The finding that surface BCR levels were increased in both OVA and endogenous HVR models of
U2932 after expression of PAG1 provides a potential explanation for our earlier results showing that
expression of PAG1 was sufficient to blunt the effects of BCR signaling in HBL-1 cells despite the
presence of mutations known to promote BCR signaling after internalization, notably MYD88L265P and
CD79BY196. If the finding that PAG1 expression reduced receptor internalization in U2932 HVR-replaced
models was also true for otherwise unmodified HBL-1 cells, it would suggest that PAG1 exerts toxicity
by physical restriction of BCR internalization, a role not previously described in the literature.
Indeed, when we examined the consequence of PAG1 expression in HBL-1 cells, we discovered
a significant increase in surface BCR relative to either GFP expression control or a PAG1 control
construct, PAG1_ΔTM, which lacks a transmembrane domain for plasma-membrane localization and is
discussed in detail in Chapter 4 (Figure 13). While we also observed a smaller increase in surface BCR in
the GCB cell line OCI-Ly7 after PAG1 overexpression, the same increase was observed in cells expressing
the PAG1_ ΔTM mutant, which cannot localize to the plasma membrane and was shown to be non-toxic
in ABC-DLBCL cell lines, suggesting that this marginal increase was experimental noise.
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Figure 13: Forced PAG1 expression increases surface BCR levels
Normalized surface staining of the BCR in the GCB line OCI-Ly7 or the ABC line HBL-1 after forced
expression of either GFP, PAG1_WT_GFP, or PAG1_ΔTM_GFP fusion proteins. GFP+ve cells were gated,
and the median fluorescence intensity (MFI) was determined for AF647: anti-IgM. MFI was normalized
per day to the mean MFI of GFP-expressing cells. Samples were cultured in triplicate, and error bars
show mean ± SD.

The consequences of PAG1 expression for Akt activity
In light of the evidence that BCR internalization was altered by the expression of PAG1 in ABC
lines, we were able to re-evaluate the data produced by our BCRsig panel (Figure 8) to hypothesize that
the relative lack of BCR-proximal kinase activity juxtaposed against the strong reduction in downstream
signaling is a consequence of reduced BCR internalization. However, this data created a seeming
paradox in the observed effects of PAG1: we previously showed that Akt activity is highly correlated
with surface BCR levels in GCB cell lines through tonic, not Ag-driven, signaling[41], and yet we observe
in ABC cells that phosphorylation of Akt and S6 are reduced by expression of PAG1 (Figure 8) while the
cells simultaneously increase the level of surface BCR (Figure 12 & Figure 13).
It has been recently demonstrated that ABC cells treated with the Btk inhibitor ibrutinib can
develop resistance to treatment through activation of Akt, which reduces apoptosis through
52

suppression of Caspase-3 activation. However, simultaneous inhibition of Akt overcomes ibrutinib
resistance and triggers caspase-3 mediated apoptotic mechanisms[106]. Our BCRsig panel results point
to inhibition of BCR-proximal SFKs, as well as clear reduction in Akt signaling, along with increased
caspase-3 activation (Figure 8), essentially mimicking the effect of dual Btk and Akt inhibition. However,
our BCRsig panel was tested only at relatively early time points after forced expression of PAG1 (24 and
48 hours), while we see that peak surface expression of the BCR in HBL-1 cells is at approximately four
days (Figure 13). We therefore sought to validate the effect of PAG1 on Akt activity.
Due to the well-documented shortcomings of using phosphorylation as a marker of Akt
activity[107–109], we used a genetically-encoded reporter of Akt kinase activity based on Förster
resonance energy transfer (FRET) which we previously developed to monitor the effect of BCR KO on
Akt activity in GCB cells by FCM[41]. We further developed and adapted the use of this reporter and
technique to examine the consequence of forced PAG1 expression in ABC cell lines, which is described
fully in Chapter 5. Briefly, we expressed a reporter construct, Lyn-AktAR2-EV (LAR-EV “Live”), which
contains variants of cyan fluorescent protein (CFP: Cerulean3) and yellow fluorescent protein (YFP:
cpVenus[E172]) separated by a linker containing an AKT phosphorylation target sequence of FOXO1;
reporter phosphorylation increases its FRET[110]. We also developed an unphosphorylatable version of
the same reporter, Lyn-AktAR2-EV-D (LAR-EV-D “Dead”), to serve as a negative control.
We generated both “Live” and “Dead” reporter-bearing cells in the GCB cell line OCI-Ly7 and
the ABC cell lines HBL-1 and TMD8, then further modified them to express either PAG1 or luciferase
(control protein expression) under dox-inducible control. Analysis of Akt activity by FRET in HBL-1 cells
expressing PAG1 aligned nicely with our previous findings using the BCRsig phosphoflow panel (Figure
8), showing an approximately 40% reduction in Akt activity vs. uninduced cells over four days, while
expression of luciferase control had no effect on Akt activity in any tested line (Figure 14). Similarly, in
TMD8 cells, expression of PAG1 caused an immediate 40-50% drop in Akt activity, confirming that
reduction of Akt is not limited to the signaling landscape of HBL-1 cells (Figure 14). Intriguingly, PAG1
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expression increased Akt activity in the GCB line OCI-Ly7 (Figure 14). Since PAG1 is already expressed in
GCB cells and the fact that forced overexpression of PAG1 was non-toxic to GCB lines, we expected that
Akt activity would be maintained in GCB cells after forced PAG1 overexpression, if only because we and
others have demonstrated that inhibition of Akt is highly toxic to GCB cells[41]. Though we did not
predict an increase in Akt activity following PAG1 expression, there has been some precedent for this
finding in work by Tauzin et al. in work establishing that a Lyn/PAG1 complex increased PI3K activity
and led to greater cell survival[111]. However, the divergent consequence of forced PAG1 expression in
ABC cells and overexpression in GCB cells again points to a complex matrix of context-dependent
functions mediated by PAG1.
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Figure 14: Consequences of forced PAG1 expression on Akt activity
Normalized FRET efficiencies (E) of active (LAR-EV) and inactive (LAR-EV-D) Akt activity reporters in
separate cultures of the ABC cell lines HBL-1 and TMD8, and the GCB cell line OCI-Ly7, also engineered
to express either PAG1 or Luciferase (Luc) under doxycycline-inducible control. Cells expressing either
active or inactive Akt reporters were cultured separately with or without doxycycline (+ Dox or - Dox) for
the times indicated, with samples collected two hours after introduction of dox on day 0, then once per
day afterwards. Calculated E values were normalized across each cell line individually. Samples were
cultured in triplicate and error bars represent Mean ± SD.
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One key difference in the cellular context of the BCR in ABC vs. GCB cells is the localization and
distribution of the BCR itself in the plasma membrane. We have previously demonstrated that ABC cell
lines exhibit spontaneous micro-clustering of the BCR, driven by recognition of cognate self-Ag[33,41],
similar to the clustering seen in normal Ag-stimulated B cells[112], while GCB cells show diffuse
distribution of the BCR along the entirety of the plasma membrane[41]. The presence of BCR clusters in
ABC cells are thought to provide platforms for Ag-driven signaling, and may also be involved in
triggering internalization of the receptor. We hypothesized that if PAG1 disrupts receptor
internalization, it may do so by breaking up spontaneous micro-clusters of BCR units, which could
plausibly be accomplished through PAG1’s role in linking lipid rafts to the cortical cytoskeleton[113–
115], thereby physically segregating BCR units.
To test whether this was the case, we examined HBL-1 cells with dox-inducible expression of
either PAG1_GFP or ΔTM _GFP by confocal microscopy. After staining surface BCR, we observed that
cells expressing the ΔTM mutant showed characteristic microclustering of the BCR[41] (Figure 15),
while cells expressing full-length, membrane-localized PAG1 had markedly less microclustering and a
general diffusion of the BCR (Figure 15). This discovery suggests that PAG1 causes toxicity in ABC cells
because it actively disrupts the distribution of the BCR to prevent constitutive Ag signaling.

56

57

Figure 15: Forced PAG1 expression reduces BCR microclustering in HBL-1 cells
Confocal microscopy of HBL-1 cells expressing either PAG1_WT_GFP (left panels) or PAG1_ΔTM_GFP
(right panels) after dox-induced expression for 24 hours. Images show maximum projection of
accumulated z-stack for entire cell field (~7 µm depth). DyLight 549-conjugated anti-IgM F(ab)’
fragments were used to stain surface IgM and Hoechst 33342 for nuclear staining for 10 minutes on ice,
then washed with cold PBS, resuspended in ProLong Glass Antifade Mountant, then mounted on a glass
coverslip and imaged immediately. BCR units are more diffusely distributed in PAG1_WT expressing cells
(red arrows) vs. PAG1_ΔTM expressing cells (white arrows), with PAG1_WT disrupting surface BCR
microculsters.
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3.3 - Discussion
Our data strongly suggest that PAG1 is involved in regulating the BCR and its signaling partners,
but the extent to which PAG1 is implicated in tolerance evasion and the pathogenesis of lymphoma is
unclear. Our discovery that restoration of PAG1 expression is highly toxic to ABC cell lines is significant,
but underscores the need for deeper insight into the mechanism of PAG1 function in normal and
disease contexts.
We showed that in GCB cell lines, PAG1 overexpression was non-toxic, but did reduce the
intensity and speed of calcium flux after BCR stimulation. We also showed that loss of PAG1 was able to
partly desensitize GCB cells to the effects of AICD. While these results are helpful in establishing that
PAG1 plays a role in modulation of BCR-mediated signaling, the translation of these findings to normal
B cells or even ABC cells is not straightforward. While GCB-DLBCL cells share many BCR-related
phenotypes with their normal precursor B cells, such as the requirement for tonic BCR signaling and
apoptotic response to AICD, these cells may have a significantly different cellular context surrounding
the BCR, as hinted at by the heterogeneity of response to PAG1 KO in three GCB cell lines (Figure 6A).
In ABC cells, we showed that forced expression of PAG1 reduces the activity of many
downstream BCR signal transduction markers and triggers activation of caspase-3, which we believe
indicates that PAG1 exerts toxicity in these cells by reducing the level of chronic BCR signaling below
the threshold required for cell survival[33]. To confirm the plausibility of this interpretation we
engineered HBL-1 cells with doxycycline-dependent expression of the BCR so that we could determine
the signaling consequences of loss of constitutive Ag signaling. We found that the effect on
downstream signal markers after BCR withdrawal was remarkably similar to the effect of forced PAG1
expression, providing circumstantial but highly suggestive evidence of BCR signaling reduction being a
driver of PAG1-induced toxicity.
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In investigating the mechanisms by which this reduction in BCR signaling is accomplished, we
went on to show that PAG1 expression increases surface expression of the BCR, and reduces the
spontaneous surface BCR microculsters associated with the ABC cell type, providing evidence that PAG1
may exert its effects by redistributing the BCR and preventing internalization of the receptor, and
thereby reducing the availability of aggregated or internalized BCR clusters to maintain signaling
platforms required for cell growth.
This phenomenon of PAG1 expression reducing the internalization and clustering of the BCR is
an exciting finding, and one that necessitates further investigation. Plausible mechanisms exist for how
the forced expression of PAG1 could reduce spontaneous clustering and internalization of the BCR, such
as linking of BCR-resident lipid rafts to the cortical actin cytoskeleton via a PAG1-EPB50-Ezrin
complex[116], or by the re-regulation of caveolin-1 dependent BCR interactions[117,118]. The PAG1EPB50-Ezrin interaction is more fully explored in Chapter 4, and remains a plausible candidate for
future research, but the possibility of a PAG1/caveolin-1 interaction that resets the organization of the
BCR is an exciting possibility. Recent work by Minguet et al. showed that disruption of caveolin-1
phosphorylation at Tyr14, previously shown to be regulated by the PAG1/Csk complex[117], was
sufficient to alter the organization of surface BCR and led to break in tolerance and B cell dependent
autoimmunity in mice[118]. Investigation of interplay between PAG1 and caveolin-1 is a critical next
step in the investigation of PAG1-dependent reorganization of BCR distribution.
More broadly, however, PAG1’s status as a relatively promiscuous scaffold protein confounds
the ability to clearly define the interactions responsible for our observed phenotypes. For example, we
observed a marked disruption in Akt signaling after forced expression of PAG1 in both GCB (Akt activity
was increased), and ABC (Akt activity decreased) cells, but establishing the mechanism of these changes
is highly complex. The current model of the role of PAG1 in B cells does not imply that PAG1 itself
exerts direct effects on signaling molecules, but instead facilitates feedback between various kinases
through a combination of enforcing localization and steric configurations that alter SFK functions in
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potentially subtle ways, so more basic research into the behavior of PAG1 and its partners in all B cell
types is necessary.
We also laid the groundwork for future discovery by establishing clear markers of PAG1
function, the most notable of which is the disruption of BCR internalization and clustering in ABC cells,
but also includes the clear reduction in Akt activity, measured by both phosphoflow and FRET, that
accompanies forced expression of PAG1. While both of these findings can be used to screen for
potential partner effector molecules, the use of confocal microscopy for the quantitation of surface
clustering is time consuming and difficult, so we refined the method of detecting kinase activity by FRET
through FCM and further report on the ability to sort single cells on the basis of FRET, as reported in
Chapter 5. This methodology was developed in part to allow for a functional KO screen of PAG1interacting genes, such that we could sort living cells that resist Akt activity reduction after PAG1
expression, using FRET as marker of Akt activity, and thereby narrow the list of potential partners that
mediate toxicity in ABC cells.
However, we reasoned that a more direct way to deal with the problem of isolating multidomain interactions was to modify PAG1 itself to alternately allow or deactivate known functions of
PAG1, thereby reducing the complexity of its scaffold function and limiting the number of potential
effectors in a given experiment. We report the results of this approach in Chapter 4.
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Chapter 4: PAG1 exerts toxicity in ABC-DLBCL through redundant domains

4.1 - Introduction
We demonstrated in Chapter 3 that forced PAG1 expression exerts toxicity in ABC DLBCL cell
lines, reduces the activity of BCR-proximal and downstream signaling markers, upregulates the level of
surface BCR, and disrupts the characteristic microclustering present in ABC cells. However, despite
evidence of impact on BCR signaling, we were not able to show what mechanisms specifically mediated
the effects on signaling, or even the specific cause of PAG1-induced toxicity. Therefore, we set out to
determine the requirements for toxicity after forced expression of PAG1 in ABC cells, beginning with a
survey of known PAG1 interactions.
An introduction to the structure and functions of PAG1 was given in Chapter 3.1, but an
additional review here is warranted.
PAG1 is a transmembrane scaffold protein with a consensus palmitoylation motif (CxxC) for
lipid raft localization immediately following the 16AA transmembrane domain. PAG1 is heavily posttranslationally modified, containing 10 tyrosine residues that, when phosphorylated, create three
separate SH2 binding sites. Additionally, PAG1 contains two distinct proline rich regions that form SH3
binding sites, as well as a PDZ binding motif that links PAG1 to the actin cytoskeleton via Ezrin[61].
Additionally, PAG1 has also been shown to interact directly with caveolin-1 in lipid rafts via a binding
motif in its transmembrane domain.
The best characterized model of PAG1 function concerns its association with Csk, which is a
negative regulator of SFKs. PAG1 localizes Csk to the plasma membrane and promotes Csk enzymatic
activity by inducing a conformational change in Csk[119], and PAG1 overexpression prevents c-Src
transformation through Csk-mediated activity[83]. Work in non-lymphoid cells demonstrated that
activation of Csk in the PAG1/Csk association generates a negative feedback loop after activation of
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SFKs through the phosphorylation of PAG1, which then recruits Csk to the plasma membrane where it
inactivates neighboring SFKs[119]. While a significant amount of research has been done on the role of
the PAG1/Csk complex in T cells, the relevance of that work to understanding PAG1 function in B cells is
unknown, since the phosphorylation of PAG1 after stimulation has been shown to be reversed in one
study: PAG1 in T cells is unphosphorylated at baseline and phosphorylated after activation, whereas
PAG1 in B cells is phosphorylated at baseline and dephosphorylated after activation[94].
However, PAG1 has been shown to interact directly with several other critical proteins, most
notably the SFKs Lyn and Fyn, which bind to multiple SH2 & SH3 binding sites on PAG1[84,120], and
show PAG1-dependent changes in kinase activity following BCR stimulation[85]. Fyn and Lyn are also
inactivated by Csk in PAG1-dependent feedback loops, with one study showing Fyn-dependent
increases in PI3K activity following disruption of PAG1-Csk binding[82], and another showing that PAG1dependent activation of Lyn regulates a negative feedback loop following BCR activation[54]. In
addition to short-term regulation of Lyn though Csk-dependent phosphorylation, PAG1 also serves as a
platform for the ubiquitination and degradation of Lyn through binding to suppressor of cytokine
signaling 1 (SOCS1)[84], which degrades PAG1-bound Lyn in a two-phase regulatory cycle. A diagram
reflecting the structure and known direct protein-protein interactions of PAG1 is shown in Figure 16.
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Figure 16: The structure and known protein interactions of PAG1
Schematic representation of human PAG protein with protein interaction motifs. The known binding
sites for interaction partners of PAG are indicated by vertical lines on the left side of the figure. TM –
transmembrane domain (green); PR1 & PR2 – proline-rich motifs (red); CxxC - palmitoylation motif
(violet); PDZ - PDZ domain-binding motif (blue); Y (with numbers), position of tyrosine residues in PAG
amino acid sequence. Diagram adapted by permission from Springer Nature Customer Service Center
GmbH: Springer Nature Oncogene, from PAG – a multipurpose transmembrane adapter protein, Hrdinka
and Horejsi, Oncogene, 2014.
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Despite facilitating a complex web of interactions between signaling molecules, notably SFKs
and Csk, PAG1 is generally believed to be an inert signaling platform used by other proteins whose
activity is modulated by localization though PAG1. Previous studies have demonstrated that mutation
of specific residues of PAG1 is sufficient to abrogate its interaction with partner proteins and thereby to
modulate and identify functional interactions[54,83,84,120,121]. We hypothesized that a similar
approach would yield insight into which PAG1 partners were critical for mediating toxicity in ABC cell
lines.
Here, we report a systematic effort to dissect the contribution of both PAG1 partner proteins
and the functions of different PAG1 domains in the exertion of toxicity when expressed in ABC cell
lines. We further demonstrate a novel role for the membrane-adjacent domain of PAG1, AA41-103,
which has not previously been attributed any function in lymphocytes.

4.2 - Results
Interactions with Csk, Lyn, and Ezrin are not sufficient to explain PAG1 toxicity in ABC lines
The first, and most plausible, candidate partner protein likely to be a major effector of PAG1induced toxicity in ABC cell lines is the kinase Csk. PAG1 effector function has been largely attributed to
the scaffold function it provides by bringing Csk into proximity of the membrane-associated SFKs. To
determine if the forced expression of PAG1 was toxic by restoring the negative BCR regulatory loop
enforced by Csk, we performed a KO of Csk in HBL-1 cells, hypothesizing that without the negative
regulatory effect of Csk, PAG1 would become functionally inert in ABC cells.
We used the CRISPR/Cas9 mediated KI/KO described above approach to KO Csk, and KI a GFP
cDNA transcript as a marker of successful Csk elimination. GFP+ve Csk KO cells were then sorted by
FCM. To confirm on-target integration of the “gene trap” GFP sequence and confirm homozygous KO,
we used primer sets specific to Csk and GFP, respectively, with genomic PCR to verify elimination of Csk
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and proper genomic placement of GFP (Figure 17A). After verification of homozygous KI/KO, we
determined that HBL-1 Csk KI/KO cells had no change in baseline growth rate relative to unmodified
cells (not shown), as expected.
Csk KI/KO cells were then further engineered to express either PAG1_BFP fusion protein (BFP
fusion was used to track expression of PAG1) or BFP only under dox-inducible control. However, after
expressing PAG1 in Csk KO cells, PAG1 remained fully toxic to HBL1 and U2932 cell lines (not shown).
These results were surprising, since much of the function of PAG1 in B and T cells has been attributed
to the negative regulatory effect that Csk exerts on the entire family of BCR/TCR-adjacent SFKs and
adjacent molecules. In light of these negative results, we hypothesized that the wholesale elimination
of Csk may have been an inaccurate model for testing the role of PAG1 in otherwise unmodified ABC
cells since the binding residues normally occupied by Csk in B cells (Y299 and Y317) can also be bound
by both Lyn and SOCS1[54,84,121], both of which are also responsible for autoregulation of BCR
signaling (Figure 16). We suspected that this alteration in protein sequestration may fundamentally
change the interactions that PAG1 facilitates, thereby causing us to artificially and artifactually miss a
role for Csk in PAG1-mediated ABC toxicity.
To address the concern that complete Csk KO fundamentally altered the binding partners of
PAG1 and therefore may present an inaccurate portrayal of the role of PAG1 in our model, we further
modified HBL-1 Csk KI/KO cells to express a panel of Csk mutants using a constitutively active Sleeping
Beauty vector in a “KO + complementation” approach. Each Csk mutant was designed to have specific
functional consequences on Csk behavior: Csk W47A[122] prevents SH3 binding to PAG1 and reduces
PKA phosphorylation; Csk K222R[123] is catalytically inactive, but retains PAG1/Csk protein-protein
binding capacity of WT Csk; and Csk S364A[124] prevents phosphorylation of PKA, but otherwise
maintains normal function. The expression of these mutants not only allows restoration of the
“normal” Csk-biased scaffold function, but also allows for discrimination of what Csk functions are
critical to its interactions with PAG1. We also included WT Csk and the control protein mCardinal in the
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complementation panel. This new panel of 5 Csk-modified cell lines (1 Csk KO + mCardinal control and 4
Csk KO + Csk WT or mutant) were then additionally engineered to express PAG1 or BFP under doxinducible control as above.
When this Csk complementation panel was evaluated for cell growth, induced BFP expression
control cells showed no meaningful change in growth relative to uninduced lines, but all five Csk variant
lines experienced uniform toxicity that was identical to expression of PAG1 in otherwise unmodified
cells (Figure 17). These surprising results demonstrate that despite the clear evidence in prior literature
for multiple roles of Csk in B and T cells, Csk and its functions are completely dispensable for PAG1induced toxicity in ABC DLBCL.

67

Figure 17: Csk is not a primary driver of PAG1-induced toxicity
A) Genomic PCR of unmodified or Csk KI/KO HBL-1 cells shows complete KI of GFP "gene trap" in
CRISPR/Cas9 modified cells. DNA primer sets recognizing genomic sites on either side of the gRNA
target site for CRISPR/Cas9 for Csk_For targeting Csk Exon 1 & Csk_Rev targeting Csk Exon 2,
respectively; or GFP sequence inserted by homologous recombination (HR) for GFP_For and GFP_Rev.
B) Growth of HBL-1 cells either unmodified or with Csk KO + complementation and dox-inducible
expression of PAG1 or BFP expression control. Each point represents a single replicate and error bars
show mean ± SD. Ind BFP (Control) and ind. PAG1_BFP groups were not significantly different after oneway ANOVA with Brown-Forsythe test. ***P<0.00168
for unpaired two-tailed t-test.

Another potential effector of PAG1-mediated toxicity is the SFK Lyn. Lyn has known roles in
both positive and negative regulation of BCR signaling. In animal models, B cells that lack Lyn are prone
to autoimmunity and cancer[102,125]. In DLBCL cell lines specifically, reduction of Lyn activity has been
observed as a consequence of the ABC DLBCL specific CD79B Y196F mutation[33], and which may
reduce the normal autoregulation of BCR signaling that would occur during chronic BCR signaling.
PAG1 serves as a scaffold protein for Lyn, but whether PAG1 serves primarily as a positive or
negative regulator of Lyn activity is a subject of debate, likely depending in large part on cell type and
cellular context[61,126]. PAG1 facilitates activation of Lyn by providing a suitable SH2-domain binding
motif for active Lyn, where docking to PAG1 locks Lyn in a steric configuration favorable for continued
kinase activity. Simultaneously, PAG1 also plays a role in the negative regulation of Lyn by providing
additional docking motifs for both Csk and SOCS1 (suppressor of cytokine signaling 1), which negatively
regulate Lyn by phosphorylation Lyn Tyr508, and by ubiquitination and proteasomal degradation,
respectively[127,128], with Csk providing short term negative regulation of Lyn on the order of
minutes, after strong Ag-based signaling through the BCR, and SOCS1 likely playing a role in long-term
signal moderation, suggesting that the SOCS1/Lyn interaction may be more relevant in the “low and
slow” chronic Ag signaling model of BCR activation in ABC cells than the Csk/Lyn interaction associated
with acute Ag-receptor crosslinking.
To examine if Lyn activity contributes materially to the observed toxicity of PAG1 forced
expression, and in the absence of clear rationale as to whether a reduction or enhancement of Lyn
activity would be more likely to result in a toxic phenotype, we sought a way to selectively eliminate
Lyn in ABC cells. We identified an engineered fusion protein designed by Whiting et al.[128] which
combines the Lyn-binding SH2 motif of PAG1, Tyr381/Tyr409, with the SB (SOCS box) of SOCS1 to
selectively facilitate the ubiquitination and degradation of Lyn in cells expressing the PAG1/SOCS1_SB
fusion protein, which is additionally fused to GFP to track expression and which we abbreviated as
SOCS_GFP. When expressed under dox-inducible control in the Sleeping Beauty system, we observed
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elimination of Lyn from HBL-1 cells in 24 hours (Figure 18) with no observable effect on the growth rate
of SOCS_GFP-expressing cells vs. unmodified HBL-1 cells (not shown). We then engineered HBL-1 doxinducible SOCS_GFP cells to additionally express either PAG1_mCardinal fusion protein (for tracking
expression of PAG1) or mCardinal alone as expression control, with both additional constructs also
being under dox-inducible control. We observed that concurrent elimination of Lyn had no effect on
the toxicity of PAG1 expression (Figure 18). Based on these findings, we concluded that regardless of
whether the net effect of PAG1 reintroduction was to positively or negatively regulate Lyn, whatever
that effect was, it was insignificant to the mechanism of PAG1-induced toxicity in ABC cells.
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Figure 18: Lyn kinase is not a primary driver of PAG1-induced toxicity
A) Western blot showing the degradation of Lyn kinase after dox-inducible expression of SOCS_GFP
construct in HBL-1 cells. B) Toxicity of forced PAG1 expression is maintained despite degradation of Lyn
kinase. Individual events are from two independent experiments performed in triplicate, with cell
counts measured by FCM on day 5. All counts were normalized to iSOCS + Vector mean cell count
value, and error bars represent mean ± SD.
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Ezrin is another protein implicated as a potential mediator of PAG1 function in B cells. Through
interactions with the C-terminal PDZ binding motif of PAG1, the scaffold protein EBP50 forms a direct
link to Ezrin and the actin cytoskeleton. The role of the Ezrin-EBP50-PAG1 complex has been shown to
have a role in negative regulation of immune synapse formation in T cells by forming a constitutive
physical link between the cortical cytoskeleton and lipid rafts in the plasma membrane[115]. This
physical link, mediated by EPB50, resulted in lower lipid raft motility and reduced diffusion of the raft
marker GM1, implicating the complex in the physical partitioning of immune signaling complexes while
cells are rest. Following strong TCR stimulation, the Ezrin-EBP50-PAG1 complex dissociates, allowing
progression to immune synapse formation[115]. A similar activation-induced decoupling of Ezrin and
lipid-raft fractions was also observed in B cells, with the additional finding that the Ezrin-EBP50-PAG1
complex reassociates by 30 minutes after BCR stimulation[116]. However, based on these reports, is it
unclear whether a) the Ezrin-EBP50-PAG1 complex plays an active or bystander role in signal activation
following BCR stimulation, b) if the association of the complex serves to negatively regulate
spontaneous BCR aggregation and signaling, or c) what role, if any, the complex plays in the context of
chronic Ag signaling in ABC DLBCL.
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Figure 19: Ezrin is not a primary driver of PAG1-induced toxicity
A) Growth of Ezrin KO cells ± dox-induced expression of PAG1 or control protein mCardinal in the HBL-1
and U2932 cell lines. Growth was measured by cell count by FCM in triplicate and all cultures were
normalized to the mean of unmodified cell count after 4 days. Error bars show mean ± SEM. B) Growth
of Ezrin KO + complementation cell lines. Ezrin KO cells as in A) were complemented with either Ezrin
WT or Ezrin K4N mutant constructs expressed constitutively. Growth was reported as in A) after doxinduced expression of PAG1 or control protein mCardinal. Error bars represent mean ± SEM.
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To investigate the role of the Ezrin-EBP50-PAG1 complex in ABC DLBCL toxicity, we performed a
series of KO and complementation experiments designed to isolate the contribution of the complex,
and specifically the Ezrin-mediated linkage of PAG1 to the actin cytoskeleton, to the observed toxicity
of forced PAG1 expression. We first used a “gene trap” KI/KO approach, described above, to KO Ezrin,
using GFP expression to sort KO cells to purity. HBL-1 and U2932 Ezrin KO cells showed a mild growth
advantage relative to unmodified cells (Figure 19A). We next introduced dox-inducible constructs to
Ezrin KO cell lines which expressed either PAG1_mCardinal fusion protein or mCardinal as expression
control. We found that expression of the mCardinal control had no effect on growth of Ezrin KO cells,
but that despite expression of PAG1 in only a fraction of induced cells, there was a marked decline in
cell growth in PAG1-induced cultures in both tested cell lines (Figure 19A), suggesting that PAG1 toxicity
is Ezrin-independent.
However, Ezrin is only one of the two Ezrin/radixin/moesin (ERM) paralogs expressed in B cells.
The redundancy of ERM protein function presents the possibility that complete KO of Ezrin merely
allowed for compensation by EBP-50 binding to moesin[129], which is expressed at lower levels relative
to Ezrin in HBL-1 cells. To reduce this possibility as an alternate mechanism of restored toxicity, we used
a previously described Ezrin construct that is defective in PIP2 binding through the result of four K to N
mutations (K4N) and which has been shown to have defective plasma membrane localization and
activation in lymphocytes, but that can still associate with EBP-50[130–132]. In cells with Ezrin KO that
were engineered for dox-inducible PAG1 or mCardinal expression, discussed above, we expressed
either WT Ezrin or the K4N Ezrin mutant by stable integration of a constitutively expressing sleeping
beauty transposon system. When these Ezrin KO + complementation cells were cultured with
doxycycline, mCardinal-expressing control cells grow at a comparable rate to unmodified cells (Figure
19B). However, once again, cells in which PAG1 was expressed experienced significant toxicity relative
to both unmodified cells and mCardinal control (Figure 19B), solidifying the conclusion that Ezrin is not
a primary driver of the observed PAG1-induced toxicity.
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PKA activity is not affected by forced PAG1 expression
Though we did not see overt reductions in toxicity with Ezrin KO or mutation, we wanted to
evaluate whether the expression of PAG1 caused changes in the activity of protein kinase A (PKA), as
has been reported in T cells[133,134]. In addition to providing a physical link between lipid rafts and the
cytoskeleton, ERM proteins also function as A-kinase anchoring proteins (AKAPs) in B cells, regulating
PKA activity. The link between PKA activity and BCR signaling is poorly understood[135], but significant
to the investigation of the role of PAG1 in ABC cells is that PKA regulates BCR proximal pools of cAMP,
which in turn regulate the phosphorylation of Syk and reduces the activation of PI3K and Akt in DLBCL
cells[136]. We hypothesized that forced expression of PAG1 may restore the localization and activity of
PKA, which, at least in principle, could be responsible for many of the observed effects of forced PAG1
expression in ABC cells discussed above in Chapter 3.
We therefore modulated the design of our genetically-encoded FRET-based reporter of Akt,
discussed above, to instead indicate the status of PKA activity, a process which is fully described in
Chapter 5. Briefly, we replaced the FOXO1 peptide sequence within the Akt reporter with peptides
based on the AKAR2 reporter of PKA activity[137], with either a central Thr residue (active reporter,
LPAR-AKAR-WT), or Val (inactive reporter, LPAR-AKAR-mt), and then validated the ability of the
reporter to correctly report on PKA activity using various pharmacological interventions and after BCR
stimulation (Chapter 5). We then generated HBL-1 cells with stable expression of the PKA reporters and
further modified these cells for dox-inducible expression of PAG1 or luciferase control. When PAG1 was
expressed, we found no significant changes in PKA activity between cells expressing PAG1 and controls
(Figure 20). Together with the lack of toxicity reduction in Ezrin KO, this data strongly suggests that the
PAG1-EBP50-Ezrin/PKA axis is not responsible for the toxicity seen in ABC cells following forced PAG1
expression.
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Figure 20: PAG1 expression does not affect PKA activity
FRET efficiencies (E) of active (LPAR-AKAR-WT) and inactive (LPAR-AKAR-mt) PKA activity reporters in
separate cultures of the ABC cell line HBL-1, also engineered to express either PAG1 or Luciferase (Luc)
under doxycycline-inducible control. Cells expressing either active or inactive PKA reporters were
cultured separately with or without doxycycline (+ Dox or - Dox) for 24 hours. Samples were cultured in
triplicate and error bars represent Mean ± SD.
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Another Approach: Manipulating PAG1
Having identified that three heavily cited drivers of PAG1 function in B cells were not
individually able to account for the effect of PAG1 expression on ABC cell lines, we pivoted to take
advantage of the available understanding of PAG1’s individual domains. We built a library of PAG1
mutants, each designed to alter known PAG1 interactions, functions, and cell localization. For reader
convenience, a complete graphical representation of the design and structure of all mutants discussed
below is included as Figure 26.
Initially, we hypothesized that the failure of our protein-partner KO approach to identify a
critical mediator of PAG1 toxicity (Figure 17-Figure 19) was due to the promiscuity of PAG1 scaffold
function[61]. Since the known critical residues of PAG1 can bind multiple proteins with analogous
function (E.g. Fyn & Lyn, CSK & SOCS1), we reasoned that mutation of the critical binding sites of PAG1
itself would yield greater insight into which domains of PAG1 were critical to its effect in ABC cells.
To corroborate our previous findings, our first panel of PAG1 mutants was designed to test
three known axes of PAG1 function: a) lipid raft localization, b) binding of Lyn & Fyn SFKs, and c)
interaction with Csk. We identified 3 previously described PAG1 mutants shown to alter PAG1
localization and scaffold function: 4M, LAD, and Y3F. Based on precedent, the PAG1_4M mutant should
increase binding affinity for both Lyn and Fyn SFKs[54,83]; the PAG1_LAD mutant replaced cysteine
residues in the palmitoylation motif of PAG1 and should reduce lipid raft localization[138]; and the
PAG1_Y3F mutant should eliminate the ability of Csk and SOCS1 to associate with PAG1[80,120]. We
expressed either full-length WT PAG1 or each of these mutants in three ABC DLBCL cell lines (HBL-1,
TMD8, and U2932), and found that each mutant was equally toxic as the unmodified WT PAG1 (Figure
21), in keeping with our previous findings with protein KO studies (Figure 17-Figure 19). We interpreted
this data to mean that the cause of PAG1-induced toxicity in these cell lines is not limited to the primary
previously described functions of PAG1, and that the mechanism of toxicity may be multi-faceted.
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Figure 21: PAG1 literature-guided mutant panel 1
Growth of ABC-DLBCL cell lines HBL-1, TMD8 and U2932 expressing PAG1_WT or PAG1 mutants 4M,
LAD, or Y3F relative to growth of mCardinal control after 4 days of doxycycline-induced expression.
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To ensure the validity of our mutant expression experiments, we wanted to confirm the
expression level of PAG1 and identified mutants to ensure that the dox-inducible level of expression
was physiologically relevant, so we additionally expressed the WT PAG1_GFP fusion described in
Chapter 3 to monitor the total level of PAG1 in GCB cells and ensure appropriate expression levels.
When expressed in the ABC lines HBL-1 & U2932, we observed that PAG1_WT and PAG1_GFP were
equally toxic (Figure 22), as expected, and that the fluorescence level of PAG1_GFP expression,
measured by FCM, was roughly equivalent to the fluorescence of mCardinal control cells (Figure 21)
given the same dosage of doxycycline. This established that control fluorescent protein expression
could be used as an indicator of gene-of-interest expression level, and further that GFP fusion to PAG1
was irrelevant to function of PAG1 in ABC cells. We therefore fused GFP to many of the PAG1 mutants
described below, as indicated in Figure 26.
We continued our exploration of PAG1 function by developing three new mutants to determine
the role of PAG1 membrane localization and tyrosine phosphorylation. The mutant PAG1_YXF replaces
all ten tyrosine residues in the PAG1 protein with the non-phosphorylatable residue phenylalanine, thus
rendering the protein unable to interact with partners dependent on those phosphorylated residues;
these include Lyn, Fyn, Src, Csk, and SOCS1[61]. We also set out to establish if PAG1-induced toxicity
was indeed dependent on proximity to the plasma membrane, and perhaps the BCR, so we also
designed PAG1_ΔTM & PAG1_103C to eliminate the ability of PAG1 to localize appropriately within the
membrane. PAG1_ΔTM lacks the transmembrane domain and palmitoylation motif portion of the
protein (deletion of AA1-40), and PAG1_103C reflects a deletion of AA 1-103. When expressed in HBL-1
and U2932 cells, we discovered that PAG1_YXF was equally toxic as PAG1_WT, but that both
PAG1_103C and PAG1_ΔTM were non-toxic in both cell lines (Figure 22).
The toxicity of the PAG1_YXF is notable, as this implies that a critical function of PAG1 in our
ABC DLBCL model is completely independent of tyrosine phosphorylation at any residue. This
represents a significant departure from the currently understood model of nearly all primary PAG1
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functions[61]. By the same token, the clear toxicity of the PAG1_YXF establishes that each of the known
tyrosine phosphorylation dependent protein interactions are dispensable for toxicity. Conversely, the
complete lack of growth arrest in ΔTM and 103C mutants establishes two important facts regarding the
mechanism of PAG1-induced growth arrest: 1) expression of PAG1 is not toxic simply by inducing a
dilution of protein partners, since both PAG1_ΔTM & PAG1_103C retain the ability to bind partners in
the cell, and thereby can serve to eliminate their function at the membrane, and most importantly 2)
the PAG1-dependent growth phenotype is reliant on localization to the plasma membrane. Taken
together, these results suggest that PAG1-induced toxicity is dependent on protein interactions and/or
signaling events taking place specifically at the plasma membrane, and that the specific mechanism of
toxicity is not dependent on PAG1 phosphorylation or phosphorylation-dependent protein-protein
interactions.
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Figure 22: PAG1 literature-guided mutant panel 2
Growth of ABC-DLBCL cell lines HBL-1 and U2932 expressing PAG1_WT or PAG1_GFP or PAG1 mutants
103C, ΔTM, or YXF relative to growth of luciferase control after 4 days of doxycycline-induced
expression.
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In order to determine which domain or domains of PAG1 were responsible for phosphorylationindependent toxicity, we built an additional mutant panel to isolate which domains were dispensable
for replicating the toxicity of full-length PAG1 in the ABC line HBL-1. We built a panel of PAG1 mutants
that sequentially deleted domains of PAG1 from the N to C terminus of the protein, the structures of
which are shown in Figure 26, and tested each for toxicity in HBL-1 cells (Figure 23). The most notable
finding from this panel is that PAG1-dependent toxicity must necessarily be caused through multiple,
independent domains, demonstrated by observation of full toxicity in every domain-deletion mutant
except for PAG1_N40, which expresses only the transmembrane domain with its palmitoylation motif.
By itself, the non-toxicity of the N40 mutant eliminated the possibility that the observed toxicity was an
artifactual effect of membrane flooding, since the PAG1_N40 mutant was expressed at a higher level
than other mutants, as evaluated by GFP fluorescence level (data not shown). However, the discovery
that the PAG1_N103 mutant containing only the transmembrane domain and membrane-adjacent
domain (MAD - AA41-103) was fully toxic was surprising because, to our knowledge, no prior study has
identified a functional role for this domain in immune cells. However, a single report by Veracini et al.
conducted in 293T cells suggested that a PAG1 truncation mutant expressing only the first 97 amino
acids was able to reduce platelet-derived growth factor receptor (PDGFR) activation and mitogenesis
through upregulation of ganglioside GM1[139]. However, we were not able to confirm evidence of this
mechanism in ABC cell lines (not shown), and the relevance of this model to B cell physiology and
signaling is unclear. More confounding was the result that the mutant Δ40-103, which deleted the
PAG1 MAD (AA40-103) while maintaining all other protein domains, was also fully toxic.
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Figure 23: PAG1 Domain Deletion Panel
Growth of ABC-DLBCL cell line HBL-1 expressing PAG1_WT or PAG1 mutants after 4 days of
doxycycline-induced expression relative to uninduced cells. Samples displaying error bars represent
samples collected in at least triplicate, with error bars showing mean ± SEM. Samples with no error bars
reflect single experimental data point. All samples with error bars were additionally fused to GFP for
expression monitoring and localization verification.

83

The duplication of toxicity by multiple domains posed a unique challenge for further
investigation: if multiple domains can independently trigger toxicity, it is impossible to determine the
effect of one domain while the others are present. Because of this unexpected dilemma, we chose to
focus our efforts on the investigation of the novel MAD domain of PAG1. We developed another series
of mutants to explore the membrane localization requirements of this novel domain, and to confirm
redundant toxicity of the remainder of the PAG1 protein, using GFP fusion to monitor both expression
level and to verify the expected cellular localization by fluorescence microscopy.
We confirmed that the C-terminal body of PAG1 (AA103-432) was toxic to ABC cells
independent of the PAG1 transmembrane and membrane-adjacent domain by expressing only AA103432 with localization to the plasma membrane by Lyn tag (Lyn_103C), which functions as a membrane
recruitment motif and lipid-raft anchor. We were thereby able to eliminate any contribution to toxicity
mediated by the PAG1 transmembrane domain and found that the Lyn_103C was indeed still as toxic as
expression of full length WT PAG1 (Figure 24).
To further investigate the lipid raft localization requirement for toxicity of the MAD domain, we
also replaced the TM domain of PAG1 (AA1-39) with the membrane localization motif of Lyn (Lyn_40103), which also resulted in full toxicity. However, replacement of the TM domain with the extracellular
and TM domains of mouse CD8a (mCD8a), which is not raft-localized[140], rendered the PAG1 MAD
domain completely non-toxic (Figure 24). While we were not able to replicate the findings of Veracini et
al. regarding the mechanism of action of the N103 mutant, their report also indicated that elimination
of lipid raft localization by elimination of the PAG1 palmitoylation motif eliminated the function of the
truncated protein in their model[139], which circumstantially reinforces our observation that raft
localization is critical for function of the N103 mutant. Finally, we suspected that evolutionarily
conserved serine residues in present in the AA40-103 domain of PAG1 may function to recruit serine
kinases and therefore play a functional role in domain toxicity, but observed that the mutation of the
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four phosphorylatable serine residues to alanine (N103_S4A) did not result in rescue of HBL-1 cells
(Figure 24). These results suggest that the novel MAD domain exerts its toxic effect through a specific
interaction with lipid raft proximal proteins, and that the specificity of those interactions is dependent
upon raft localization.
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Figure 24: PAG1 membrane-adjacent domain (MAD) Panel
Growth of ABC-DLBCL cell line HBL-1 expressing PAG1_WT or PAG1 mutants after 4 days of
doxycycline-induced expression relative to uninduced cells. Samples displaying error bars represent
samples collected in at least triplicate, with error bars showing mean ± SEM. All expressed proteins
were fused to GFP for verification of expression level and localization.
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With the discovery that the MAD domain of PAG1 is rendered non-toxic to ABC cells if not
properly localized to lipid rafts, we constructed a final panel of full-length PAG1 mutants to determine if
the remainder of PAG1 shared the same localization-based specificity of toxicity. For this purpose, we
replaced the transmembrane domain of PAG1 with each of several alternate membrane localization
domains or motifs derived from other proteins. We chose Lyn, SHP-1, and KRAS tags for localization to
membrane rafts, with the KRAS and SHP-1 tags being used to determine the orientation requirement of
PAG1, since both the KRAS and SHP-1 tags are C-terminal membrane localization motifs which localize
PAG1 to the membrane in the opposite orientation relative to normal localization[141].
Additionally, we explored replacement of the full PAG1 TM domain with the TM domains of
either mCD8a, LAT2, or CD71Y20H. As described above, the TMD of mCD8a is not raft localized, and
therefore can be used to evaluate the requirement for the entire full-length intracellular portion of
PAG1 to be raft localized for proper function[140]. We also used the first 100 AA of the non-raft
localized transferrin receptor 1 (TfR1), or CD71, modified with a mutation that eliminates activation and
internalization, Y20H[142,143]. LAT2 (linker for activation of T cells 2) is a transmembrane adapter
protein (TRAP) in the same family as PAG1, with potentially overlapping function and similar membrane
localization[144] and is used as a positive TM-replacement control.
When these mutants were expressed in HBL-1 cells, replacement of the PAG1 TMD with other
membrane-localizing protein domains was largely irrelevant to PAG1-induced toxicity. As expected, the
LAT2 TMD mutant was fully toxic (Figure 25). However, in contrast to the clear rescue of non-raft
localization of the MAD domain of PAG1 (Figure 24), the full length protein remained fully toxic even
while excluded from lipid rafts, as in the mCD8a, and CD71 variants (Figure 25). This restoration of
toxicity while expressing the remaining domains of PAG1 demonstrates further evidence of redundant
mechanisms of toxicity between multiple protein domains. Additionally, the full intracellular portion of
the protein was fully toxic when localized by Lyn- and KRAS-tags (Figure 25) despite the lack of full
transmembrane insertion or even correct orientation relative to the membrane in the case of the KRAS87

tagged mutant, though the relative lack of toxicity in the SHP-1 TM mutant was curious in that its lack
of toxicity contradicts those of the KRAS mutant. We concluded that this reduction in toxicity was likely
due to problems with the expression or stability of this particular construct, since expression measured
by GFP fluorescence (tagged at the 5’end) was much lower than that of the other mutants in this panel,
and visual observation by fluorescence microscopy showed some diffusion of GFP throughout the
cytoplasm, as opposed to clear membrane localization with Lyn- and KRAS-tagged mutants (not shown).
Taken together, these data assert that the toxicity of forced PAG1 expression in ABC DLBCL cells
can be characterized in three ways: 1) multiple non-redundant domains of PAG1 can each generate
toxicity independently, and by different mechanisms; 2) plasma membrane localization is key to all
effects of PAG1, and at least for PAG1 AA40-103 domain, lipid raft localization is additionally required;
and 3) the current models of PAG1 activity and function are not sufficient to fully explain the
phenotypic effect on growth, specifically noting the apparent, and lipid-raft specific activity of the novel
MAD domain.
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Relative Growth of PAG1 Mutants in HBL-1 Cells:
Transmembrane Replacement Panel
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Figure 25: PAG1 TM replacement panel
Growth of ABC-DLBCL cell line HBL-1 expressing PAG1_WT or PAG1 mutants after 4 days of
doxycycline-induced expression relative to uninduced cells. Samples displaying error bars represent
samples collected in at least triplicate, with error bars showing mean ± SEM. All expressed proteins
were fused to GFP for verification of expression level and localization.
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Figure 26: PAG1 Mutant Guide
Diagrams of PAG1 structural mutations for each used mutant, organized by toxicity to ABC-DLBCL cells
and further by structural mutation. Original PAG1_WT diagram shown as Figure 16 and adapted by
permission from Spring er Nature Customer Service Center GmbH: Springer Nature Oncogene, from
PAG – a multipurpose transmembrane adapter protein, Hrdinka and Horejsi, Oncogene, 2014.
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Another approach: Biotin Ligase assays
In light of the confounding discovery that the known interactions and functions of PAG1 would
be insufficient to fully explain the toxicity phenotype in ABC cells, we used a proximity biotin ligase
assay using TurboID[145] and a custom-designed Split TurboID to examine the PAG1-proximal proteins
in an unbiased discovery screen. TurboID is an engineered biotin ligase which converts biotin into
biotin-AMP, a reactive molecule which then covalently labels adjacent proteins. However, our
preliminary data (not shown) suggested that TurboID was highly active and was able to biotinylate
proteins immediately after translation in the ER and throughout transit to the plasma membrane (in the
case of PAG1). Therefore, we additionally developed a separate, Split TurboID system, in which we
adapted the design of a split BioID concept developed by De Munter et al.[146] to TurboID and paired it
with a drug-inducible dimerization system developed by Miyamoto et al.[147], which uses a gibberellin
analog (GA3-AM) to facilitate dimerization, to allow greater control over the timing and localization of
biotinylation. By requiring drug-induced assembly of two separate proteins before enzymatic function is
possible, we reduced the potential for biotinylation of proteins not associated with the functional
location of the bait – PAG1.
We expressed fusion proteins linking either PAG1 or mCardinal control to either TurboID or
split-TurboID in a dox-inducible vector. After expression of PAG1 or mCardinal, we treated cells with
biotin or biotin plus GA3-AM to activate TurboID and split-TurboID, respectively, prepared protein
lysates from each sample and purified biotinylated proteins from each lysate and performed
quantitative mass spectrometry. We then compared the enrichment of each identified protein as a log2
ratio of PAG1/control vs. the log2 sum of PAG1 + control (Figure 27).
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Figure 27: PAG1 + TurboID and split-TurboID biotin ligase assay
Results of quantitative mass spectrometry analysis of samples prepared from A) Split TurboID and B)
TurboID assays using PAG1 or mCardinal (irrelevant protein control) as bait. Selected proteins shown in
red. All other proteins identified targets shown as blue.

Both the TurboID and split-TurboID screens identified PAG1 as the highest-enriched protein, as
expected, and also identified known PAG1 binding partners, such as Csk, Lyn, Src, and Ezrin as being
highly enriched in PAG1-expressing cells, implying proper performance of the assay. However, the
degree of separation of potential proteins of interest was unsatisfactory, and in the context of the
previous findings of overlapping toxic domains and lack of reduction in toxicity following KO of major
PAG1 partners identified in this screen, we were unable to isolate a plausible protein partner to
continue individual protein KO experiments. However, the agreement between the enrichment
patterns of captured proteins (PAG1, Csk, Lyn, moesin and Btk are aligned quite similarly in both
TurboID and Split TurboID analysis) suggests that this assay may be accurately portraying the breadth of
PAG1 interactions. It is clear from the literature and the research presented here that many partner
proteins and interactions contribute to the role of PAG1 toxicity in ABC cells, and it may simply be that
PAG1 does not have a single binding partner, but instead has many, which is reflected in the relative
lack of highly enriched targets. Thus, it is likely that this strategy may be more likely to yield results
when paired with the MAD domain constructs, such as PAG1_N103, which are likely to have a more
restricted set of partners and increased novelty of discovery.
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4.3 - Discussion
The discovery that forced expression of PAG1 exerts a toxic effect on ABC DLBCL cell lines
suggests the possibility of a previously underutilized molecular pathway that could be therapeutic in
the treatment of DLBCL.
Because much of the previously reported roles of PAG1 rely on the function of a few protein
partners, we investigated the role of the known primary effectors of PAG1: Csk, Lyn, and Ezrin. We
found that the toxic phenotype following forced PAG1 in ABC lines was not solely dependent on the
modulation of the activity of these individual proteins alone, as demonstrated through KO and mutant
complementation studies (Figure 17 - Figure 19). Though our panel of tested KO genes was by no
means exhaustive, we corroborated our findings in PAG1 mutant expression experiments,
demonstrating that mutation or elimination of the putative binding residues for each of these three
known targets was insufficient to rescue ABC cells from PAG1-induced toxicity.
Using an extensive panel of PAG1 mutants, we also established that toxicity in ABC cells can be
induced independently by multiple domains of PAG1. The most notable of these is a novel membraneadjacent domain (MAD) of PAG1 (AA41-103), which we demonstrated is completely sufficient to exert
toxic effect on ABC cells, but only when localized to lipid rafts (Figure 24). This localization-dependent
effect suggests that the MAD domain of PAG1 plays a direct role in raft-based protein interactions or
signaling dynamics, and that the disruption of the steady-state of raft-localized proteins is one potential
mechanism of PAG1-induced toxicity. Additionally, we showed that the MAD domain was not
exclusively responsible for PAG1 toxicity by demonstrating that membrane-localized PAG1 mutants
were fully toxic after deletion of AA41-103, and without direct localization to lipid rafts (Figure 25).
A critical question that remains unanswered by these findings is whether the expression of
PAG1 is directly related to modulation of the BCR signaling pathway, as we hypothesized. Though the
circumstantial evidence that lipid raft localization was required for toxicity of the MAD domain of PAG1
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is certainly suggestive of a disruption of generally raft-localized BCR signaling platforms, and the
duplication of toxicity by domains of PAG1 that selectively recruit SFKs involved in regulation of BCR
signaling is promising, no conclusive link to BCR signaling is established here. However, the finding that
PAG1 possesses multiple, independently-acting domains which are deleterious to ABC cells raises
multiple questions about the nature of PAG1-facilitated interactions in ABC lines, and perhaps more
interesting, hints at the underlying biological cause for the complete silencing of PAG1 expression,
rather than simple mutation, in ABC-DLBCL, and enriches the case for further study into the mechanism
of toxicity in ABC cells.
However, the presumed independent action of each PAG1 domain poses unique challenges to
experimental design. The discovery that AA40-103 of PAG1 is sufficient to fully induce toxicity in ABC
cells necessitates a reevaluation of our studies using KO of Csk, Lyn, and Ezrin, since toxicity caused by
the AA40-103 domain may have obfuscated the effect of these knockouts, and indeed, these proteins
may play a significant role in the toxicity caused by expression of the PAG1_Lyn_103 mutant. The
therefore compromised nature of these experiments necessitates further experimentation which would
further separate the domains of PAG1 to determine the specific molecular requirements unique to the
toxicity of each domain and its protein partners.
Another critical limitation of the studies detailed above is that despite the consistently
demonstrated replication of the PAG1-induced growth phenotype, several critical caveats should be
declared in interpretation of the data. First, while the system used for expression of PAG1, the doxinducible Sleeping Beauty transposon system[71], was desirable for the ability to stably integrate
constructs expressing genes of interest (GOI) in pure cultures and maintain control over expression, it
was also necessary to closely monitor expression of the GOIs by the use of a GFP tag since the vector
showed higher expression of shorter vs. longer transcripts. While we were able to maintain consistent
expression control by successive dox titration quality control experiments (not shown), it is possible
that better control of gene expression could lead to a more nuanced understanding of the
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contributions of each PAG1 domain to the overall effect in ABC cell lines. As demonstrated in GCB lines
(Figure 6), the net effect of PAG1 expression may be highly dependent on titration of context-specific
complexes, which we are currently unable to fully evaluate.
Finally, the most obvious limitation of these assays is the crudeness of the experimental
readout: toxicity. While measuring the gross effect of PAG1 expression by simple growth phenotype is a
valid readout, especially since the desired consequence of any attempted therapeutic intervention in
cancer is cell death, simply cataloging the growth disadvantage provides little insight into how or why
the cells experience their growth arrest and death and thus has only limited usefulness. As detailed
above, this limitation is brought into stark relief when considering the consequences of multi-domain
toxicity and the impotence of these assays to explain the behavior of particular mutants.
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Chapter 5: Development of Akt and PKA FRET-based kinase activity reporters

This chapter is based on a paper submitted for publication to Cytometry: Part A:
Jared Henderson, Ondrej Havranek, Man Chun John Ma, Vaclav Herman, Kristyna Kupcova, Tereza
Chrbolkova, Mariana Pacheco-Blanco, Zhiqiang Wang, Justin M. Comer, Tomasz Zal, and R. Eric Davis,
Detecting FRET in living cells by conventional or spectral flow cytometry. Cytometry A.

5.1 - Introduction
A particularly challenging issue in B cell biology, and especially in the biology of B cell
lymphomas, is the lack of tools for precisely evaluating the activity of key signaling pathways.
Commonly used methods such as detection of phosphorylation by western blot or phosphoflow by FCM
rely on detection of specific residues on specific proteins by antibodies in a highly artificial setting,
usually after fixation and permeabilization or lysing of the cell. While these techniques are both valid
and widely used, one of the major drawbacks to their use is that phosphorylation of residues on target
kinases is not always a reliable indicator of protein activity and function[107–109]. Further, the
particular method by which biological activity is halted prior to preparation of the assay, by
temperature change, chemical fixation, etc., may have unknown consequences, such as disparate
activity rates of kinases and phosphatases at varying temperatures and pH, which can generate
spurious results. Perhaps more importantly, these methods are poorly quantitative, subject to a great
deal of experimental noise, and can be unreliable when changes in the activity of probed molecules is
subtle. To overcome some of these challenges, our lab previously used a genetically-encoded reporter
of Akt kinase activity based on Förster resonance energy transfer (FRET) by FCM, which we developed
further in the pursuit of better understanding the role of PAG1 in DLBCL cells.
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Detecting FRET in living cells by conventional or spectral cytometry
Förster resonance energy transfer (FRET) between fluorophores depends on several factors, the
most dynamic of which is their proximity. This property is the basis for the many assays in which FRET
provides the readout for a molecular or biological phenomenon[148,149], FRET-based assays have
many attractive features, but their utility in practice depends on the ease and accuracy with which FRET
can be measured. FRET affects the lifetime and polarization of fluorescence emission, but its effect on
intensity is the basis by which FRET is most commonly measured. Fluorescence microscopy has been
used most extensively to measure FRET in cells, with the advantages of providing subcellular
localization and enabling the use of photobleaching. However, microscopy has relatively low
throughput regarding the number of cells or samples that can be assessed, and its requirement for cells
to be immobilized (or nearly so) prevents certain potential applications of FRET assays in cells.
Conventional flow cytometry (FCM) provides an alternative approach for detecting
FRET in cells. FCM measures per-cell fluorescence emission from thousands of cells per second, in a
limited number of wavelength ranges set by filters. With a laser that largely excites the donor
fluorophore but not the acceptor, FRET causes a relative reduction in the donor’s characteristic
fluorescence emission range (donor quenching), accompanied by increased emission attributable to the
acceptor (acceptor sensitization). FCM can easily compare the intensity of acceptor-range emission (IDA)
to donor-range emission (IDD) per cell in real time after donor excitation, graphically or by a “FRET ratio”
(IDA/IDD). However, this measure of FRET suffers from a limited dynamic range[150] and nonlinearity[151], is affected by the abundance of the acceptor, and varies with other factors that make it
“instrument-dependent”.
FRET efficiency (E) is an intensity-based measure of FRET that is instrument-independent. As
first reported by Zal et al.[76] for microscopy, the “3-cube method” calculates E from IDD, IDA, and the
intensity of acceptor-range emission after acceptor excitation (IAA). These intensities are subject to
bleedthrough (cross-talk), so corrective approaches have been reported that provide reliable
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determinations of E from FCM measurements[74,152]; more elaborate correction procedures have
recently been reported[153,154]. However, these approaches are not sufficient to allow the use of
additional fluorophores, and calculation of E is only done after data have been acquired, limiting realtime assessment of FRET by FCM to use of the FRET ratio.
“Spectral” techniques measure fluorescence emission in far more than 3 channels (wavelength
ranges), creating a “spectral fingerprint” that is characteristic of each fluorophore. When multiple
fluorophores are present simultaneously, spectral “unmixing” algorithms can use these fingerprints to
determine the contribution of each fluorophore to the total fluorescence, and thus their abundance.
Spectral microscopy has been used for intensity-based determination of FRET[155–158], but through
post-acquisition data analysis. Spectral flow cytometry (SFCM) has become popular in recent years for
the advantages that it provides in sensitivity and the simultaneous use of multiple
fluorophores[159,160], but the detection of FRET by SFCM has not previously been reported.
Among genetically-encoded biosensors based on FRET[161], those that report on the enzymatic
activity of protein kinases are widely used and offer several advantages[162,163]. We further optimize
the AKT activity reporter, and demonstration of its use with FCM for time-course, dose-response, and
kinetic studies. We also show the flexibility of the assay, by changing the reporter’s target peptide to be
specific for protein kinase A. Finally, we show that SFCM can detect changes in the reporter’s spectral
fingerprint, by unmixing based on the spectral fingerprints of low-FRET and high-FRET controls, to
provide real-time graphical assessment of FRET.

5.2 - Results
Features of the Akt activity reporter construct
Protein kinases are critical mediators of many biological processes, and are therefore the
subject of extensive research efforts in cell signaling and drug development. Many genetically-encoded
reporters of protein kinase activity rely on FRET to reflect the phosphorylation state of a kinase target
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peptide domain in the reporter[162,163]. Reporter FRET is generated by two fluorescent domains in
the reporter, one serving as donor and the other as acceptor; its magnitude depends on the relative
proximity and orientation of these fluorophores, which in turn are affected by phosphorylation of a
target peptide and its recognition by a phosphoamino acid binding domain.
AKT, also known as protein kinase B, refers to three highly homologous serine/threonine
kinases that are conserved in mammalian genomes and affect many aspects of cell biology, especially in
cancer[164]. AktAR2[110,165] (Figure 28A) is a cell-based reporter of AKT kinase activity, originally
applied in fluorescence microscopy[107]. The reporter’s donor and acceptor fluorophores are
respectively Cerulean3 (C3), a cyan variant of green fluorescent protein (GFP), and cpVenus E172 (cpV),
a circularly-permuted yellow GFP variant. These are connected by a linker containing a target peptide
(residues flanking Thr24 in the AKT substrate FOXO1) and the FHA1 phospho-amino acid binding
domain (from yeast RAD53)[137]. When the target Thr is phosphorylated by AKT, binding by FHA1
alters reporter conformation and brings the fluorophores closer together and/or into more FRETfavorable orientation. Since FRET efficiency (E) is increased by proximity, E of AktAR2 is an indicator of
the degree of reporter phosphorylation, which reflects the level of AKT kinase activity.
In classical AKT activation, phosphatidylinositol (3,4,5)-trisphosphate (PIP3) generated
by phosphatidylinositol 3-kinase (PI3K) isoforms binds to AKT proteins and causes their translocation to
the plasma membrane, where they undergo activating phosphorylations at Ser473 (by the mTORC2
complex) and Thr308 (by PDPK1)[164]. Since PIP3 has additional positive allosteric effects on AKT and is
predominantly membrane-localized, AKT is principally active at membranes[166]. Therefore, we
modified AktAR2 by adding the 10 N-terminal amino acids from mouse Lyn kinase (“Lyn”) to the Nterminus of AktAR2 (Figure 28B), as done previously[165] to localize AktAR2 to lipid rafts. In multiple
cell lines representing the germinal center subtype of diffuse large B-cell lymphoma (GCB-DLBCL),
expression of Akt-AR2 and Lyn-AktAR2 produced fluorescence attributable to C3 and cpV, exclusively in
either the cytoplasm or plasma membrane respectively, as expected[41]. In GCB-DLBCL lines, “tonic”
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(antigen-independent) signaling by the B-cell receptor (BCR) contributes to activation of AKT, through
PI3K and the tyrosine kinase SYK. By confocal microscopy-based measurement, E in two GCB-DLBCL
lines was higher with membrane-targeted Lyn-AktAR2, and was lowered more in response to knockout
(KO) of the BCR (Figure 29). Therefore, Lyn-tagged forms of AktAR2 were used for all subsequent
experiments.
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Figure 28: AktAR2-based AKT activity reporters and control constructs
A) Principle of the AktAR2 reporter. Phosphorylation of threonine (T) in a peptide domain based on a
known AKT target (flanking T24 of FOXO1) leads to its binding by the FHA1 domain of the reporter; this
brings donor (Cerulean3) and acceptor (cpVenus[E172]) fluorophores of the reporter into greater
proximity, and increases the Förster resonance energy transfer (FRET) signal between them when
illuminated. B) Schematic diagrams of AktAR2-based AKT kinase activity reporters used in this study, and
fluorescent control constructs used for calibration of FRET determination.
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Figure 29: Technical aspects of AKT activity detection by FRET
Used by permission from Ondrej Havranek, who generated the data shown. A) Detection of FRET
efficiency (E) of Akt-AR2 reporters by fluorescence microscopy in two GCB-DLBCL lines. E is reduced by
B-cell receptor (BCR) elimination (via IGHM knockout, KO) to a small degree, but more with the Lyntagged reporter. Error bars represent mean and SD. * p < 0.05, *** p < 0.001, **** p < 0.0001 (twotailed unpaired t test). B) High precision (reproducibility) of E from low-FRET and high-FRET controls in
OCI-Ly7 cells, measured by flow cytometry (FCM) on 10 different days on two different flow cytometers
with different detection filters and PMT settings. For the high-FRET control, ECV = 1.9%; for the lowFRET control, ECV = 16.4%. Error bars represent mean and SD. C) Difference between FCM-measured E
values for “live” (active) and “dead” (inactive, non-phosphorylatable) forms of AktAR2 reporters in
DLBCL lines, either containing the Lyn tag alone or with the Lyn tag and flexible linker (EV). A greater
difference between active and inactive reporters is seen for the EV-containing reporters, especially
from a relative standpoint. The mean absolute difference in E between active and inactive reporters is
9.5% for the EV versions and 2.9% for the non-EV versions. Error bars represent mean and SD. *** p <
0.001 (two tailed unpaired t test) D) Effect of BCR KO on FCM-measured E values for active forms of
AktAR2 reporters in the GCB-DLBCL line SUDHL-6. A greater difference is seen with the EV-containing
reporter. Values for one control and the mean of three replicates of BCR KO are displayed. Error bars
represent SD. E) Relative proportion over time of SUDHL-4 cells with the active Lyn-tagged, EVcontaining reporter, in mixed culture with unmodified SUDHL-4 cells. There is no significant change,
suggesting that the reporter does not affect overall AKT activity. Mean values of three replicates are
displayed. Error bars represent SD.
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Measuring reporter FRET by conventional flow cytometry (FCM)
Assessed by fluorescence microscopy, E from the Lyn-AktAR2 reporter in GCB-DLBCL lines was
decreased by BCR KO, roughly matching the degree to which BCR KO reduced their proliferation[41],
However, measurement of E by microscopy was laborious, such that it was practical to evaluate only a
limited number of cells. Especially since subcellular mapping of E was not needed, we used
conventional flow cytometry (FCM) to measure E in thousands of reporter-expressing cells. Specifically,
FCM was used to measure the fluorescence intensities of each passing cell in channels spectrally
optimized to detect donor or acceptor-range emissions during either donor or acceptor excitation: IDD,
IAA, and IDA according to Zal et al.[76]. FCM measurements from cells expressing Lyn-AktAR2 or control
constructs (Figure S1B) were processed with software (see Materials and Methods), according to the
spectral correction method of Chen et al.[74], to yield a single average value per sample. As expected, E
values for low- and high-FRET control constructs were highly constant, regardless of the cell line in
which they were expressed or the day of a particular assay (Figure 29B), even across different
cytometers and PMT settings, and despite substantial variation in raw values for autofluorescence and
fluorescence from controls and reporters (data not shown). Values of individual coefficients required
for E calculation were also stable for a particular cytometer and settings.
Further-optimized and control forms of the AKT activity reporter
To assist interpretation of E values from the Lyn-AktAR2 reporter, we also made a version (LynAktAR2-D) with mutation of the target Thr residue (Figure 28B)[165], E of this “dead”, inactive
(unphosphorylatable) reporter approximates what would be the E value of the “live” (active) LynAktAR2 reporter without AKT kinase activity, providing a lower bound by which to estimate how much
AKT kinase activity is reduced by BCR KO or other manipulation, and a control for non-specific effects
(e.g., in drug studies; see below).
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We previously found only a small positive difference between E values (E) for Lyn-AktAR2 vs.
Lyn-AktAR2-D in unstimulated cells of GCB-DLBCL lines[41], indicating substantial intramolecular
proximity between fluorophores when the AktAR2 reporter is unphosphorylated. To increase the
dynamic range of Lyn-AktAR2, we inserted a flexible “EV” linker[167], between the FHA1 and FOXO1
domains to create Lyn-AktAR2-EV, and a corresponding inactive version (Lyn-AktAR2-EV-D; Figure 28B).
EV increased the ΔE between active and inactive reporters in several GCB-DLBCL lines (Figure 29C), and
between BCR-unmodified and BCR-KO cells of SUDHL-6 with active reporters (Figure 29D).
Several other observations regarding AktAR2-based reporters were made. Expression of the
active reporter did not affect the growth of SUDHL-4 cells (Figure 29E), suggesting that the reporters do
not interfere with AKT function. E values for unmanipulated cells of each cell line, assayed on different
days, were relatively constant for active and inactive Lyn-AktAR2-EV reporters, further showing assay
precision (Figure 30A). Reporter abundance varied greatly between cells of each reporter-expressing
line, likely due to expression via a transposon vector; furthermore, for cells at any particular level of
reporter abundance, FCM yielded considerable variation in per-cell E values. We addressed these
variations by calculating E as a moving median (Ē) over the range of reporter abundance, and found
that Ē values of each reporter or control were relatively stable, at characteristic levels, over a wide
range of IAA (Figure 30B). This is consistent with theory; other than a potential increase in intermolecular FRET with increasing reporter concentration, which appears to be negligible, and unless the
underlying AKT activity is limiting, E should be unaffected by the reporter’s cellular abundance.
To calculate a single E value for a particular sample, an intermediate but wide range of IAA with
stable Ē was selected, avoiding cells with reporter levels that were either very high, which might
overwhelm AKT capacity, or very low, which might cause problems in background subtraction. A
consistent range of IAA was chosen for all samples in a particular experiment, and the final single E value
of each sample was calculated as a mean of moving median Ē values in the selected IAA range. Applied
to cells of GCB-DLBCL lines in their baseline state, this approach showed a slight increase in Ē values of
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the Lyn-AktAR2-EV reporters with increasing IAA (Figure 30B), but the active reporter’s Ē value was
consistently higher than that of the inactive reporter across the range of IAA.
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Figure 30: Additional technical aspects of AKT activity detection by FRET
Used by permission from Ondrej Havranek, who generated the data shown. A) High precision
(reproducibility) of FCM-measured baseline values of E from Lyn-tagged, EV-containing active and
inactive forms of AktAR2 reporters, measured in two GCB-DLBCL lines. Each point represents an E value
measured on a different day. For each cell line, the significance of the difference between active and
inactive values was determined by an unpaired Student’s t test. Values for OCI-Ly7: active Emean + ESD =
17.6% + 1.1%, inactive Emean + ESD = 12.2% + 0.6%; for SUDHL-4: active Emean + ESD = 14.5% + 1.0%,
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Validation of the AKT activity reporter
To verify that E determined by FCM with the active Lyn-AktAR2-EV reporter reflects AKT kinase
activity, we performed a variety of experimental manipulations with expected effects on AKT kinase
activity. Using a transposon vector with a doxycycline (Dox)-inducible promoter[71], found previously
to be very non-leaky and Dox-titratable[41], we expressed a constitutively-active (myristoylated) form
of murine AKT1 (MyrAKT)[41,168]. In two GCB-DLBCL lines with the active Lyn-AktAR2-EV reporter, AKT
activity in cells with inducible MyrAKT was markedly increased at 48 hours after Dox addition (also at 24
hours; data not shown), but largely unchanged with induction of luciferase (Luc) as a control protein
(Figure 31A).
Other manipulations involved the lipid phosphatase PTEN, which negatively regulates AKT
kinase activity by hydrolyzing PIP3 to phosphatidylinositol (4,5)-bisphosphate. Stable PTEN KO
increased E values of Lyn-AktAR2-EV in GCB-DLBCL lines (Figure 31B), consistent with our previous
findings that it increased AKT pS473 and rescued from the effects of BCR KO[41]. After additionally
introducing a transposon vector for Dox-inducible PTEN re-expression in PTEN-KO cells, we found that E
from Lyn-AktAR2-EV declined with increasing Dox concentration(Figure 31C), as expected.
Feasibility of the AKT activity reporter assay for dose-response, time-course, and kinetic studies
Ease of use, the low numbers of cells required, and precision from averaging measurements
from many cells makes this assay suitable for testing dose-dependent effects on AKT kinase activity in
living cells. We previously showed that clinical-grade, small-molecule inhibitors of kinases involved in
AKT activation by tonic BCR signaling (P505-15 for SYK, and idelalisib for the PI3K p110δ isoform)
caused dose-dependent inhibition of AKT kinase activity in GCB-DLBCL lines[41]. We now performed
dose-response studies of additional inhibitors of AKT and its activation, in which the inactive LynAktAR2-EV reporter was useful: the baseline ΔE between active and inactive reporters can be set as
100% AKT activity for each line (Figure 32A&B) ), thereby facilitating the interpretation of inhibitor
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studies across different lines. The inactive reporter can also identify inhibitor concentrations above
which E of both reporters is non-specifically affected (Figure 32D).
After one-hour incubations, similar dose-response curves of two GCB-DLBCL lines were
observed for two allosteric inhibitors of AKT, MK2206[169] and AKT-VIII (SC66)[170], as well as the ATPcompetitive AKT inhibitor ipatasertib (GDC-0068)[171] (Figure 31D). We also evaluated inhibitors of
kinases respectively responsible for activating phosphorylation of AKT at residues Ser473 and Thr308:
the pan-mTORC complex inhibitor MLN0128 (TAK-228) and the PDPK1 inhibitor GSK-2334470 (Figure
32D)[172,173]. All inhibitors achieved nearly-complete inhibition of AKT activity at sub-micromolar
concentrations, indicating their potency. Specificity of these results was shown by the lack of response
to the BTK inhibitor acalabrutinib (Figure 33A) at concentrations at which it inhibits calcium flux
induced by BCR crosslinking in GCB-DLBCL lines (Figure 33B). However, in DLBCL cell lines of the
activated B-cell (ABC) subtype, some of which constitutively utilize antigen-driven BCR signaling to
activate BTK[33], acalabrutinib showed dose-dependent inhibition of AKT activity (Figure 33C).
The assay was able to perform kinetic monitoring of AKT activity, similar to an assay for calcium
flux, by data acquisition immediately after addition of reagents. After addition of ipatasertib, maximal
inhibition of baseline AKT kinase activity was reached in minutes (Figure 31E), implying that the
reporter is dephosphorylated by an active process in the absence of AKT activity, despite the high
affinity of the FHA1 domain for phosphorylated threonine (estimated at KD = 61-73 nM[174] ). The
reporter also detected rapid increases in AKT kinase activity in GCB-DLBCL lines after BCR crosslinking
by antibodies, mimicking antigen-induced BCR signaling, above their baseline E dependent on tonic BCR
signaling. Kinetic monitoring showed that the maximum increase in AKT activity, by ~3 times the
baseline E between active and inactive reporters, is reached in minutes (Figure 31F);a time course
showed that this maximal level was sustained for ~2 hours, declining to baseline after 8-24 hours
(Figure 33D).
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Figure 31: Effects on FRET of AKT kinase activity reporters of stable knockout and/or inducible
expression of proteins affecting AKT activity
Used by permission from Ondrej Havranek, who generated the data shown. A) 48 hours of doxycycline
(Dox)-induced expression of a constitutively active form of AKT (myristoylated murine AKT1, mAKT)
increases FRET efficiency (E) of a “live” (active) AKT activity reporter (Lyn-AktAR2-EV) in two GCB-DLBCL
lines. No increase in E is seen after induction of a control protein (luciferase, Luc). Baseline E of a
“dead” (inactive, non-phosphorylatable) AKT activity reporter (Lyn-AktAR2-EV-D) is shown for
comparison. The absolute increase of E with induction of MyrAKT vs. Luc was 10.8% vs. 0.5% in SUDHL4, and 8.3% vs. 0.4% in OCI-Ly7. Means of three biological replicates are displayed; error bars represent
the standard deviation (SD). (*** p < 0.001; two-tailed paired t test) B) E of the active reporter is
increased by stable PTEN knockout in the same GCB-DLBCL lines, with baseline E of the inactive
reporter shown for comparison. The absolute increase of E with PTEN KO was 1.4% in OCI-Ly7 and 7.8%
in SUDHL-4. Means of four biological replicates are displayed; error bars represent the SD. (** p < 0.01;
two-tailed paired t test) C) In two GCB-DLBCL lines with stable PTEN knockout and a Dox-inducible
expression vector for PTEN re-expression, E of the active reporter is decreased by increasing
concentrations of Dox. Means of three biological replicates are displayed; error bars represent the SD.
D) Dose-response curves of inhibition of AKT activity, measured with the active reporter, by ipatasertib
and allosteric AKT inhibitors MK-2206 and AKT-VIII in two GCB-DLBCL lines. E values are normalized
according to the range of E values between those of untreated cells with the active reporter (100%) or
the inactive reporter (0%); negative values are attributed to measurement imprecision and noise. E)
Kinetic monitoring with the Lyn-AktAR2-EV active reporter shows rapid inhibition of baseline AKT
activity by ipatasertib (final concentration, 2 µM) in the GCB-DLBCL line OCI-Ly7; there is no effect on
FRET of the inactive reporter. F) AKT activity of two GCB-DLBCL lines is rapidly increased by BCR
crosslinking with antibodies specific for the immunoglobulin heavy chain (IgH) isotype expressed by
each line; there is no effect on the inactive reporter, or with antibodies to other IgH isotypes.
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Figure 32: Measurement of dose-response effect of various small-molecule inhibitors on AKT
kinase activity
Used by permission from Ondrej Havranek, who generated the data shown. A) FRET efficiencies (E)
of the active (Lyn-AktAR2-EV) and inactive (non-phosphorylatable) (Lyn-AktAR2-EV-D) AKT activity
reporters in separate cultures of OCI-Ly7 cells treated for one hour with the ATP-competitive AKT
inhibitor ipatasertib (GDC-0068). Dose-dependent inhibition of the active reporter is shown, but the
inactive reporter is unaffected over a wide range of concentrations. B) Effect of allosteric AKT
inhibitor MK-2206 on values of E from Lyn-tagged, EV-containing active and inactive forms of
AktAR2 reporters in SUDHL-4 cells. Specific concentration-dependent inhibition from the active
reporter is seen at low concentrations, but there is non-specific lowering of E for both reporters at
concentrations above 1 µM, attributable to the known fluorescence of MK-2206. C) Effect of PDPK1
inhibitor GSK-2334470 on values of E from Lyn-tagged, EV-containing active and inactive forms of
AktAR2 reporters in SUDHL-4 cells. Specific concentration-dependent inhibition from the active
reporter is seen at low concentrations, but there is non-specific increase in E for both reporters at
concentrations above 0.1 µM. D) AKT activity in two GCB-DLBCL lines (OCI-Ly7 and SUDHL-4) treated
with inhibitors of two kinases involved in phosphorylation and activation of AKT: PDPK1 inhibitor
GSK-2334470 and the pan-mTORC complex inhibitor MLN0128 (TAK-228).
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Figure 33: Results of dose-response and kinetic monitoring of AKT activity
Used by permission from Ondrej Havranek, who generated the data shown. A) Lack of effect of
acalabrutinib on E from Lyn-tagged, EV-containing active and inactive forms of AktAR2 reporters in in
two GCB-DLBCL lines, over a wide range of concentrations. B) Acalabrutinib depresses stimulation by
BCR crosslinking of calcium flux in two GCB-DLBCL lines, indicating that the negative results in C are not
due to inactive drug. C) Acalabrutinib potently inhibits E from the Lyn-tagged, EV-containing active
reporter Lyn-AktAR2-EV in two ABC-DLBCL lines (HBL-1 and TMD8) whose growth is reduced by
acalabrutinib (data not shown), but does not affect E in the ABC-DLBCL line U2932, whose growth is not
affected by acalabrutinib. D) Duration of increased AKT activity in response to anti-BCR stimulation in
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The studies above suggested that this reporter assay might also be able to assess the effect of
inhibitors of kinases mediating AKT activation by BCR crosslinking. As an example, we used kinetic
monitoring to determine the effect of pre-incubation with the SYK inhibitor P505-15 on the AKT activity
response to anti-BCR. Although pre-incubation lowered the AKT activity somewhat, due to the fact that
such inhibitors also inhibit the baseline activation of AKT by tonic BCR signaling in GCB-DLBCL lines, this
provided a new baseline against which dose-dependent inhibition of the BCR crosslinking-induced rise
in AKT activity could be measured (Figure 33E & F).
Changing the target peptide creates a reporter of PKA activity
To demonstrate that a FRET-based reporter and FCM can be used to measure the activity of a
kinase other than AKT, we first created a transposon-based vector (LPAR) for expression of a Lyn-tagged
reporter, identical to the Lyn-AktAR2-EV reporters except that the AKT substrate FOXO1 peptide has
been replaced by an AarI cassette for seamless cloning. Into the LPAR vector we then cloned target
peptides for protein kinase A (PKA), a serine/threonine kinase, based on the AKAR2 reporter of PKA
kinase activity[137], with either a central Thr residue (active reporter, LPAR-AKAR-WT) or Val (inactive
reporter, LPAR-AKAR-mt) (Figure 34A).
We validated this PKA reporter in GCB-DLBCL lines by several manipulations that have known
effects on PKA. Forskolin, an activator of adenylyl cyclases, is commonly used to elevate intracellular
levels of cyclic adenosine 3′,5′-monophosphate (cAMP), a “second messenger” that allosterically
stimulates PKA kinase activity by promoting assembly of the tetrameric holoenzyme[175]. In the OCILy7 cell line, forskolin reproducibly increased E from LPAR-AKAR-WT, without a change in E from LPARAKAR-mt, in a classic dose-response pattern (Figure 34B). cAMP is normally hydrolyzed by
phosphodiesterases[176], among which PDE4B is a prominent member in DLBCL cells[177]. Similar to
the effect of forskolin, E from LPAR-AKAR-WT was increased by two PDE4 inhibitors, RS25344[178] and
FDA-approved roflumilast[179], without affecting LPAR-AKAR-mt, while the PKA inhibitor KT5720
produced a slight reduction (Figure 34C).
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Figure 34: Detection of PKA kinase activity by a FRET-based reporter
A) Principle of the FRET-based reporter of PKA activity. Phosphorylation of threonine (T) in a peptide
domain based on a known PKA target leads to its binding by the FHA1 domain of the reporter; this
brings donor (Cerulean3) and acceptor (cpVenus[E172]) fluorophores of the reporter into greater
proximity, and increases the FRET signal between them when illuminated. B) Dose-response effect of
forskolin (1-hour incubation) on PKA kinase activity, reflected by E values of the active LPAR-AKAR-WT
reporter, in the GCB-DLBCL line OCI-Ly7. Means of 4 biological replicates, performed on different days,
are displayed; error bars represent the standard error of the mean. There is no effect of forskolin on
the inactive LPAR-AKAR-mt reporter. C) Effect of 1-hour incubation with additional modulators of PKA
activity: the PKA inhibitor KT5720, and two inhibitors of PDE4 phosphodiesterases (roflumilast and
RS25344). D) Time course of elevation in PKA activity, measured by LPAR-AKAR-WT, in response to
specific BCR crosslinking antibody in the IgM-expressing GCB-DLBCL line OCI-Ly19. There is no response
with antibody to the IgG isotype. E) Effect of the SYK inhibitor P505-15 and/or anti-BCR antibodies on
PKA activity in GCB-DLBCL lines. Agents were used in 1-hour incubations, plus a 15-minute
preincubation with P505-15 when used with anti-BCR antibodies. In both lines, SYK inhibition lowers
basal and BCR crosslinking-induced PKA activity.
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PKA is well-established as an important negative regulator of signaling by the T-cell
receptor[180,181], but its role in BCR signaling is understood less well[135]. We found that BCR
crosslinking by antibodies, mimicking antigen-induced BCR signaling, elevated E from LPAR-AKAR-WT in
GCB-DLBCL lines, over a time course (Figure 34D) similar to that of AKT activation by BCR crosslinking
(Figure 33D). Aguiar and colleagues showed that forskolin and PDE4 inhibitors increased cAMP levels in
DLBCL cell lines, presumably also increasing PKA activity, resulting in inhibition of the BCR signaling
mediator SYK[136], with the further consequence that the BCR signaling mediator PI3K is also
inhibited[182]. SYK has been shown to inhibit PKA activity in breast cancer cells by phosphorylating
Y330 of the PKA catalytic subunit[183], but others reported that PKA activity was increased by
phosphorylation of the same site by receptor tyrosine kinases in other non-lymphoid cell types[184]. In
GCB-DLBCL lines, we found that the SYK inhibitor P505-15 reduced basal E from LPAR-AKAR-WT and
blocked its increase by BCR crosslinking (Figure 2E). This indicates that SYK, which is activated by both
the tonic[41] and antigen-induced types of BCR signaling (Figure 33E&F), promotes PKA activity as an
additional consequence of BCR signaling, possibly providing negative feedback to dampen BCR
signaling.
Evaluating reporter FRET by spectral flow cytometry
Because FRET assessment by FCM requires data post-processing, we investigated whether
spectral flow cytometry (SFCM) with real-time channel unmixing may provide a useful alternative.
SFCM measures fluorescence in multiple channels for each exciting laser, whose combination
constitutes a “spectral fingerprint” that is characteristic for each fluorophore[185,186]. For a reference,
we first evaluated FRET determination on the Aurora spectral flow cytometer (Cytek Biosciences) by the
3-channel method, using raw intensity values from 3 of the 48 channels to represent IDD, IDA, and IAA for
post-acquisition calculation of E by the method of Chen et al. E values from the Aurora agreed well with
corresponding E values from the Fortessa for the low-FRET and high-FRET controls, and for resting cells
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with live or dead kinase activity reporters, confirming E as an instrument-independent measure of
FRET. The stability of moving median Ē values from the Aurora, over the wide range of reporter
abundance selected for analysis, was similar to that from the Fortessa (Figure 35A), but the Aurora
provided greater precision in single-cell E values (Figure 35B), consistent with previous reports of less
“spreading error”[78]. The dose-response assessment of PKA activity stimulation by forskolin on the
Aurora (Figure 35C) was similar to results on the Fortessa (Figure 34B).
We then used the full set of fluorescence measurements by the Aurora, and its built-in
capability of spectral unmixing, to evaluate real-time display of FRET assessment. When multiple
fluorophores are used in combination, unmixing algorithms use their spectral fingerprints to determine
their respective contributions to the total “raw” fluorescence of each event, and thus their intensity
values. To apply spectral unmixing for FRET assessment (SU-FRET), we used cells bearing low-FRET or
high-FRET controls to generate spectral fingerprints, respectively designated FRET-Low and FRET-High
(Figure 36A), and added them to the library of fluorophore spectra in the SpectroFlo software. With
these fingerprints, the instrument can unmix the fluorescence of reporter-bearing cells into an
intensity-weighted linear combination of FRET-Low and FRET-High emission (and autofluorescence).
Those intensities are calculated in real time and displayed in an orthogonal 2-parameter plot. As
expected, the calculated intensities of low-FRET and high-FRET control cells lie along the two axes of
this plot, defining an easily visualized range of FRET in which reporter cells lie somewhere in between
(Figure 37A).
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Figure 35: Using the Aurora spectral flow cytometer for FRET determination by the 3-cube method
gives results comparable to those of a conventional flow cytometer
A) fRET output graphs showing that the Fortessa conventional flow cytometer (left) and Aurora spectral
flow cytometer (right) have equivalent stability in moving median Ē values over the IAA range. The data
are from AKT reporter-bearing OCI-Ly7 cells, with and without anti-BCR stimulation (1 µg/mL) for 30
minutes at 37°C. B) Single-cell precision and FRET discrimination using the 3-cube method on the
Fortessa (left) are somewhat less than by the 3-cube method on the Aurora (right). The data are from
AKT reporter-bearing TMD8 cells. C) Dose-response assessment of PKA activity stimulation by forskolin,
using the 3-cube method on the Aurora spectral flow cytometer. The data are from PKA reporterbearing OCI-Ly7 cells.
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Figure 36: Characteristics and performance of detecting FRET by spectral unmixing (SU-FRET)
A) Creation of FRET-Low and FRET-High spectral fingerprints, used for unmixing on the Cytek Aurora.
Events from OCI-Ly7 cells expressing the low-FRET (top panels) or high-FRET controls (middle panels),
or unmodified OCI-Ly7 cells (bottom panels), are first gated by light scatter (left panels) and then by
gating for events in the predominant, central subset of events according to channel V7 (IDA; center
panels). The complete, raw emission spectral fingerprints for these events are shown in the right
panels. FRET-Low (top) and FRET-High (middle) fingerprints are used in spectral unmixing by Spectroflo
software, along with the autofluorescence fingerprint of unmodified cells (bottom).
B) Relationship between SU-FRET and FRET efficiency (E). Data are from a dose-response test of PKA
agonist forskolin in OCI-Ly7 cells, additional to the experiments shown in Figure S6C. A single 3-channel
E value was calculated for cells bearing the low-FRET and high-FRET controls, and for each sample of
cells bearing the live and dead PKA reporters, as the median per-cell E value of events in the range
chosen for E determination as per usual. An “SU-FRET” value was also calculated for each sample,
according to the following formula: SU-FRET = sin(y/sqrt(x2+y2)), in which y is the median per-cell value
of unmixed High-FRET intensity for these same events, and x is the median of their unmixed Low-FRET
intensity.This formula, based on the angle created by x and y in the 2-parameter plot of unmixed
intensities, was chosen to represent SU-FRET by a parameter that ranges between 0 and 1, as does E,
and that does not exhibit the extreme variability of the SU-FRET ratio (y/x) for the FRET-High control
(whose x values are small and centered around 0). The table at right shows the paired SU-FRET and E
values. The plot of these values at left shows that there is a tight linear correlation between SU-FRET
and E values for reporter-bearing cells, implying that an E value could be estimated from a calibration
curve of SU-FRET values. It is unknown why the FRET-High sample does not match the predicted value,
but its E value is far outside the range observed for any condition of reporter-bearing cells.
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Among notable features of SU-FRET, prominent is that it provides much better discrimination
between different states of FRET than is possible with the real-time alternative of a “FRET ratio” (Figure
37B). In addition, a greater spread of SU-FRET values is seen for the live PKA reporter than for the dead
reporter or the low-FRET and high-FRET controls (Figure 37B); a similar greater spread was seen for the
live AKT reporters by the 3-channel method, at least with the Aurora (Figure 35B). Since a change in
FRET can only occur for the live reporter, as its level of phosphorylation changes, this suggests that
there is baseline biological variability in the activity of these kinases. Finally, although SU-FRET does not
directly yield an E value, we found a remarkably linear relationship between a derivative of the
unmixed FRET-Low and FRET-High intensities of reporter-bearing cells and their E values (Figure 36B).
We performed several tests to confirm the validity of SU-FRET, relying on the predictable
increase in AKT activity caused by BCR crosslinking. When OCI-Ly7 cells expressing Lyn-AktAR2-EV were
either left untreated or stimulated with non-fluorescent anti-BCR, then washed and mixed in different
proportions, distinct populations were seen on the SU-FRET dot plot, and the proportions of cells
identified in regions of lower or higher SU-FRET matched their expected proportions (Figure 38A). We
then tested whether the distinction between BCR-stimulated and unstimulated reporter-bearing cells
by SU-FRET could be simultaneously verified by using fluorescently-labeled anti-BCR. We found that the
increase in SU-FRET from Lyn-AktAR2-EV was the same when using anti-BCR labeled with Alexa Fluor
647 (AF647), whose excitation and emission spectra are separated well from those of C3 and cpV, as
when using unlabeled anti-BCR.
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Figure 37: Spectrally-unmixed FRET (SU-FRET) discriminates differences in FRET, in real time and
without interference from other fluorophores
A) Principle of SU-FRET. The fluorescence of cells with FRET reporters or controls is measured by the
Cytek Aurora spectral flow cytometer and unmixed in real time into a linear combination of intensities of
FRET-Low and FRET-High emission, displayed in an orthogonal 2-parameter plot. The calculated
intensities of low-FRET and high-FRET control OCI-Ly7 cells lie along the two axes of this plot, as
expected, whereas those of cells expressing the live AKT activity reporter (Lyn-AktAR2-EV) lie
somewhere in-between. Unmodified cells are at the origin. B) FRET from OCI-Ly7 cells expressing
controls or PKA reporters, including strong PKA stimulation of the live reporter with forskolin,
determined in real time. SU-FRET (left panel) provides superior discrimination of FRET differences, as
compared to assessment by a “FRET ratio” (center and right panels). C) Independence of SU-FRET from
other fluorophores. OCI-Ly7 cells with the Lyn-AktAR2-EV reporter were treated as two groups, either
unstained (top panels) or stained with labeled antibodies (bottom panels) recognizing B-cell surface
markers (CD19-APC, CD44-BV785, CD10-PE-Cy7, CD27-APC-Cy7, CXCR4-BV421, and IgM-AF647) or the Tcell marker CD3 (FITC-labeled). Single-cell events from both groups were gated first by FSC-A vs. SSC-A
and then FSC-A vs FSC-H (not shown). Gated events from the two groups were then separately and
sequentially gated by the antibody combinations shown, from left to right. The unmixed High-FRET and
Low-FRET intensities for final gated events from the stained and unstained groups were then overlaid in
different colors in the SU-FRET contour plot at the far right, demonstrating no change in SU-FRET due to
the presence of other fluorophores.
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Figure 38: Characteristics and performance of detecting FRET by spectral unmixing (SU-FRET)
A) OCI-Ly7 cells expressing Lyn-AktAR2-EV were either left untreated or stimulated with 1µg/mL Alexa
Fluor 647-conjugated anti-BCR for 10 minutes, then immediately placed on ice, washed, mixed in
different proportions, and then analyzed for SU-FRET. The proportions of cells identified in low- and
high-FRET groups corresponded to their expected proportions, indicated by the percentage ratio
(unstimulated/stimulated) above each panel. B) Kinetic assay on the Aurora shows that acute
crosslinking of OCI-Ly7 cells expressing Lyn-AktAR2-EV (Live reporter) or Lyn-AktAR2-EV-D (Dead
reporter) with anti-BCR, either unlabeled or AF647-labeled, shows no effect of AF647 on FRET. The same
data are shown after processing into E values by the 3-cube method (middle), or as SU-FRET acquired
real time and subsequently displayed as the ratio of intensities (FRET-High/FRET-Low; right). Binding by
anti-IgM, as measured by detection of AF647-labeled antibody, occurs in advance of a FRET response
(left). C) Mixing experiment of OCI-Ly7 cells expressing Lyn-AktAR2-EV and pre-incubated with A647labeled anti-BCR (red) or left unstimulated (blue). There is excellent concordance between the BCR
stimulation status of cells (left) and their levels of spectrally-unmixed FRET intensities (right).
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Similarly, the binding of AF647-labeled anti-BCR did not change SU-FRET from Lyn-AktAR2-EV-D
(Figure 38B). Since SU-FRET from the AKT reporter was free from interference by AF647, we mixed LynAktAR2-EV cells that were either unstimulated or stimulated with AF647-labeled anti-BCR, and found
that AF647 signal (indicative of BCR crosslinking) marked cells with increased SU-FRET (Figure 38C). This
also made possible a kinetic assay to demonstrate that the binding of AF647-labeled anti-BCR precedes
AKT activation, detected post facto by an increase in E or the “SU-FRET ratio” of unmixed intensities
(FRET-High/FRET-Low; Figure 38B), or in real time by two-parameter mapping of SU-FRET.
In addition to providing a real-time assessment of FRET, SU-FRET differs from FCM-FRET in
requiring no additional efforts to allow the use of additional or multiple fluorophores, even when
spectrally similar to the FRET donor and acceptor. We compared spectral unmixing and 3-channel
methods in kinetic assays after the addition of anti-BCR to cells that were either otherwise-unlabeled or
labeled with fluorophores with increasing spectral similarity to cpV: AF647, phycoerythrin (PE), or
DyLight 488 (Figure 39A). Binding of DyLight 488-labeled anti-BCR interfered with the 3-channel
method, producing an artifactual increase in FRET from Lyn-AktAR2-EV, as compared to unlabeled antiBCR and the other fluorophores, but SU-FRET was equivalent with all fluorophores (Figure 39B). After
finding that SU-FRET from Lyn-AktAR2-EV was stable when cells are placed on ice (Figure 39C), we
placed unstimulated AKT reporter-bearing cells on ice, and either left them unstained or stained them
with a panel of differently-labeled antibodies to B-cell surface markers (Figure 39D), resembling the
type of multiparameter staining often used to define subsets of hematopoietic cells[187]. SU-FRET from
Lyn-AktAR2-EV was the same for both sets of cells (Figure 37C), indicating that SU-FRET was unaffected
by those additional fluorophores, or by anti-BCR when used on ice.
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Figure 39: SU-FRET from the AKT reporters is tolerant of other fluors, and stable in the cold
A) Emission spectra of fluors used in test of potential interference on SU-FRET from Lyn-AktAR2-EV,
which has mCerulean3 and cpVenus as donor and acceptor. Data are obtained from fpbase.org.
B) Kinetic assay of BCR stimulation (final concentration, 1 µg/mL) shows that FRET by spectral unmixing
(shown as the FRET-High/FRET-Low ratio value, third panel from the top) was equivalent with all fluorlabeled anti-BCR reagents, whereas DyLight 488-labeled anti-BCR had an artifactual effect by
conventional FRET ratio (top panel) and the 3-cube method E (second panel from the top). Bottom
panel shows the kinetic of binding of the anti-BCR reagents.
C) Stability of FRET from the Lyn-AktAR2-EV reporter in intact OCI-Ly7 cells kept on ice. The left panel
shows that when unstimulated cells were either left at 37 °C or placed on ice for 30 minutes, there was
no difference in their SU-FRET. There was also no difference when cells were BCR-stimulated with antiIgM (1 µg/mL) for 10 minutes, then either analyzed for SU-FRET immediately or placed on ice for 30
minutes before analysis (center panel). The stability on ice of SU-FRET from the live reporter is further
emphasized by overlaying the histograms from these two experiments (right panel).
D) Emission spectra of fluors used for multiparameter staining, of OCI-Ly7 cells with the Lyn-AktAR2-EV
live AKT activity reporter, with a panel of antibodies that recognize B-cell surface markers (except CD3FITC). Data are obtained from fpbase.org.
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Using spectrally-unmixed FRET (SU-FRET) in studies of gene knockout
Our previous studies of gene KO (Figure 31) utilized delivery of plasmids via electroporation,
which is typically successful in only a fraction of cells, and associated with varying degrees of toxicity.
We therefore tested the use of lentiviral transduction for KO of genes involved in BCR signaling and/or
AKT activity. We first used a single lentivirus for stable expression of both Cas9 and a guide RNA (gRNA),
along with resistance to the rapidly-toxic antibiotic puromycin. Only a small proportion of OCI-Ly7 cells
bearing the Lyn-AktAR2-EV reporter were initially resistant to puromycin, but these were expanded and
then examined for their SU-FRET response to BCR stimulation with AF647-labeled anti-IgM. Targeting of
CXCR4 was used as a negative control, since its KO by electroporation was previously shown to have no
effect on AKT activity in GCB-DLBCL lines[41], and almost all CXCR4-targeted cells bound by anti-IgM
were found in a region of high SU-FRET (Figure 40A), indicating preservation of the AKT response to BCR
stimulation. With a viral gRNA targeting two of the 3 genes of human AKT (AKT1 and AKT2), a large
fraction of cells binding IgM failed to increase their SU-FRET, suggesting that KO of AKT1/2 had
occurred, but only in a subset of cells. This was supported by findings in cells with targeting of IGHM,
used as a positive control because IgM is required for BCR expression and stimulation: only a fraction of
cells showed reduced IgM staining, but those cells also failed to show increased SU-FRET (Figure 40A).
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Figure 40: SU-FRET detects effects of gene knockout on AKT activation by BCR signaling
A) SU-FRET response to BCR crosslinking varies with the gene targeted and the degree of knockout (KO).
Lentiviral vectors were used to deliver Cas9 protein, puromycin resistance, and a guide RNA (gRNA)
targeting the genes shown in OCI-Ly7 cells expressing Lyn-AktAR2-EV. Puromycin-resistant cells were
then stimulated with AF647-labeled anti-IgM (1 µg/mL for 10 minutes) and analyzed for SU-FRET
response. There was no effect of targeting CXCR4, but targeting IGHM was inhibitory to cells in which KO
was achieved, as shown by the level of surface IgM. B) Effect of gRNAs targeting various genes relevant
to AKT activation by BCR signaling, on OCI-Ly19 cells with live (top row) and dead (bottom row) AKT
reporters. Lentiviral vectors were used to deliver gRNAs and puromycin resistance, in cells with Doxinducible Cas9. SFCM data were obtained 5 days after Dox addition, and at 60 minutes after stimulation
with AF647-labeled anti-IgM (1 µg/mL). SU-FRET is displayed as the per-cell ratio (FRET-High/FRET-Low)
of unmixed intensities (left panels); other panels show surface expression of 3 targeted genes.
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Because the combined Cas9/gRNA virus gave low transduction efficiency and incomplete KO,
we tested a lentivirus expressing only gRNA and puromycin resistance in AKT reporter-bearing OCI-Ly19
cells that had also been engineered for Dox-inducible expression of Cas9. After puromycin selection,
Dox was added and cells were evaluated by SFCM over several days for SU-FRET, before and after
periods of acute anti-BCR stimulation. Cells were also evaluated for the expression of targeted proteins:
surface-detectable proteins (IgM, CXCR4, and CD19) were stained and detected simultaneously with
SU-FRET measurement, while intracellular proteins (SYK, AKT, and PTEN) were stained in separate,
parallel aliquots after fixation and permeabilization. Five days after Dox addition, BCR stimulation
produced increases in SU-FRET from Lyn-AktAR2-EV (but not Lyn-AktAR2-EV-D), to a degree that varied
as expected with the function of the gene targeted, but also with the uniformity and degree of the KO
and protein loss achieved, which we attribute to differences in gRNA efficiency. As before, targeting
IGHM produced loss of surface IgM in only a fraction of cells, which showed less SU-FRET response to
BCR stimulation (Figure 40B, Figure 41A&B). However, CXCR4 was lost in all cells, with preservation of
their response to anti-BCR as expected (Figure 40B, Figure 41B). The entire population of SYK-targeted
cells showed reduced SU-FRET response to anti-IgM by 10 minutes (Figure 41C), consistent with
uniform loss of SYK protein (Figure 41B) and its known critical role in BCR signal transduction. A fraction
of PTEN-targeted cells showed increased basal SU-FRET with Lyn-AktAR2-EV (Figure 41C), as expected
from stable KO studies (Figure 31) and its role as a negative regulator of AKT activation, and consistent
with staining that showed PTEN protein loss in only a fraction of cells (Figure 41B). A fraction of PTENtargeted cells also showed a reduction in surface CXCR4 (Figure 40B), consistent with the negative
regulation of CXCR4 transcription by AKT[41]. Surface CD19 protein was lost from all CD19-targeted
cells, but to a highly variable degree at 5 days of Dox, and CD19-targeted cells showed only a modest
reduction in SU-FRET response to anti-IgM, which was even less at shorter durations of stimulation
(Figure 41B&C). AKT-targeted cells showed only a modest reduction in SU-FRET response to anti-IgM,
likely because only 2 of the 3 AKT genes were targeted by the gRNA used.
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Figure 41: Efficiency of KO in reporter cells
A) OCI-Ly19 cells expressing Lyn-AktAR2-EV were transduced with a lentivirus expressing a gRNA and
puromycin resistance, selected with puromycin, and then induced to express Cas9. 5 days later, the SUFRET response to AF647-labeled anti-IgM (1 µg/mL for 60 minutes) in cells with IGHM-targeting gRNA
was inhibited in the fraction that had lost surface IgM expression, but equivalent to untransduced cells
for the fraction in which KO was not achieved. B) As in A, OCI-Ly19 cells bearing Lyn-AktAR2-EV
reporters underwent gRNA targeting of various genes specified in parallel. After 5 days, the expression
of the corresponding targeted gene was analyzed by SFCM. IgM surface expression was measured as an
adjunct to BCR stimulation with AF647-labeled anti-IgM. Other targeted surface markers (CXCR4 and
CD19) were simultaneously measured with additional fluors. Targeted genes with intracellular proteins
(PTEN, AKT1, and SYK) were assessed separately, after fixation and permeabilization. A histogram gate
was drawn to encompass greater than 97% of cells expressing no gRNA (Red). The table shows the
percentage of cells with and without gRNA expression that fall within the gate. C) As in A, OCI-Ly19 cells
bearing the live Lyn-AktAR2-EV AKT activity reporter underwent gRNA targeting of various genes
specified, stimulation with AF647-labeled anti-IgM, and analysis at various times afterwards for SU-FRET,
shown either in a 2-parameter contour plot (top row) or as the histogram of per-cell ratios of unmixed
intensities (FRET-High/FRET-Low, bottom row).
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Figure 42: Combined results of KO in reporter cells
A) SFCM data from the gene KO experiment, in which OCI-Ly19 cells bearing the live Lyn-AktAR2-EV AKT
activity reporter underwent separate targeting of 6 different genes relevant to BCR signaling and AKT
activation, were combined (“digitally mixed”) according to whether cells were unstimulated (left) or had
been BCR-stimulated for 60 minutes (right). B) Basis of gates applied to SU-FRET from digitally-mixed
unstimulated cells. The region of basal SU-FRET was established by the 10% contour gate in the negative
control sample transduced with gRNA targeting CXCR4, using automatic contour gating in FlowJo
software. C) Basis of gates applied to SU-FRET from digitally-mixed cells stimulated with anti-BCR. In the
IGHM-targeted sample, surface staining for IgM distinguished two populations, i.e., cells with normal
levels of anti-IgM binding (and therefore experiencing BCR stimulation), versus cells with reduced
binding of anti-IgM (left panel). Cells from High and Low regions in the histogram of anti-IgM binding
were used to define corresponding High and Low regions of SU-FRET (right panel). D) Because the
numbers of cellular events acquired during SFCM analysis of the gene KO experiment differed between
gRNAs, these numbers were “scaled” to provide a normalized comparison between gRNAs, particularly
when examining the fractional enrichment of events derived from each gRNA target culture defined by
SU-FRET level and the expression of surface markers (IgM and/or CD19).

142

The results of this KO experiment suggest that if an SFCM instrument with sorting capability
were available, a gRNA library screen could be done to identify genes whose KO has an effect
detectable by changes in SU-FRET. To support this, and present the results more succinctly, we
combined the SFCM results for Lyn-AktAR2-EV from all 6 gRNAs, separately for unstimulated cells and
at 60 minutes after BCR stimulation, as if they had been acquired from a single culture (Figure 42A). We
then analyzed the results by gating first on defined regions of SU-FRET, and then by surface IgM and
CD19 status. For unstimulated cells, regions of normal, high and low basal FRET were set based on the
CXCR4-KO negative control (Figure 42B); for BCR-stimulated cells, regions of high and low were set
based on the populations of unmodified and BCR-KO cells in the IGHM-targeted positive control (Figure
42C). For each gRNA, the numbers of events in each region were “scaled” as a percentage of all events
for that gRNA, to normalize differences between gRNA species in the number of events acquired (Figure
42D). In the unstimulated sample, cells with elevated SU-FRET were found to be highly enriched for
PTEN gRNA (Figure 43A), even though KO of PTEN protein was only partial (Figure 42B). BCR-stimulated
events with low SU-FRET (representing cells with impaired AKT activation) were enriched for CD19 and
IgM gRNAs in regions with respective loss of those proteins, as expected, and for SYK gRNA in cells with
retained expression of CD19 and IgM (Figure 43B). Events with high SU-FRET were similarly enriched for
CD19 and IgM gRNAs in regions with respective loss of those proteins, but depleted of SYK gRNA in cells
with retained CD19 and IgM expression.
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Figure 43: Gating on SU-FRET implicates genes regulating AKT activation
A) Combined SFCM data from the KO experiment shown in Figure 4B, for unstimulated cells bearing the
live AKT reporter. In SU-FRET regions based on cells with gRNA targeting the negative control CXCR4,
donut plots show the scaled proportions of cells according to gRNA-targeted genes. Cells with high
basal SU-FRET are found to be enriched for cells with targeting of PTEN. B) Similar to A, but for the live
reporter sample at 60 minutes after AF647-labeled anti-IgM (1 µg/mL). Cells were gated first by SUFRET response to BCR stimulation, and then by surface expression of IgM and/or CD19. SYK gRNA is
enriched in low-response cells that retain expression of IgM and CD19. Among cells with normal SUFRET response to BCR stimulation, the SYK gRNA proportion is reduced.
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5.3 - Discussion
FRET is a potentially quantitative indicator of proximity between donor and acceptor
fluorophores in the 1-10 nm range, well below the ~20 nm limit of resolution of super-resolution
fluorescence imaging microscopy methods such as stochastic optical reconstruction microscopy. With
proper assay design, donor-acceptor proximity and/or orientation change can directly reflect a
biomolecular phenomenon, such as protein-protein interaction[154,188], protein-membrane
proximity[189,190], or protein conformation[191,192], or enable an artificial construct to report
indirectly on a phenomenon such as enzymatic activity of a kinase or protease[193]. FRET reporters are
well-established for the reliable measurement of kinase activity[162,163], and provide many
advantages: fast response, desirable for real-time studies; application to single live cells, thereby
maintaining cellular context and allowing kinetic analyses and the analysis of subpopulations; low cost
per assay, since no reagents are needed for signal detection; parallel use of a non-phosphorylatable
reporter, as a control[165]; and flexible application to different kinases, by changing the target peptide
used.
FRET is therefore a powerful tool that has been used in many studies of cell biology, as well as
for molecular studies in vitro. However, the full application of FRET to cell biology research has been
hindered by requirements for specialized instrumentation and data processing, and the low throughput
or cell immobilization required for fluorescence microscopy. Because conventional flow cytometry
(FCM) is well-established, widely available for measuring fluorescence in cell biology research, and has
high throughput capability, it is desirable for FRET-based applications. FCM has been used to assess
intensity-based FRET, but most commonly by a simple FRET ratio (IDA vs. IDD) that is instrumentdependent. Using spectral corrections and other calibrations, determination of the apparent FRET
efficiency (E) by FCM has been shown to measure FRET with high reliability and in instrumentindependent terms[74,152], including from FRET-based kinase activity reporters[41,194]. Processing
FCM-generated data for the calculation of E is required, for which we and others[195,196] have
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provided software to expedite the task. Furthermore, FRET measurement by FCM is suitable for
applications other than kinase activity reporters, such as protein-protein interaction[154,188]. Recently
developed single-fluorophore biosensors can also report on kinase activity, and should be suitable for
FCM[197–199].
As we have shown, FRET assessment by FCM can be a valuable tool for studies of cell biology.
However, with current commercially-available instruments and software, determination of E by FCM
cannot be done in real time, thereby limiting FRET-based sorting to the less-informative FRET ratio.
Perhaps more importantly, limited sampling of the emission spectrum by FCM, combined with
tediousness of cross-talk compensation, makes the use of FRET in the presence of other fluorophores
rather difficult. We found that these problems are overcome by spectral flow cytometry (SFCM), whose
built-in spectral unmixing feature enables real-time precise and sensitive discrimination between cells
with different FRET levels. Assessing FRET by spectral unmixing (SU-FRET) is simple, requiring only onetime data acquisition from cells expressing low-FRET or high-FRET constructs and unmodified cells. With
the increasing availability of instruments capable of SFCM, which improves discrimination between
fluorophores, the simplicity of SU-FRET may increase the use of FRET in cell biology research, especially
with the ability to employ additional fluorophores. For example, SU-FRET may enable transgenic FRET
reporters to be evaluated in cell subsets that require multiple fluorophores to define, such as many
types of hematopoietic cells.
SU-FRET also provides a non-graphical index of FRET, through the SU-FRET ratio of
unmixed FRET-High and FRET-Low intensities; however, this is not the same as E, although it could be
used to estimate E from a calibration (Figure 36B), nor is it similarly independent of instrumentation or
experimental conditions. One obvious conditional factor is the choice of low-FRET and high-FRET
controls that provide spectral fingerprints for unmixing; the controls that we used varied greatly in their
FRET efficiency (E values of ~5% and ~65%, respectively). Using controls that encompass a more narrow
range of E, as might be accomplished empirically with linkers of slightly different lengths to separate
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the donor and acceptor fluorophores[74], might expand the graphical separation between samples
with intermediate E values. Likewise, substituting the low-FRET control with a zero-FRET one would
extend the dynamic range of SU-FRET to E values below 5%. An additional potential limitation of SUFRET is that it has not yet been shown to be reliable for non-stoichiometric FRET systems, such as to
monitor protein:protein interactions in cells, in which donor and acceptor fluorophores are attached to
different proteins rather than stoichiometrically linked in a single reporter construct. In such situations,
the spectral signatures of low-FRET and high-FRET controls may be insufficient to calibrate FRET
signatures across variable acceptor-to-donor ratios, and therefore this more general type of FRET
application is currently best served using the quantitative E-FRET method. However, as compensation
for these limitations, SU-FRET is simple to use, gives results in real time, and facilitates the use of
multiple fluorophores.
We focused our study of FRET by flow cytometry on the use of reporters of kinase activity,
which is of widespread interest in diverse areas such as cell signaling, metabolism, and drug
development. Many methods used to assess kinase activity have significant shortcomings, such as low
throughput, loss of cellular context, or applicability only to cells in aggregate. Because AKT kinase
activity is promoted by phosphorylation at certain highly-conserved AKT residues (Ser473 and Thr308 of
AKT1), detection by specific antibodies is often used as a surrogate indicator of AKT activity. However,
we found that this did not provide results that agreed with other evidence of AKT activity, in contrast to
using FCM with AktAR2-based reporters[41]. pS473 may be an especially poor surrogate for AKT kinase
activity, being less reliable than pT308[108], or rendered non-essential by phosphorylation of S477 and
T479[107], and both S473 and T308 are paradoxically hyperphosphorylated after treatment with ATPcompetitive AKT inhibitors[109], whose effect on AKT activity was reliably detected by FCM and
AktAR2-based reporters.
With the PKA reporter, we found a particular mechanism by which BCR signaling and PKA
activity are interconnected. In its function as a negative regulator of BCR signaling, PKA activity is
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increased by cAMP after BCR signaling, perhaps through PTGER4, which is strongly induced by BCR
crosslinking[200]. PTGER4, a receptor for prostaglandin E2, generates cAMP in B cells[201] and has a
negative effect on the proliferation of normal mouse B cells and human B cell lymphoma, for which it
may function as a tumor suppressor[200]. However, we found another mechanism by which BCR
signaling activates PKA, enabling it to function as a negative regulator of BCR signaling: PKA
phosphorylation by BCR-activated SYK. Previous reports differed as to whether phosphorylation of the
PKA catalytic subunit, likely at Y330 and mediated by SYK in B cells, was activating[184] or
inhibitory[183] of PKA kinase activity; our reporter studies showed that inhibition of SYK, which is
activated by both tonic and antigen-induced BCR signaling, inhibited PKA activity in GCB-DLBCL lines.
An exciting possibility suggested by our studies is that cells could be sorted on the basis of
functional difference detectable by a real-time assay based on SU-FRET. The example that we modeled
was one that could be used to detect genes involved in the increase of AKT activity by acute BCR
stimulation; after introduction of a library of gRNA species, cells with less BCR-induced increase in SUFRET from a live AKT reporter could be sorted and analyzed for their gRNA composition, thus
implicating genes necessary for the normal increase. It is plausible that a similar screen could be done
with reporters specific for other kinases, or with other types of stimuli. Our example was somewhat
complicated by not being able to achieve KO in all cells for some targeted genes, but in effect the
resulting mixed cultures provided further evidence that SU-FRET can detect and discriminate the effect
of KO in individual cells on the basis of FRET. Similarly, an actual full-library screen might suffer from
incompleteness of KO for certain gRNA species targeting phenotype-essential genes, but that would not
affect the true positivity of their representation in the population of cells sorted on the basis of SUFRET.
The most prominent limitation of reporter assays is that cells must be engineered to express
the reporter construct; this requires time and effort in advance of its use, may have unknown artifacts
or non-physiologic aspects, and excludes certain applications, such as analysis of primary tumor or
148

tissue samples. The results are also limited to providing an assessment of relative changes in activity of
the enzyme interrogated, and not an absolute measure in biochemical term. In addition, the
performance of kinase activity reporters is highly dependent on the target peptide for specificity, and
on subcellular localization for sensitivity. Specificity is an issue that has levels of complexity; in the case
of AKT, AktAR2-based reporters are presumed to report on the combined activity of all AKT isoforms
(although this has not been established), which is generally desirable but makes them unsuitable for
studies of specific AKT isoforms. Similarly, the different isoforms of PKA are presumably all capable of
phosphorylating the target peptide used in AKAR2, but it is well-known that PKA activity is often
compartmentalized by A-kinase anchoring proteins (AKAPs); reporter localization, which is controlled
by the Lyn peptide tag in our reporters, may therefore be especially important. In all cases, it is
important to establish that a particular reporter performs as expected, reporting faithfully on activity of
the kinase(s) in question; genetic and pharmacologic manipulations are important in this process, and
validated the target peptides that we used respectively for AKT and PKA.
Among other limitations of our kinase reporter assays, using reporter phosphorylation (as
reflected by FRET) to measure kinase activity depends on the assumption that reporter
dephosphorylation is insignificant or unchanged between conditions being compared. This may not
always be the case; we observed a rapid decline in E from the active AKT reporter after AKT inhibition,
implying that the E value reflects a balance between reporter phosphorylation and active
dephosphorylation. However, even if a change in E is not solely due to kinase activity (i.e., is affected by
a change in dephosphorylation), the reporter may ultimately provide relevant information about the
net activity of the pathway in question. Finally, while it is advantageous that the reporter assay works
well in live cells, we found that it does not work reliably in fixed cells (data not shown), limiting the
collection of samples at different times for later batch analysis, although we did find that reporter
signal was stabilized by keeping cells in the cold.
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In summary, we have provided methods and applications that illustrate and extend the use of
flow cytometry to measure FRET in live cells.
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Chapter 6: Discussion and Future Directions

6.1 - Overall Conclusions
The role of PAG1 in DLBCL
Despite recent advances in treatment options, DLBCL continues to be a deadly disease, and its
more aggressive form, ABC-DLBCL, is unique in its escape from immunological tolerance mechanisms. I
believe that this uniqueness can be co-opted to develop efficacious therapies. Extensive preliminary
data suggests that PAG1 downregulation, ubiquitously seen in ABC-DLBCL, may allow escape from
immune tolerance via an incompletely understood mechanism.
The major goal of this investigation was to determine what role the downregulation of PAG1 in
ABC-DLBCL plays in the survival and proliferation of tumor cells, with the hypothesis that PAG1 is a
mediator of immune tolerance and that its absence in ABC tumors contributes to escape from the
tolerance mechanisms that prevent normal B cells from surviving chronic Ag stimulation through the
BCR.
To evaluate this hypothesis, we demonstrated that forced re-expression of PAG1 was indeed
toxic to ABC-DLBCL cell lines, which experience chronic antigen stimulation; but not to GCB-DLBCL
cells[33], which instead rely on tonic BCR signaling for survival[41]. We further established that PAG1
plays a role in both positive and negative regulation of initial BCR signaling following Ag-induced
crosslinking through a combination of PAG1 KO and overexpression studies in GCB cell lines. Using
PAG1 KO in GCB cells, we additionally showed that PAG1 KO is moderately protective against GCB
models of activation induced cell death (AICD), demonstrating that the role of PAG1 in B cells is
dynamic and likely context specific.
In ABC cell line models, we showed that forced PAG1 expression reduced activation of several
major BCR signal transducers, most notably in the PI3K/Akt/mTOR signaling axis, but also reduced BCR151

proximal SFK activity markers and slightly reduced activation of NFκB. These reductions aligned nicely
with the signaling consequences observed after withdrawal of the BCR, suggesting that PAG1 may be
acting to disable chronic Ag signaling in ABC cells. We further showed that expression of PAG1 increases
surface expression of the BCR in both an engineered HVR-replaced model of BCR signaling and in
otherwise normal ABC cell lines, providing evidence that PAG1 may also function by reducing the
endocytosis of the BCR. Lastly, we demonstrated that forced PAG1 expression has the effect of
disrupting spontaneous microclustering of the BCR at the plasma membrane in the ABC line HBL-1,
demonstrating both a phenotypic effect on BCR localization and a plausible mechanism by which PAG1
may be reducing the activation of BCR signaling transducers while maintaining the BCR at the cell
surface.
We also investigated the mechanisms by which PAG1 exerts its toxic effect in ABC cells through
a systematic evaluation of the known protein effectors of PAG1 function identified in literature, as well
as through the development of a library of PAG1 mutants. Through this work, we established that the
effects of PAG1 are not limited to simple scaffold functions with known protein associates, as
evidenced by the failure of Csk, Ezrin, and Lyn elimination to rescue cells from PAG1 dependent toxicity.
We showed that a domain of PAG1, AA40-103, which has not previously been ascribed a functional role
in PAG1-dependent interactions, when localized to lipid rafts, was sufficient to cause toxicity in HBL-1
cells. Additionally, we determined that even without this novel membrane-adjacent domain, the
remainder of the PAG1 protein was also able to mediate toxicity in ABC cells.
These findings hint at a complex set of interactions mediated by PAG1 that may play a role in
the molecular mechanisms and requirements of BCR signaling in both DLBCL cells and in normal cells,
with potential for mechanistic understanding that can translate into better understanding of the
pathology of B cell malignancies or the treatment of ABC-DLBCL.
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The use of FRET-based kinase activity reporters by flow cytometry
We also developed a robust methodology for the evaluation of kinase activity in live cells by
flow cytometry. We demonstrated two ways to measure FRET in living cells: by use of a conventional
flow cytometer and “3-cube” method for intensity-based calculations in post-acquisition analysis, and
by use of a spectral flow cytometer and linear unmixing to add the capability of detecting FRET in realtime and in the presence of additional fluorophores. We demonstrated the modularity of our kinase
reporter design by detecting and validating the activity of Akt and PKA phosphorylation. Most
importantly, this work laid the foundation for the ability to perform a functional sort for kinase activity
on the basis of FRET in live cells.

6.2 - Future Directions
Despite making key discoveries about the role of PAG1 in DLBCL cells, much more work is
needed to properly identify the full effects of PAG1 on the BCR signaling environment generally, and
more specifically the mechanisms that produce toxicity in ABC cells. While I believe that the work
presented above represents a promising first step towards understanding the complexity of BCR signal
regulation in DLBCL and the role of PAG1 in that regulation, significantly more work needs to be done
before it is possible to definitively make the case for the role of PAG1 in DLBCL.
Given the challenges of elucidating the mechanisms of PAG1 in DLBCL cells, I believe the most
relevant work in the investigation of PAG1 is to fully and systematically catalog the role it plays in
normal B cell biology. As discussed in Chapter 1, PAG1 is expressed differentially through early B cell
development, and then significantly upregulated during the GC reaction, which implies a role in
mediating some aspect of B cell development[52,56,57], but previously examined mouse models of
germline PAG1 KO showed little evidence of B-cell developmental impairment[58,59] despite later
evaluations in T cells using the same models demonstrating resistance to anergy and predisposal to
autoimmunity after more rigorous study[60]. I believe that the role of PAG1 in normal B cells has not
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been adequately investigated, and that more work needs to be done in normal B cells to fully
categorize the effect of PAG1 in B cell development.
More to point of the hypothesis explored by our group, existing animal models have not
answered a critical question regarding the role of PAG1 in lymphomagenesis: what is the effect of PAG1
loss in mature, antigen-experienced B cells, and more specifically, do B cells become more susceptible
to tolerance evasion as in T cells, and is this a pathway to autoimmunity or cancer?
The most relevant work in this regard would be the development and characterization of a
conditional PAG1 KO animal model, with elimination of PAG1 after entry to the germinal center.
Previous studies have suggested possible compensatory mechanisms for the loss of PAG1, especially if
PAG1 is never expressed, but our hypothesis regarding the role of PAG1 in lymphomagenesis is that the
loss of PAG1 expression after entry to the GC necessitates a model in which B cells develop “normally,”
then experience PAG1 loss. The knowledge gained by establishing if conditional loss of PAG1
contributes to lymphomagenesis or autoimmune phenotypes could provide significant insight into how
PAG1 functions during and after the GC reaction, and establish if PAG1 loss is a driver of B cell
malignancy.
Future work regarding PAG1 expression in DLBCL also likely necessitates a careful re-evaluation
of strategy in cell line models as well. Our discovery of novel functionality of the AA40-103 domain of
PAG1 will need to be fully explored before other aspects of PAG1 interactions in DLBCL can be
understood. During the period of study represented here, we were not able to catalog the molecular or
signaling consequences of forced expression of this novel domain, but significant effort should be
afforded to the characterization of phenotypes associated with it, since as we have shown, the effects
of this single domain may functionally dominate the other known interactions of PAG1 in ABC cells and
block the discovery of significant interactions barring the development of significantly improved tools
for investigating PAG1 interactions.
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Independent of and complementary to our investigation of PAG1 in DLBCL was the work done
in optimizing kinase activity sensors in live cells, and developing the methods to functionally identify
and sort single cells on the basis of FRET. I believe this is an exciting set of tools with broad applicability
to a number of questions in cell biology, but especially for investigations of treatment resistance in
DLBCL.
We developed our Akt and PKA kinase activity reporters for just this reason, however, both of
these reporters are designed to understand the early-stage consequences of antigen cross-linking (PKA)
or PI3K signaling, reflecting only the most BCR-proximal signaling. A fascinating and potentially
impactful area of future development would be to apply the developed kinase reporter to the various
signaling kinases in the BCR pathway, notably Btk, Syk, PLCγ2. If these reporters could be applied down
the BCR signaling cascade, the consequences of various therapeutic interventions as well as the
mechanisms of resistance to therapy could be more easily discerned, expediting the research into the
disparate patient responses to BCR signaling inhibitors such as ibrutinib.
Together this research continues the goal of understanding the mechanisms of B cell
malignancy by beginning the work of understanding the role of PAG1 in the regulation of the BCR in
DLBCL, and developing the tools to continue and advance the work of molecular biology research.
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Appendix
Appendix 1: Sequences of inducible and HVR-replaced BCRs
HBL-1 inducible IgM
SfiI sites: GGCCTGTCAGGCC
C – disruptions of additional AarI sites
Splice donor and acceptor sites: GT AG
Introns: GAGTGTCTC
HBL-1 H-HVR sequence: AAACACCT
Stop codon: TGA
GGAAGGCCTCTGAGGCCACCATGGGACCCAAACACCTGTGGTTCTTCCTCCTCCTGGTGGCAGCTCCCGG
ATGTGAGTGTCTCAGGAATGCGGATATGAAGATATGAGATGCTGCCTCTGATCCCAGGACTCACTGTGGG
TTTCTCTGTTCACAGGGGTCCTGTCCCAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTC
GGAGACCCTGTCCCTCACTTGCGCTGTCTATGGTGGGTCCTTCAGTGATTACTACTGGACCTGGATCCGT
CAGTCCCCAGGAAAGGGGCTGGAGTGGATTGGGGAAATCAATCGTAGTGGAAGTACCGACTACAACCCGT
CCCTCAAGAGTCGAGTCACCATATCACTAGACACGTCCAAGAACCAATTCTCCCTGCATCTGACCTCTGT
GACCGCCGCGGACACGGCTCTATATTACTGTGCGGGGGGACAAGACTACGGTGACTATGTTAGGGGGGGT
AGTGACTACTGGGGCCAGGGAAACCTGGTCACCGTCTCCTCAGGTAGTGCATCCGCCCCAACCCTTTTCC
CCCTCGTCTCCTGTGAGAATTCCCCGTCGGATACGAGCAGCGTGGCCGTTGGCTGCCTCGCACAGGACTT
CCTTCCCGACTCCATCACTTTCTCCTGGAAATACAAGAACAACTCTGACATCAGCAGCACCCGGGGCTTC
CCATCAGTCCTGAGAGGGGGCAAGTACGCAGCCACCTCACAGGTGCTGCTGCCTTCCAAGGACGTCATGC
AGGGCACAGACGAACACGTGGTGTGCAAAGTCCAGCACCCCAACGGCAACAAAGAAAAGAACGTGCCTCT
TCCAGTGATTGCTGAGCTGCCTCCCAAAGTGAGCGTCTTCGTCCCACCCCGCGACGGCTTCTTCGGCAAC
CCCCGCAAGTCCAAGCTCATCTGCCAGGCCACGGGTTTCAGTCCCCGGCAGATTCAGGTGTCCTGGCTGC
GCGAGGGGAAGCAGGTCGGGTCTGGCGTCACCACGGACCAGGTGCAGGCTGAGGCCAAAGAGTCTGGGCC
CACGACCTACAAGGTGACCAGCACACTGACCATCAAAGAGAGCGACTGGCTCGGCCAGAGCATGTTCACA
TGCCGCGTGGATCACAGGGGCCTGACCTTCCAGCAGAATGCGTCCTCCATGTGTGTCCCCGATCAAGACA
CAGCCATCCGGGTCTTCGCCATCCCCCCATCCTTTGCCAGCATCTTCCTCACCAAGTCCACCAAGTTGAC
CTGCCTGGTCACAGACCTGACCACCTATGACAGCGTGACCATCTCCTGGACCCGCCAGAATGGCGAAGCT
GTGAAAACCCACACCAACATCTCCGAGAGCCACCCCAATGCCACTTTCAGCGCCGTGGGTGAGGCCAGCA
TCTGCGAGGATGACTGGAATTCCGGGGAGAGGTTCACGTGCACCGTGACCCACACAGACCTGCCCTCGCC
ACTGAAGCAGACCATCTCCCGGCCCAAGGGGGTGGCCCTGCACAGGCCCGATGTCTACTTGCTGCCACCA
GCCCGGGAGCAGCTGAACCTGCGGGAGTCGGCCACCATCACGTGCCTGGTGACGGGCTTCTCTCCCGCGG
ACGTCTTCGTGCAGTGGATGCAGAGGGGGCAGCCCTTGTCCCCGGAGAAGTATGTGACCAGCGCCCCAAT
GCCTGAGCCCCAGGCCCCAGGCCGGTACTTCGCCCACAGCATCCTGACCGTGTCCGAAGAGGAATGGAAC
ACGGGGGAGACCTACACATGCGTGGTGGCCCATGAGGCCCTGCCCAACAGGGTCACCGAGAGGACCGTGG
ACAAGTCCACCGAGGGGGAGGTGAGCGCCGACGAGGAGGGCTTTGAGAACCTGTGGGCCACCGCCTCCAC
CTTCATCGTCCTCTTCCTCCTGAGCCTCTTCTACAGTACCACCGTCACCTTGTTCAAGGTGAAATGAGGC
CTGTCAGGCCAAGC
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Homology arms for HVR replacement with inserted FP and F2A sequences
Fragments of DNA as inserted in the into pSC-B-amp/kan plasmid
(Agilent Technologies) and used for ligation mediated assembly of
repair template plasmids for H-HVR and L-HVR replacement.
The sequences are marked as follows:
Introns: GTTATAT
Exons in bold: CCTTAAA
GFP: ATGGTGA
mTurquoise2: ATGGTGA
F2A: GTGACAG
Splice donor and acceptor sites: GT AG
Silent changes to prevent re-targeting of repair template plasmid and
modified genomic locus: ACTGG
BsmBI restriction cassette: GGAGACGCCCTCGTCTCC
BsmBI restriction sites: GAGACG and CGTCTC
BbsI restriction sites: GAAGAC and GTCTTC
Cas9/sgRNA sites: underlined
U2932_IgH endogenous
GGGTTGAACAGTACTGACCCTATTCCAAAATCTGTCCTTGATCCAGGATCACACTCATCTCTCAGACCAG
CTCCTTCAGCACATCTCTTTACCTGGAAGAAGAGGACTCTGGGCTTGGAGAGGGGAGGCCCCAAGAAGAG
AACTGAGTTCTCAAAGGGCACAGCCAGCATTCTCCTCCCAGGGTGAGCTCAAAAGACTGGCGCCTCTCTC
ATCCCTTTTCACTGCTCCGTACAAACGCACCACCCCCATGCAAATCCTCACTTAGGCGCCCACAGGAAGC
CACCACACATTTCCTTAAATTCAGGTCCAACTCATAAGGGAAATGCTTTCTGAGAGCCATGTATCTCATG
TGCAAGAAAATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACG
GCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGAC
CCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCTTCACCTAC
GGCGTGCAGTGCTTCGCCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCG
AAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAA
GTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATC
CTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAGGTCTATATCACCGCCGACAAGCAGAAGAACG
GCATCAAGGTGAACTTCAAGACCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCA
GCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCC
CTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCA
CTCTCGGCATGGACGAGCTGTACAAGGTGACAGAGTTGCTGTACAGGATGAAGCGGGCCGAGACCTACTG
TCCAAGGCCTCTGCTGGCAATTCACCCAACGGAGGCTCGGCATAAGCAAAAGATTGTGGCCCCTGTCAAG
CAGACTCTGAACTTCGATTTGCTCAAACTGGCCGGCGATGTGGAGTCCAATCCGGGACCCAAGCACCTGT
GGTTCTTCCTCCTGCTGGTGGCGGCTCCCAGATGTGAGTGTTTCTAGGATGCAGACATGGAGATATGGGA
GACTGCCTCTGATCCCAGGGCTCACTGTGGGTTTTTCTGTTCACAGGGGTCCTGTCCCAGCTGCAGCTGC
AGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTCGTGTCTC
CATCAGCAGTAGTAATTACTACTGGGGCTGGATCCGCCAGCCCCCAGGGAAGGGGCTGGAATGGATTGGG
AGTGACTATTATGGTGGCAGTACCTCCTACAACCCGTCCCTCAAGGGTCGAGTCATTATATCCGTAGACA
CGTCCAAGAACCACTTCTCCCTGAAACTGACCTCTGTGACCGCCGCAGACACGGCTCTATATTACTGTGC
GAGAGCGCTGTCTTACTATGATACTGGTGGTTTCAGGTACTTCTTCGATTATTGGGGCCAGGGAACACTG
GTCACAGTGTCCTCAGGTGAGTACTTACGACCTCTCTCCTGCTTTAACTCTTAAGGATTTTGCTGCATTT
TTGGGGGGAAATAAGCGTGCTGGGTCTCCTGCCAAGAGAGCCTCGGGCTGGGTCTCCTGCCATGAGAGCC
CCGGAGCAGCCTGGGGCTCAGGAGGATGCCCTGAGGCAACAGCGGCCACACAGACGAGGGGCAAAGGCTC
CAGATGTTCCTTCCTCCTGAGCCCAGCAGCACGGGTCTCTCTGTGGCCAGGGCCACCCTGGGCCTCTGGG
GTCCAATGTCCAACAACCCCCGGGCCCTCCCCGGGCTCAGTCTGAGAGGGTCCCAGAGACTTAACGGGGT
GCCAGTTCTTGCCTGGGGTCCTCC
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U2932_IgH OVA
GGGTTGAACAGTACTGACCCTATTCCAAAATCTGTCCTTGATCCAGGATCACACTCATCTCTCAGACCAG
CTCCTTCAGCACATCTCTTTACCTGGAAGAAGAGGACTCTGGGCTTGGAGAGGGGAGGCCCCAAGAAGAG
AACTGAGTTCTCAAAGGGCACAGCCAGCATTCTCCTCCCAGGGTGAGCTCAAAAGACTGGCGCCTCTCTC
ATCCCTTTTCACTGCTCCGTACAAACGCACCACCCCCATGCAAATCCTCACTTAGGCGCCCACAGGAAGC
CACCACACATTTCCTTAAATTCAGGTCCAACTCATAAGGGAAATGCTTTCTGAGAGCCATGTATCTCATG
TGCAAGAAAATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACG
GCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGAC
CCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCTTCACCTAC
GGCGTGCAGTGCTTCGCCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCG
AAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAA
GTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATC
CTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAGGTCTATATCACCGCCGACAAGCAGAAGAACG
GCATCAAGGTGAACTTCAAGACCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCA
GCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCC
CTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCA
CTCTCGGCATGGACGAGCTGTACAAGGTGACAGAGTTGCTGTACAGGATGAAGCGGGCCGAGACCTACTG
TCCAAGGCCTCTGCTGGCAATTCACCCAACGGAGGCTCGGCATAAGCAAAAGATTGTGGCCCCTGTCAAG
CAGACTCTGAACTTCGATTTGCTCAAACTGGCCGGCGATGTGGAGTCCAATCCGGGACCCGGATGGAGCT
GTATCATCCTCTTTTTGGTAGCAACAGCTACAGGTAAGGGGCTCACAGTAGCAGGCTTGAGATCTGGCAA
TACACTTGGGTGACAATGACATCCACTCTCTCTTTCTCTCCATAGGTGTCCACTCCCAGGTCCAACTGCA
GCAGCCTGGGGCTGTGTTGGTGAGGCCTGGGGCTTCAGTGAAGCTGTCCTGTAAGGCTTCTGGCTACATC
TTCACCAGTTACTGGATGAATTGGGTGAAACAGAGGCCTGGACAAGGCCTTGAATGGATTGGTATGATTG
ATTGTTCAGACAGAAAAACTCACTACAATCAAATGTTCAAAGACAAGGCCACATTGACTGTTGACAAGTC
CTCCAATATAGCCTACATTCAGCTCATCAGTCTGACATCTGAGGACTCTGCGGTCTATTACTGTTCAAGG
GGGAGTAAATACTGGGGCCAAGGGACTCTGGTCACTGTCTCTTCAGGTGAGTACTTACGACCTCTCTCCT
GCTTTAACTCTTAAGGATTTTGCTGCATTTTTGGGGGGAAATAAGCGTGCTGGGTCTCCTGCCAAGAGAG
CCTCGGGCTGGGTCTCCTGCCATGAGAGCCCCGGAGCAGCCTGGGGCTCAGGAGGATGCCCTGAGGCAAC
AGCGGCCACACAGACGAGGGGCAAAGGCTCCAGATGTTCCTTCCTCCTGAGCCCAGCAGCACGGGTCTCT
CTGTGGCCAGGGCCACCCTGGGCCTCTGGGGTCCAATGTCCAACAACCCCCGGGCCCTCCCCGGGCTCAG
TCTGAGAGGGTCCCAGAGACTTAACGGGGTGCCAGTTCTTGCCTGGGGTCCTCC

158

U2932_IgL endogenous
CCATCATGCATTTAGGGAGCTGACTGGGCACAAGTTGGAGCAGAAAGAGAAAAATGAAACCACAGCCTTC
TATTTTGTTTCTAACAGACTTGTACCAAACATTCTGTGGCTCAATCTAGGTGATGGTGAGACAAGAGGAC
ACAGGGGTTAAATTCTGTGGCCGCAGGGGAGAAGTTCTACCCTCAGACTGAGCCAACGGCCTTTTCTGGC
CTGATCACCTGGGCATGGGCTGCTGAGAGCAGAAAGGGGAGGCAGATTGTCTCTGCAGCTGCAAGCCCAG
CACCCGCCCCAGCTGCTTTGCATGTCCCTCCCAGCCGCCCTGCAGTCCAGAGCCCATATCAATGCCTGGG
TCAGAGCTCTGGAGAAGAGCTGCTCAGTCAGTACCCTGCGGGAACCATGGTGAGCAAGGGCGAGGAGCTG
TTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCC
CGTGCCCTGGCCCACCCTCGTGACCACCCTGTCCTGGGGCGTGCAGTGCTTCGCCCGCTACCCCGACCAC
ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCA
AGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGA
GCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACTTTAGC
GACAACGTCTATATCACCGCCGACAAGCAGAAGAACGGCATCAAGGCCAACTTCAAGATCCGCCACAACA
TCGAGGACGGCGGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGATCAC
ATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGGTGACAG
AGTTGCTGTACAGGATGAAGCGGGCCGAGACCTACTGTCCAAGGCCTCTGCTGGCAATTCACCCAACGGA
GGCTCGGCATAAGCAAAAGATTGTGGCCCCTGTCAAGCAGACTCTGAACTTCGATTTGCTCAAACTGGCC
GGCGATGTGGAGTCCAATCCGGGACCCGAAACCCCAGCGCAGCTTCTCTTCCTCCTGCTACTCTGGCTCC
CAGGTGAGGGGAACATGGGATGGTTTTGCATGTCAGTGAAAACCCTCTCAAGTCCTGTTACCTGGCAACT
CTGCTCAGTCAATTCAATAATTAAAGCTCAATATAAAGCAATAATTCTGGCTCTTCTGGGGAGACAATGG
GTTTGATTTAGATTACATGGGTGACTTTTCTGTTTTATTTCCAATCTCAGATACCACCGGAGAAATTGTG
TTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTC
AGAGTGTTAGCAGCAGCTACTTAACCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTA
TGGTGCGTCCAACAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACT
CTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATCGTAGCTCACCTC
CGACGTGGACGTTCGGCCAAGGGACAAAAGTCGAGATCAAACGTGAGTAGAATTTAAAGTTTGCTTACTT
AGTTGTCTGTGTCTTCTGCTTCCGGTGTCTATGAAGTGATCTATAAACTGACTCTGCAATCAGCCTCTGA
TATCCTTCAGGGAAAAGAAAAAGATAAGTCTGTAGTCAAACTCGAGAATTGATTGCACATTTTCTTTGAA
GAGCAAGCAAGATTCAGTCATTGGGTGAGAATAACTTGTCTAAGTAATAGCTTCAGAAATGTCCTGGGGA
ACATAACATGTTCTGGACAGAGCCTTGGTCAATTGTCAGAAAGGGAGTTTTTGTATAGGAGGGAAGTTAA
GAGGAACCATTGTGTGTACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAACGTAAGTACTTTTTTCCA
CTGATTCTTCACTGTTGCTA
U2932_IgL OVA
CCATCATGCATTTAGGGAGCTGACTGGGCACAAGTTGGAGCAGAAAGAGAAAAATGAAACCACAGCCTTC
TATTTTGTTTCTAACAGACTTGTACCAAACATTCTGTGGCTCAATCTAGGTGATGGTGAGACAAGAGGAC
ACAGGGGTTAAATTCTGTGGCCGCAGGGGAGAAGTTCTACCCTCAGACTGAGCCAACGGCCTTTTCTGGC
CTGATCACCTGGGCATGGGCTGCTGAGAGCAGAAAGGGGAGGCAGATTGTCTCTGCAGCTGCAAGCCCAG
CACCCGCCCCAGCTGCTTTGCATGTCCCTCCCAGCCGCCCTGCAGTCCAGAGCCCATATCAATGCCTGGG
TCAGAGCTCTGGAGAAGAGCTGCTCAGTCAGTACCCTGCGGGAACCATGGTGAGCAAGGGCGAGGAGCTG
TTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCC
CGTGCCCTGGCCCACCCTCGTGACCACCCTGTCCTGGGGCGTGCAGTGCTTCGCCCGCTACCCCGACCAC
ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCA
AGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGA
GCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACTTTAGC
GACAACGTCTATATCACCGCCGACAAGCAGAAGAACGGCATCAAGGCCAACTTCAAGATCCGCCACAACA
TCGAGGACGGCGGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
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GCTGCCCGACAACCACTACCTGAGCACCCAGTCCAAGCTGAGCAAAGACCCCAACGAGAAGCGCGATCAC
ATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGGTGACAG
AGTTGCTGTACAGGATGAAGCGGGCCGAGACCTACTGTCCAAGGCCTCTGCTGGCAATTCACCCAACGGA
GGCTCGGCATAAGCAAAAGATTGTGGCCCCTGTCAAGCAGACTCTGAACTTCGATTTGCTCAAACTGGCC
GGCGATGTGGAGTCCAATCCGGGACCCATGAGTCCTGCCCAGTTCCTGTTTCTGTTAGTGCTCTGGATTC
GGGGTAAGGAGTTCTGGAATGGGAGGGATGAGAATGGGGATGGAGGGTGATCTCTGGATGCCTATGTGTG
CTGTTTATTTGTGGTGGGGCAGGTCATATCTTCTAGGATGTGAGGTTTTGTTACATCCTAATGAGATATT
CCAGATGGAACAGTAGCTGTACTAAGATCAATATTCTGACATAGATTGGATGGAGTGGTATAGACTCTGA
TGTTTAGAACCTTCAACATTTGTTTTATGACAAGATATTTGATATATCATATCTTTAAATCTGAAAAACT
GCTAGGATCTTACTTGAAAGGAATAGCATTTTCAAGTAAGATTTCAAGTAGATTTTCAAGTAGATTTCAC
AAAGGTTGCTCAGGACCTTTGCACATGATTTTCCACTATTGTATTGTAATTTCAGAAACCAACGGTGATG
TTGTGATGACCCAGACTCCACTCACTTTGTCGGTTACCATTGGACAACCAGCCTCCATCTCTTGCAAGTC
AAGTCAGAGCCTCTTAGATAGTGATGGAAAGACATATTTGAATTGGTTGTTACAGAGGCCAGGCCAGTCT
CCAAAGCGCCTAATCTATCTGGTGTCTAAACTGGACTCTGGAGTCCCTGACAGGTTCAGTGGCAGTGGGT
CTGGAACGGATTTCACACTGAAAATCAGCAGAGTGGAGGCTGAGGATTTGGGAGTTTATTATTGCTGGCA
AGCTACACATTTTCCTCAGACGTTCGGTGGAGGTACCAAGTTGGAAATCAAACGTGAGTAGAATTTAAAG
TTTGCTTACTTAGTTGTCTGTGTCTTCTGCTTCCGGTGTCTATGAAGTGATCTATAAACTGACTCTGCAA
TCAGCCTCTGATATCCTTCAGGGAAAAGAAAAAGATAAGTCTGTAGTCAAACTCGAGAATTGATTGCACA
TTTTCTTTGAAGAGCAAGCAAGATTCAGTCATTGGGTGAGAATAACTTGTCTAAGTAATAGCTTCAGAAA
TGTCCTGGGGAACATAACATGTTCTGGACAGAGCCTTGGTCAATTGTCAGAAAGGGAGTTTTTGTATAGG
AGGGAAGTTAAGAGGAACCATTGTGTGTACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAACGTAAGT
ACTTTTTTCCACTGATTCTTCACTGTTGCTA
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Appendix 2: Sequences of split Turbo-ID
The sequences are marked as follows:
SfiI Sites
Hinges: GTTATAT
3’ half of TurboID split at E256/G257
GAI_AA11-93;
Stop Codon
Last segement of FRB (not translated)
PAG1_WT cDNA
mCardinal cDNA
PAG1_GA3-AM_SplitTurboID
GGCCTCTGAGGCCACCATGGGGCCCGCGGGGAGCCTGCTGGGCAGCGGACAGATGCAGATCACCCTGTGG
GGAAGTCTGGCTGCTGTCGCCATTTTCTTCGTCATCACCTTCCTCATCTTCCTGTGCTCTAGTTGTGACA
GGGAAAAGAAGCCGCGACAGCATAGTGGGGACCATGAGAACCTGATGAACGTGCCTTCAGACAAGGAGAT
GTTCAGCCGTTCAGTTACTAGCCTGGCAACAGATGCTCCTGCCAGCAGTGAGCAGAATGGGGCACTCACC
AATGGGGACATTCTTTCAGAGGACAGTACTCTGACCTGCATGCAGCATTACGAGGAAGTCCAGACATCGG
CCTCGGATCTGCTGGATTCCCAGGACAGCACAGGGAAACCAAAATGTCATCAGAGTCGGGAGCTGCCCAG
AATCCCTCCCGAGAGCGCAGTGGATACCATGCTCACGGCGAGAAGTGTGGACGGGGACCAGGGGCTGGGG
ATGGAAGGGCCCTATGAAGTGCTCAAGGACAGCTCCTCCCAAGAAAACATGGTGGAGGACTGCTTGTATG
AAACTGTGAAAGAGATCAAGGAGGTGGCTGCAGCTGCACACCTGGAGAAAGGCCACAGTGGCAAGGCAAA
ATCTACTTCTGCCTCGAAAGAGCTCCCAGGGCCCCAGACTGAAGGCAAAGCTGAGTTTGCTGAATATGCC
TCGGTGGACAGAAACAAAAAATGTCGTCAAAGTGTTAATGTAGAGAGTATCCTTGGAAATTCATGTGATC
CAGAAGAGGAGGCCCCACCACCTGTCCCTGTTAAGCTTCTGGACGAGAATGAAAACCTTCAGGAGAAGGA
AGGGGGAGAGGCGGAAGAGAGTGCCACAGACACGACCAGTGAAACTAACAAGAGATTTAGCTCATTGTCA
TACAAGTCTCGGGAAGAAGACCCCACTCTCACAGAAGAAGAGATCTCAGCTATGTACTCATCAGTAAATA
AACCTGGACAGTTAGTGAATAAATCGGGGCAGTCGCTTACAGTTCCGGAGTCCACCTACACCTCCATTCA
AGGGGACCCACAGAGGTCACCCTCCTCCTGTAATGATCTCTATGCTACTGTTAAAGACTTCGAAAAAACT
CCAAACAGCACACTTCCACCAGCAGGGAGGCCCAGCGAGGAGCCAGAGCCTGATTATGAAGCGATACAGA
CTCTCAACAGAGAGGAAGAAAAGGCCACCCTGGGGACCAATGGCCACCACGGTCTCGTCCCAAAGGAGAA
CGACTACGAGAGCATAAGTGACTTGCAGCAAGGCAGAGATATTACCAGGCTCGGAGGAGGCAGCGGCGGA
GGATCCGGAGGCCTGGCTCCATATCTGCCACGGTGGGAGAAGCTGGATAACTTCATCAATAGACCCGTGAAGCT
GATCATTGGGGACAAAGAGATTTTCGGGATTAGCCGGGGGATTGATAAACAGGGAGCCCTGCTGCTGGAACAG
GACGGAGTTATCAAACCCTGGATGGGCGGAGAAATCAGTCTGCGGTCTGCCGAAAAGCTGCAGCTGCCTCCCCT
GGAGCGCCTGACCCTGGACGGCGGAGGATCCGGAGGCGGAAGTGGACAAGACAAGAAGACTATGATGATGA
ATGAAGAAGATGATGGTAATGGAATGGATGAGCTTCTGGCCGTGCTCGGTTATAAGGTGCGCTCATCCGA
AATGGCCGACGTGGCACAGAAGCTGGAACAATTGGAGGTTATGATGTCTAATGTTCAAGAAGATGATTTG
TCTCAGCTCGCCACGGAGACTGTTCATTATAATCCGGCGGAACTCTATACTTGGCTGGATTCTATGCTGA
CTGATCTGAATCCTTGACAGGCGTGGGACCTCTACTACCACGTGTTCAGGAGGATCAGCAAGCAGCTCTG
AGGCCTGTCAGGCCAAT
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mCardinal_GA3-AM_SplitTurboID

GGCCTCTGAGGCCACCATGGGCAAGCCCATCCCCAACCCCCTGCTGGGCCTGGACAGCACCGCTAGCAAAGAC
AATACTGTGCCTCTGAAGCTGATCGCTCTCCTGGCTAATGGCGAGTTCCATAGTGGCGAACAGCTGGGAGAAACC
CTGGGCATGTCCAGGGCCGCTATCAACAAGCACATTCAGACTCTGCGCGACTGGGGCGTGGACGTGTTCACCGT
GCCCGGAAAGGGCTACTCTCTGCCCGAGCCTATCCCGCTGCTGAACGCTAAACAGATTCTGGGACAGCTGGACG
GCGGGAGCGTGGCAGTCCTGCCTGTGGTCGACTCCACCAATCAGTACCTGCTGGATCGAATCGGCGAGCTGAAG
AGTGGGGATGCTTGCATTGCAGAATATCAGCAGGCAGGGAGAGGAAGCAGAGGGAGGAAATGGTTCTCTCCTT
TTGGAGCTAACCTGTACCTGAGTATGTTTTGGCGCCTGAAGCGGGGACCAGCAGCAATCGGCCTGGGCCCGGTC
ATCGGAATTGTCATGGCAGAAGCGCTGCGAAAGCTGGGAGCAGACAAGGTGCGAGTCAAATGGCCCAATGACC
TGTATCTGCAGGATAGAAAGCTGGCAGGCATCCTGGTGGAGCTGGCCGGAATAACAGGCGATGCTGCACAGATC
GTCATTGGCGCCGGGATTAACGTGGCTATGAGGCGCGTGGAGGAAAGCGTGGTCAATCAGGGCTGGATCACAC
TGCAGGAAGCAGGGATTAACCTGGACAGGAATACTCTGGCCGCTACGCTGATCCGAGAGCTGCGGGCAGCCCTG
GAACTGTTCGAGCAGGAAGGAGGAGGCAGCGGCGGAGGATCCGGAGGCCTGGCTCCATATCTGCCACGGTGG
GAGAAGCTGGATAACTTCATCAATAGACCCGTGAAGCTGATCATTGGGGACAAAGAGATTTTCGGGATTAGCCG
GGGGATTGATAAACAGGGAGCCCTGCTGCTGGAACAGGACGGAGTTATCAAACCCTGGATGGGCGGAGAAATC
AGTCTGCGGTCTGCCGAAAAGCTGCAGCTGCCTCCCCTGGAGCGCCTGACCCTGGACGGCGGAGGATCCGGAGG
CGGAAGTGGACAAGACAAGAAGACTATGATGATGAATGAAGAAGATGATGGTAATGGAATGGATGAGCTT
CTGGCCGTGCTCGGTTATAAGGTGCGCTCATCCGAAATGGCCGACGTGGCACAGAAGCTGGAACAATTGG
AGGTTATGATGTCTAATGTTCAAGAAGATGATTTGTCTCAGCTCGCCACGGAGACTGTTCATTATAATCC
GGCGGAACTCTATACTTGGCTGGATTCTATGCTGACTGATCTGAATCCTTGACAGGCGTGGGACCTCTAC
TACCACGTGTTCAGGAGGATCAGCAAGCAGCTCTGAGGCCTGTCAGGCCAAT
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Appendix 3: Sequences for Csk KI/KO

Csk Homology Arms
Fragments of DNA as inserted in the into pSC-B-amp/kan plasmid
(Agilent Technologies) and used for ligation mediated assembly of
repair template plasmids Csk KIKO – “gene trap”.
The sequences are marked as follows:
Introns: GTTATAT
Exons: GGTACC
Splice donor and acceptor sites: GT AG
GFP: ATGGTGA
PolyA: CTTCT
F2A: GTGACAG
Silent changes to prevent re-targeting of repair template plasmid and
modified genomic locus: ACTGG
In-frame stop codon: TGA
BsmBI restriction cassette: GGAGACGCCCTCGTCTCC
CSK_HA_02 + GFP for KI
GGTACCACAGGGGTGAGGGTCTGGGACATGCAAGCATTCCCACCAGCCCCAGCGGGGTGCTTAGCAGAGGAGA
GAGGATGCAGCTTAGATCAACCCACTCCCCTTTTTCCCAGCACTCAGTCAGGTACAGGCCTGGGGAAGTGGGGGA
GTCTCAACAGGAAGGGACCCAGGGCTCGTTCTCCGGGCAGAGCACCTCACCCAGGCTCACAGAGGCCAGCTCAG
AGGCTGTGACCACGAGGGTGCGCCAGCAGGTGGCTGGAGGGGGCCCAGGCTGCACCCGCCCACGTGTCACCTGC
CTTGCAGGCCGCTTGGCCACCCGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGA
GCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGC
AAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCT
TCACCTACGGCGTGCAGTGCTTCGCCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGC
CATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCC
GAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACG
GCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAAGGTCTATATCACCGCCGACAAGCA
GAAGAACGGCATCAAGGTGAACTTCAAGACCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGAC
CACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCC
AGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGC
CGGGATCACTCTCGGCATGGACGAGCTGTACAAGGTGACAGAGTTGCTGTACAGGATGAAGCGGGCCGAG
ACCTACTGTCCAAGGCCTCTGCTGGCAATTCACCCAACGGAGGCTCGGCATAAGCAAAAGATTGTGGCCC
CTGTCAAGCAGACTCTGAACTTCGATTTGCTCAAACTGGCCGGCGATGTGGAGTCCAATCCGGGACCCGG
AGACGCCCTCGTCTCCGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCC
CCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATC
GCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGC
ATGCGTACAGAATGTATTGCCAAGTACAACTTCCACGGCACTGCCGAGCAGGACCTGCCCTTCTGCAAAGCAGAC
GTGCTCACCATTGTGGCCGTCACCAAGGTAATCAGGTGACGCCCACCCCACCATCCCACTGCTGGGCCTTCCCTCT
GCAGGGGGAGGTGGGCCTGAGAGCATGTCTGGGCTGCCCTCTCCCCAGGACCCCAACTGGTACAAAGCCAAAAA
CAAGGTGGGCCGTGAGGGCATCATCCCAGCCAACTACGTCCAGAAGCGGGAGGGCGTGAAGGCGGGTACCAAA
CTCAGCCTCATGCCGTGAGTACCACGAGGAGGG

163

Appendix 4: Sequence for SOCS_GFP construct
The sequences are marked as follows:
PAG1_361-432, WT
Sfi-IIS-PAG1wt-SOCS1-Sfi
Splice donor and acceptor sites: GT AG
GFP: ATGGTGA
SfiI sites
AarI cassette
Stop Codon
GAGAGGCCTCTGAGGCCACCATGGGACCCGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCC
TGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTA
CGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCTTC
ACCTACGGCGTGCAGTGCTTCGCCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCC
GAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTT
CGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGG
CACAAGCTGGAGTACAACTACAACAGCCACAAGGTCTATATCACCGCCGACAAGCAGAAGAACGGCATCAAGGT
GAACTTCAAGACCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCA
TCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACG
AGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTAC
AAGACGTCCACTGTTAAAGACTTCGAAAAAACTCCAAACAGCACACTTCCACCAGCAGGGAGGCCCAGCGAGGA
GCCAGAGCCTGATTATGAAGCGATACAGACTCTCAACAGAGAGGAAGAAAAGGCCACCCTGGGGACCAATGGC
CACCACGGTCTCGTCCCAAAGGAGAACGACTACGAGAGCATAAGTGACTTGCAGCAAGGCAGAGATATTACCAG
GCTCATGTTGGGAGCCCCACTTAGGCAACGGCGAGTAAGACCGCTGCAAGAGTTGTGTAGACAGCGCATAGTAG
CTACGGTGGGGCGGGAGAACCTCGCACGGATTCCTCTTAACCCTGTCCTTCGGGACTATCTCAGTTCCTTTCCGTT
TCAGTGAGGCCTGTCAGGCCAAGC
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